[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 13181
1. Kanellis G, Mollejo M, Montes-Moreno S, Rodriguez-Pinilla SM, Cigudosa JC, Algara P, Montalban C, Matutes E, Wotherspoon A, Piris MA: Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features. Haematologica; 2010 Jul;95(7):1122-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features.
  • BACKGROUND: Splenic diffuse red pulp small B-cell lymphoma is an uncommon B-cell lymphoma, now recognized as a provisional entity in the 2008 update of the WHO Classification.
  • DESIGN AND METHODS: We have retrospectively analyzed the disease features in a highly selected series of 17 patients diagnosed as splenic diffuse red pulp small B-cell lymphoma.
  • Clinical manifestations were mainly derived from splenomegaly.
  • All cases showed a purely diffuse pattern of splenic infiltration by monomorphous small cells with small round nuclei and pale cytoplasm.
  • Peripheral blood cells were small to medium-sized, with clumped chromatin and round nuclear outline and villous cytoplasm.
  • Neoplastic cells had a CD20(+), CD23(-), bcl6(-), Annexin A1- phenotype, with frequent expression of DBA44+ (15/17) and IgG (10/15).
  • FCM data had a B-cell phenotype (CD19(+), CD20(+), CD22(+)) with FMC7 (10/11) and CD11c (5/8) expression.
  • CONCLUSIONS: Our data suggest that splenic diffuse red pulp small B-cell lymphoma is a distinct entity with morphological and immunophenotypical features that differ from those of other splenic lymphomas.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Splenic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 1999 Nov;23(11):1041-5 [10576509.001]
  • [Cites] Haematologica. 2008 May;93(5):670-9 [18367492.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1299-304 [11830479.001]
  • [Cites] Histopathology. 2002 Jan;40(1):22-30 [11903595.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2464-72 [12446449.001]
  • [Cites] Best Pract Res Clin Haematol. 2003 Mar;16(1):41-56 [12670464.001]
  • [Cites] Lancet. 2004 Jun 5;363(9424):1869-70 [15183626.001]
  • [Cites] Leukemia. 1987 Apr;1(4):294-8 [3499540.001]
  • [Cites] Am J Surg Pathol. 1996 Feb;20(2):211-23 [8554111.001]
  • [Cites] Histopathology. 1996 Dec;29(6):571-5 [8971565.001]
  • [Cites] Semin Hematol. 1999 Apr;36(2):148-54 [10319383.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1583-9 [10329610.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):438-46 [17325486.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2253-60 [18042795.001]
  • [Cites] Leukemia. 2008 Mar;22(3):487-95 [18094718.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3552-8 [11369650.001]
  • (PMID = 20220064.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2895036
  •  go-up   go-down


2. Birgersdotter A, Baumforth KR, Porwit A, Sundblad A, Falk KI, Wei W, Sjöberg J, Murray PG, Björkholm M, Ernberg I: Three-dimensional culturing of the Hodgkin lymphoma cell-line L1236 induces a HL tissue-like gene expression pattern. Leuk Lymphoma; 2007 Oct;48(10):2042-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-dimensional culturing of the Hodgkin lymphoma cell-line L1236 induces a HL tissue-like gene expression pattern.
  • To overcome some limitations of in vitro established cell-line tumor models for Hodgkin lymphoma (HL), we explored whether culturing in a three-dimensional (3D) matrix could improve the quality of the model.
  • The gene expression profile of the 3D-cultured HL derived cell-line L1236 was compared with that of suspension-cultured (2D) L1236, as well as to the gene expression profile found in HL tumor samples.
  • To validate our results we also included a gene expression data set of laser captured Hodgkin-Reed - Sternberg (H-RS) cells.
  • We found that the 3D culture affected gene expression of a HL derived cell-line inducing a more tumor-related expression profile.
  • 3D culture affected the expression of 500 genes in L1236, upregulating genes involved in immune response and apoptosis and downregulating genes involved in cell division.
  • [MeSH-major] Cell Culture Techniques / methods. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Hodgkin Disease / pathology. Reed-Sternberg Cells / pathology
  • [MeSH-minor] Apoptosis. Biopsy. Cell Line, Tumor. Computational Biology. Humans. Lymph Nodes / pathology. Models, Genetic. Oligonucleotide Array Sequence Analysis. Peptides / chemistry. RNA, Neoplasm / metabolism

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17917972.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Peptides; 0 / RNA, Neoplasm
  •  go-up   go-down


3. Mito A, Ohashi N, Akita S, Shiomi K, Daga H, Arita K, Fujiwara M: [A case of natural killer cell lymphoma with high adenosine deaminase level in pleural effusion]. Nihon Kokyuki Gakkai Zasshi; 2005 Jun;43(6):360-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of natural killer cell lymphoma with high adenosine deaminase level in pleural effusion].
  • We finally diagnosed the case as natural killer (NK) cell lymphoma from CT-guided needle biopsy just before death, and necropsy.
  • In this case, the high level of ADA in the pleural effusion suggested lymphoma.
  • [MeSH-major] Adenosine Deaminase / metabolism. Killer Cells, Natural. Lymphoma, Non-Hodgkin / diagnosis. Pleural Effusion, Malignant / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Pleura / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15997786.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 3.5.4.4 / Adenosine Deaminase
  •  go-up   go-down


Advertisement
4. Wöhrer S, Troch M, Zwerina J, Schett G, Skrabs C, Gaiger A, Jaeger U, Zielinski CC, Raderer M: Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases. Ann Oncol; 2007 Apr;18(4):647-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases.
  • BACKGROUND: As patients with B-cell lymphomas suffering from an underlying autoimmune condition undergoing therapy with the CD20 antibody rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) offer the unique possibility of monitoring effects of therapy on various rheumatologic parameters, we have evaluated serologic autoimmune markers and the clinical outcome of patients with autoimmune diseases (ADs) who received lymphoma treatment with R-CHOP during the course of their disease.
  • PATIENTS AND METHODS: We have retrospectively analysed 13 patients with non-Hodgkin's lymphoma who concurrently suffered from ADs and were treated with the R-CHOP regimen.
  • Ten (77%) patients showed clinical improvement of their autoimmune symptoms, two (15%) reported no difference and one (7%) patient with rheumatoid arthritis-related worsening symptoms during therapy with R-CHOP.
  • In terms of lymphoma response, 11 patients achieved a complete remission and two a partial remission.
  • CONCLUSIONS: This analysis indicates that R-CHOP given for lymphoma treatment is also effective for therapy of concurrent rheumatoid diseases.
  • Both rheumatoid parameters as well as clinical symptoms showed a significant decrease during treatment with this immunochemotherapy.

  • Genetic Alliance. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Oncol. 2007 Apr;18(4):615-8 [17355949.001]
  • (PMID = 17218490.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9009-79-4 / Rheumatoid Factor; VB0R961HZT / Prednisone
  •  go-up   go-down


5. Kalia S, Bansal MP: Diethyl maleate-induced oxidative stress leads to testicular germ cell apoptosis involving Bax and Bcl-2. J Biochem Mol Toxicol; 2008 Nov-Dec;22(6):371-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diethyl maleate-induced oxidative stress leads to testicular germ cell apoptosis involving Bax and Bcl-2.
  • Testicular germ cell apoptosis is normally a continuous process throughout life.
  • However, massive testicular germ cell loss is known to result from a wide variety of cellular stresses including toxicant exposure.
  • Thus, the present study was aimed to investigate the mechanisms of germ cell loss under stress conditions following diethyl maleate (DEM) exposure.
  • The germ cell apoptosis was found to be increased as assessed by terminal deoxynucleotidyl transferase (TdT)-mediated deoxy-UTP biotin nick end labeling (TUNEL) staining, evaluation of histoarchitechture of testis, and germ cell numbers.
  • It was found that the germ cell number was significantly reduced in DEM-treated sections.
  • RT-PCR was carried out to assess Bax/Bcl-2 mRNA expression levels.
  • Immunohistochemistry of Bax and Bcl-2 revealed Bax activation.
  • The prevalence and cellular localization of the above markers in testicular tissues of DEM-treated animals suggest the possible involvement of Bax/Bcl-2 in the male germ cell apoptosis.
  • [MeSH-major] Apoptosis / drug effects. Maleates / toxicity. Oxidative Stress / drug effects. Spermatozoa / cytology. Spermatozoa / drug effects. Testis / cytology. bcl-2-Associated X Protein / metabolism
  • [MeSH-minor] Animals. Cell Shape / drug effects. Gene Expression Regulation / drug effects. Immunohistochemistry. In Situ Nick-End Labeling. Male. Mice. Mice, Inbred BALB C. RNA, Messenger / genetics. RNA, Messenger / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley Periodicals, Inc.
  • (PMID = 19110998.001).
  • [ISSN] 1099-0461
  • [Journal-full-title] Journal of biochemical and molecular toxicology
  • [ISO-abbreviation] J. Biochem. Mol. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Maleates; 0 / RNA, Messenger; 0 / bcl-2-Associated X Protein; G81WQB56OL / diethyl maleate
  •  go-up   go-down


6. Carmagnat M, Drénou B, Chahal H, Lord JM, Charron D, Estaquier J, Mooney NA: Dissociation of caspase-mediated events and programmed cell death induced via HLA-DR in follicular lymphoma. Oncogene; 2006 Mar 23;25(13):1914-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dissociation of caspase-mediated events and programmed cell death induced via HLA-DR in follicular lymphoma.
  • Human leukocyte antigens (HLA) class II antigen-mediated apoptosis has been documented in antigen-presenting cells and B lymphoproliferations.
  • Characteristics of the apoptosis include rapidity and selectivity for mature cells.
  • Follicular lymphomas are particularly refractory to apoptosis.
  • The B-cell lymphoma Ramos shares characteristics of this subgroup and is insensitive to apoptosis via simple HLA-DR engagement.
  • However, inhibition of caspase activation simply delayed the apoptotic phenotype but neither protected against cell death nor prevented mitochondrial injury.
  • Finally, blockade of caspase activation in parallel with HLA-DR mAb stimulation could provide a potent autovaccination stimulus by leading to necrotic death of B-cell lymphomas.
  • [MeSH-major] Apoptosis. Caspase Inhibitors. Caspases / metabolism. HLA-DR Antigens / physiology. Lymphoma, Follicular / genetics. Lymphoma, Follicular / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16301998.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Caspase Inhibitors; 0 / HLA-DR Antigens; EC 3.4.22.- / Caspases
  •  go-up   go-down


7. West J, Perkins J, Hok S, Balhorn R, Lightstone FC, Cosman M, DeNardo SJ, DeNardo GL: Direct antilymphoma activity of novel, first-generation "antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cells. Cancer Biother Radiopharm; 2006 Dec;21(6):645-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Direct antilymphoma activity of novel, first-generation "antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cells.
  • A first-generation series of novel small molecules, collectively known as selective high-affinity ligands (SHALs), were designed and synthesized to mimic the binding of Lym-1, a monoclonal antibody (mAb) shown to be an effective cytotoxic and radionuclide carrier molecule for targeting non-Hodgkin's lymphoma (NHL).
  • Micromolar concentrations of all three SHALs showed binding to Raji, an HLA-DR10-positive human malignant B-cell line but no binding to CEM or Jurkat's, HLA-DR10-negative malignant T-cell lines.
  • Additionally, the Raji cell membrane distributions of all three SHALs and of Lym-1 were remarkably similar.
  • Unlike Lym-1, which causes substantial growth inhibition and cell death in NHL cell lines, these SHALs had no direct antilymphoma activity.
  • In summary, three first-generation SHALs lacked direct antilymphoma activity, although they had selective NHL B-cell binding like Lym-1 mAb.
  • Because of their small size, these SHALs have potential as radionuclide carrier substitutes for Lym-1 mAb to target the HLA-DR10 NHL-related cell-surface protein.
  • [MeSH-major] Antibodies, Monoclonal / chemistry. Antineoplastic Agents / chemistry. Antineoplastic Agents / pharmacology. Biomimetic Materials / chemistry. Biomimetic Materials / pharmacology. HLA-DR Antigens / metabolism. Lymphoma, Non-Hodgkin / metabolism
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Cell Line, Tumor. Cell Survival / drug effects. Enzyme-Linked Immunosorbent Assay. HLA-DR Serological Subtypes. Humans. Ligands. Streptavidin / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17257080.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 47829
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / HLA-DR Antigens; 0 / HLA-DR Serological Subtypes; 0 / HLA-DR10 antigen; 0 / Ligands; 0 / Lym-1 monoclonal antibody; 9013-20-1 / Streptavidin
  •  go-up   go-down


8. Sabah M, Cummins R, Leader M, Kay E: Immunoreactivity of p53, Mdm2, p21(WAF1/CIP1) Bcl-2, and Bax in soft tissue sarcomas: correlation with histologic grade. Appl Immunohistochem Mol Morphol; 2007 Mar;15(1):64-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoreactivity of p53, Mdm2, p21(WAF1/CIP1) Bcl-2, and Bax in soft tissue sarcomas: correlation with histologic grade.
  • Tumor growth depends on 2 distinctive pathways: cell proliferation and apoptosis.
  • The p53 pathway is an important regulator of the cell cycle as it triggers growth arrest or leads to apoptosis in response to cellular stress and therefore is commonly targeted during tumorigenesis.
  • Apoptosis is also controlled by the Bcl-2 family, which includes proapoptotic and antiapoptotic proteins.
  • Immunohistochemical stains for p21(WAF1/CIP1), p53, Mdm2, Bcl-2, and Bax proteins were carried out on tissue microarrays.
  • Expression of Bax protein was a common finding in soft tissue sarcoma cases.
  • Bcl-2 was identified in 59 tumors (38.8%) and was more prevalent in high-grade sarcomas (low grade, 25.9%; intermediate grade, 32.5%; high grade, 55.2%).
  • The expression of p53, p21(WAF1/CIP1), and Bcl-2 is closely associated with the histologic grade of the tumor, and therefore these proteins may be used as prognostic markers.

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17536310.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


9. Wessely MA, Kettner N, Pierre-Jerome C: Postlymphoproliferative disorder affecting bone after a renal transplantation. J Manipulative Physiol Ther; 2005 Jan;28(1):64-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postlymphoproliferative disorder affecting bone after a renal transplantation.
  • OBJECTIVE: To illustrate a posttransplant lymphoproliferative lymphoma presenting as a solitary osseous lesion situated in the rib.
  • CLINICAL FEATURES: A 53-year-old man was referred to a surgical department because of persistent local pain over the lower part of his left posterior hemithorax.
  • The histological study of the surgically removed tissue revealed diffuse infiltration of the marrow by lymphoid-like cells.
  • There was evidence of interstitial fibrosis, and further immunohistochemical examination showed the presence of B cells in the specimen confirming the diagnosis of B-cell lymphoma.
  • CONCLUSION: This case report discusses an unusual presentation of a lymphoma induced by immunosuppressive therapy in a patient who had received an organ transplant.
  • [MeSH-major] Bone Neoplasms / etiology. Immunosuppression / adverse effects. Kidney Transplantation. Lymphoma, B-Cell / etiology. Ribs

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15726037.001).
  • [ISSN] 1532-6586
  • [Journal-full-title] Journal of manipulative and physiological therapeutics
  • [ISO-abbreviation] J Manipulative Physiol Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Kojima M, Nakamura N, Shimizu K, Tamaki Y, Itoh H, Nakamura S: Marginal zone B-Cell lymphoma among primary B-Cell lymphoma of Waldeyer's ring: histopathologic and immunohistochemical study of 16 tonsillectomy specimens. Int J Surg Pathol; 2008 Apr;16(2):164-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marginal zone B-Cell lymphoma among primary B-Cell lymphoma of Waldeyer's ring: histopathologic and immunohistochemical study of 16 tonsillectomy specimens.
  • Two subtypes of marginal zone B-cell lymphoma (eg, mucosa-associated lymphoid tissue [MALT] type and splenic type) have been reported in the lymph node.
  • To determine the presence or absence of marginal zone B-cell lymphoma of MALT type and the splenic type among Waldeyer's ring (WR) lymphomas, 16 tonsillectomy specimens were studied.
  • Ten cases (63%) were marginal zone B-cell lymphoma.
  • Among marginal zone B-cell lymphoma, 7 were the MALT type and the remaining 3 cases of marginal zone B-cell lymphoma were the splenic type.
  • Moreover, 4 cases of 7 MALT-type lymphomas contained numerous large cells (diffuse large B-cell lymphoma arising from a low-grade marginal zone B-cell lymphoma of MALT type).
  • The low incidence of primary mucosa-associated lymphoid tissue type lymphoma of WR in previous reports may be because it is difficult to correctly identify the characteristic histologic findings of MALT-type lymphoma because of the small biopsy size.
  • [MeSH-major] Lymphoid Tissue / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Tonsillar Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417673.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


11. Riccioni R, Carulli G, de Maria M, Pacini S, Cagno C, Selli C, Petrini M: Primary lymphoma of the bladder: case report. Am J Hematol; 2006 Jan;81(1):77-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the bladder: case report.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Cyclophosphamide / administration & dosage. Lymphoma, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Urinary Bladder Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16369978.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


12. Hirt C, Dölken G, Janz S, Rabkin CS: Distribution of t(14;18)-positive, putative lymphoma precursor cells among B-cell subsets in healthy individuals. Br J Haematol; 2007 Aug;138(3):349-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of t(14;18)-positive, putative lymphoma precursor cells among B-cell subsets in healthy individuals.
  • The t(14;18)(q32;q21) is the characteristic chromosomal translocation of follicular lymphoma (FL).
  • The aim of this study was to determine the immunophenotypic markers of t(14;18)-positive cells in HI and to relate these features to lymphocyte maturation.
  • B cells from 10 subjects with t(14;18)-positive and three subjects with t(14;18)-negative peripheral blood mononuclear cells (PBMC) were fluorescence-activated cell sorted for antigen-naïve (CD27(-)), immunoglobulin M (IgM) memory (IgM(+)CD27(+)) and switched memory (IgM(-) CD27(+)) cells. t(14;18)-recombinations were detected by quantitative PCR.
  • Among PBMC-positive subjects, t(14;18)-frequency was significantly higher in IgM memory (median: 380/10(6)) than in antigen-naïve (median: 16/10(6)) or switched memory (median: 5/10(6)) B cells.
  • All PBMC-negative subjects nevertheless had detectable t(14;18) in sorted B cells; levels were lower than in PBMC-positive subjects, but had the same relative predominance.
  • These results suggest that t(14;18) is generated during early B-cell development in the bone marrow and that affected cells may mature and expand in germinal centres. t(14;18)-frequency was highest in IgM memory cells, a B-cell subset that shares immunophenotypic similarities with FL.
  • The significance of these cells as lymphoma precursors or indicators of lymphoma risk remains to be established.
  • [MeSH-minor] Clone Cells. Gene Frequency. Genes, Immunoglobulin. Genes, bcl-2. Humans. Immunologic Memory. Immunophenotyping. Lymphoma, Non-Hodgkin / immunology. Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17614821.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] England
  •  go-up   go-down


13. Meredith RF, Knox SJ: Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys; 2006;66(2 Suppl):S15-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma.
  • Over the past several decades, several biomolecules have been investigated for their ability to deliver radiation to cancer cells, but antibodies have been the carriers of choice in systemic targeted radionuclide therapy (STaRT).
  • Food and Drug Administration for the treatment of patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL), and clinical trials have shown that they are effective as monotherapies in the salvage setting, producing response rates that are often higher and durations of response that are often longer than those with chemotherapy.
  • Escalated doses of these agents can be supported with stem cell transplantation and can produce high rates of complete response and greater survival in patients with relapsed NHL.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy / methods

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16979433.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / Iodine Radioisotopes; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan; 0 / iodine-131 anti-B1 antibody
  • [Number-of-references] 45
  •  go-up   go-down


14. Pilka R, Mícková I, Lubuský M, Dusková M, Rícánková M, Kudela M: [Expression of p53, Ki-67, bcl-2, c-erb-2, estrogen, and progesterone receptors in endometrial cancer]. Ceska Gynekol; 2008 Jul;73(4):222-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of p53, Ki-67, bcl-2, c-erb-2, estrogen, and progesterone receptors in endometrial cancer].
  • [Transliterated title] Exprese p53, Ki-67, bcl-2, c-erb-2, estrogenového, a progesteronového receptoru v endometriálním karcinomu.
  • OBJECTIVE: To assess the immunohistochemical expression of p53, bcl-2, c-erb-2, Ki-67, estrogen and progesterone receptors in endometrial cancer patients.
  • METHODS: We studied 103 cases of primary untreated endometrial carcinoma in which the p53, bcl-2, c-erb-2, Ki-67, estrogen and progesterone receptor antigens were investigated by an immunohistochemical method.
  • We evaluated the correlations among the immunohistochemical staining assessed by histoscore, and the age, grading, depth of invasion, stage of the neoplasia and extrauterine disease.
  • p53, bcl-2, c-erb-2, Ki-67, estrogen and progesterone receptors were positive in 49 (48%), 81 (79%).
  • There was no clear association between immunohistochemical parameters and the age of patients. p53 and Ki-67 overexpression was found to be related to poor grade of differentiation, deeper myometrial invasion, advanced stage of neoplasia and extrauterine spread of disease.
  • Immunostaining for bcl-2 correlated inversely with FIGO stage, while c-erb-2 was overexpressed in tumors with deeper myometrial invasion.
  • Estrogen and progesterone receptor positive tumors showed a statistically significant association with clinicopathological parameters of better clinical outcome.
  • CONCLUSION: The overexpression of p53 and Ki-67 seems to indicate more malignant phenotype, while bcl-2 and c-erb-2 may have a limited role in the identification of high-risk tumors.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18711961.001).
  • [ISSN] 1210-7832
  • [Journal-full-title] Ceska gynekologie
  • [ISO-abbreviation] Ceska Gynekol
  • [Language] CZE
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


15. Nencioni L, De Chiara G, Sgarbanti R, Amatore D, Aquilano K, Marcocci ME, Serafino A, Torcia M, Cozzolino F, Ciriolo MR, Garaci E, Palamara AT: Bcl-2 expression and p38MAPK activity in cells infected with influenza A virus: impact on virally induced apoptosis and viral replication. J Biol Chem; 2009 Jun 5;284(23):16004-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2 expression and p38MAPK activity in cells infected with influenza A virus: impact on virally induced apoptosis and viral replication.
  • Previous reports have shown that various steps in the influenza A virus life cycle are impaired in cells expressing the antiapoptotic protein Bcl-2 (Bcl-2(+) cells).
  • We demonstrated a direct link between Bcl-2 and the reduced nuclear export of viral ribonucleoprotein (vRNP) complexes in these cells.
  • However, despite its negative impact on viral replication, Bcl-2 did not prevent host cells from undergoing virally triggered apoptosis.
  • In infected Bcl-2(+) cells, activated p38MAPK was found predominantly in the cytoplasm, colocalized with Bcl-2, and both Bcl-2 phosphorylation and virally induced apoptosis were diminished by specific inhibition of p38MAPK activity.
  • In contrast, in Bcl-2-negative (Bcl-2(-)) cells, which are fully permissive to viral infection, p38MAPK activity was predominantly nuclear, and its inhibition decreased vRNP traffic, phosphorylation of viral nucleoprotein, and virus titers in cell supernatants, suggesting that this kinase also contributes to the regulation of vRNP export and viral replication.
  • This could explain why in Bcl-2(+) cells, where p38MAPK is active in the cytoplasm, phosphorylating Bcl-2, influenza viral replication is substantially reduced, whereas apoptosis proceeds at rates similar to those observed in Bcl-2(-) cells.
  • Our findings suggest that the impact of p38MAPK on the influenza virus life cycle and the apoptotic response of host cells to infection depends on whether or not the cells express Bcl-2, highlighting the possibility that the pathological effects of the virus are partly determined by the cell type it targets.
  • [MeSH-major] Influenza A Virus, H1N1 Subtype / physiology. Kidney / physiology. Proto-Oncogene Proteins c-bcl-2 / genetics. p38 Mitogen-Activated Protein Kinases / metabolism
  • [MeSH-minor] Animals. Apoptosis. Cell Line. DNA Primers. Dogs. Down-Regulation. Humans. Life Cycle Stages. Plasmids. Polymerase Chain Reaction. RNA, Small Interfering / genetics. Transfection. Virus Replication

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gen Virol. 2000 Jan;81(Pt 1):135-42 [10640551.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):6961-5 [1871110.001]
  • [Cites] Life Sci. 2000 Jan 14;66(8):663-73 [10680575.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4507-11 [7753834.001]
  • [Cites] J Virol. 1996 Jan;70(1):663-6 [8523590.001]
  • [Cites] J Virol. 1997 Dec;71(12):9690-700 [9371635.001]
  • [Cites] EMBO J. 1998 Jan 2;17(1):288-96 [9427762.001]
  • [Cites] J Immunol. 1998 May 1;160(9):4175-81 [9574517.001]
  • [Cites] Am J Respir Cell Mol Biol. 1998 Jun;18(6):794-9 [9618384.001]
  • [Cites] Virology. 1998 Jun 20;246(1):1-23 [9656989.001]
  • [Cites] Pharmacol Ther. 1999 May-Jun;82(2-3):389-97 [10454214.001]
  • [Cites] Cell Mol Life Sci. 1999 Aug 15;55(10):1230-54 [10487205.001]
  • [Cites] Am J Respir Crit Care Med. 2005 Apr 1;171(7):764-72 [15618464.001]
  • [Cites] J Infect Dis. 2005 May 15;191(10):1719-29 [15838800.001]
  • [Cites] J Immunol. 2000 Mar 15;164(6):3222-8 [10706714.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Nov 30;278(3):753-9 [11095980.001]
  • [Cites] EMBO J. 2000 Dec 15;19(24):6751-8 [11118210.001]
  • [Cites] J Virol. 2001 Jan;75(1):408-19 [11119609.001]
  • [Cites] J Virol. 2001 Mar;75(6):2710-28 [11222695.001]
  • [Cites] Nat Cell Biol. 2001 Mar;3(3):301-5 [11231581.001]
  • [Cites] Leukemia. 2001 Jun;15(6):869-74 [11417471.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):39027-36 [11495898.001]
  • [Cites] Virus Res. 2002 Mar 20;84(1-2):37-44 [11900837.001]
  • [Cites] J Gen Virol. 2002 Apr;83(Pt 4):723-34 [11907320.001]
  • [Cites] Trends Mol Med. 2003 Feb;9(2):46-52 [12615037.001]
  • [Cites] FASEB J. 2003 Apr;17(6):758-60 [12594179.001]
  • [Cites] EMBO J. 2003 Jun 2;22(11):2717-28 [12773387.001]
  • [Cites] Vet Microbiol. 2003 Aug 29;95(1-2):1-13 [12860072.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Aug 8;307(4):870-6 [12878192.001]
  • [Cites] Virus Res. 2003 Sep;95(1-2):3-12 [12921991.001]
  • [Cites] EMBO J. 2003 Sep 15;22(18):4646-55 [12970177.001]
  • [Cites] J Virol. 2004 Feb;78(3):1263-70 [14722281.001]
  • [Cites] Appl Microbiol. 1968 Apr;16(4):588-94 [5647517.001]
  • [Cites] J Gen Virol. 1989 Sep;70 ( Pt 9):2421-31 [2778438.001]
  • [Cites] J Immunol Methods. 1991 Jun 3;139(2):271-9 [1710634.001]
  • [Cites] Nature. 1993 Feb 25;361(6414):739-42 [8441470.001]
  • [Cites] J Cell Biol. 1994 Jan;124(1-2):1-6 [8294493.001]
  • [Cites] J Virol. 1994 Jun;68(6):3667-73 [8189504.001]
  • [Cites] Am J Pathol. 1994 Jun;144(6):1195-202 [8203460.001]
  • [Cites] Antimicrob Agents Chemother. 2000 Jan;44(1):200-4 [10602750.001]
  • [Cites] J Virol. 2005 Aug;79(16):10147-54 [16051807.001]
  • [Cites] J Virol. 2005 Sep;79(18):11788-800 [16140756.001]
  • [Cites] Brain Res Bull. 2006 Feb 15;68(6):406-13 [16459194.001]
  • [Cites] Cell Microbiol. 2006 Mar;8(3):375-86 [16469051.001]
  • [Cites] J Biol Chem. 2006 Jul 28;281(30):21353-61 [16714293.001]
  • [Cites] FASEB J. 2006 Aug;20(10):1683-5 [16790527.001]
  • [Cites] Intervirology. 2007;50(2):99-107 [17139186.001]
  • [Cites] Virus Res. 2007 Mar;124(1-2):12-21 [17081640.001]
  • [Cites] J Virol. 2007 Dec;81(23):12730-9 [17881440.001]
  • [Cites] PLoS Pathog. 2008 May;4(5):e1000018 [18516228.001]
  • [Cites] J Virol. 2000 Feb;74(4):1781-6 [10644350.001]
  • (PMID = 19336399.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Small Interfering; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ PMC2708894
  •  go-up   go-down


16. Marmey B, Boix C, Barbaroux JB, Dieu-Nosjean MC, Diebold J, Audouin J, Fridman WH, Mueller CG, Molina TJ: CD14 and CD169 expression in human lymph nodes and spleen: specific expansion of CD14+CD169- monocyte-derived cells in diffuse large B-cell lymphomas. Hum Pathol; 2006 Jan;37(1):68-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD14 and CD169 expression in human lymph nodes and spleen: specific expansion of CD14+CD169- monocyte-derived cells in diffuse large B-cell lymphomas.
  • The mononuclear phagocyte system of human lymphoid tissue comprises macrophages and dendritic cells (DCs).
  • The heterogeneity of the non-DC mononuclear phagocyte population in human lymphoid tissue has been little addressed.
  • Here, we studied the expression of 2 monocyte-derived markers, CD14 and CD169 (sialoadhesin), in reactive human lymphoid tissue as well as in a series of 51 B-cell lymphomas by immunohistochemistry on paraffin-embedded tissue.
  • We confirmed that lymph node sinusoidal monocyte-derived cells were the only population staining for CD169.
  • Although most sinusoidal histiocytes also expressed CD14, monocyte-derived cells with phagocytosis such as erythrophagocytosis, anthracosis, or tingible bodies macrophage lacked CD14 and CD169.
  • Among B-cell lymphomas, splenic marginal zone lymphoma was the only one associated with an expansion of the CD14(+)CD169(+) cells in the cords.
  • With respect to nodal B-cell lymphomas, CD14(+) cells were rare among B-chronic lymphocytic leukemia, follicular lymphoma (FL), mantle cell lymphoma (MCL).
  • However, strikingly, we found a strong expansion of CD14(+)CD169(-) cells in numerous diffuse large B-cell lymphomas (DLBCLs), except in cases associated with numerous mitoses, apoptotic bodies, and tingible bodies macrophages.
  • When cultivated in granulocyte/macrophage colony stimulating factor/interleukin 4, DLBCL purified CD14(+) cells differentiate into plasmacytoid cells, expressing DC-specific intercellular adhesion molecule 3-grabbing nonintegrin, suggesting dendritic cell differentiation potential.
  • [MeSH-major] Antigens, CD14 / metabolism. Lymph Nodes / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Membrane Glycoproteins / metabolism. Monocytes / metabolism. Receptors, Immunologic / metabolism. Spleen / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cell Separation. Dendritic Cells / metabolism. Dendritic Cells / pathology. Flow Cytometry. Fluorescent Antibody Technique, Direct. Humans. Immunoenzyme Techniques. Lymphadenitis / metabolism. Lymphadenitis / pathology. Sialic Acid Binding Ig-like Lectin 1

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16360418.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD14; 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / Receptors, Immunologic; 0 / SIGLEC1 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 1
  •  go-up   go-down


17. Sørensen RB, Hadrup SR, Køllgaard T, Svane IM, thor Straten P, Andersen MH: Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient. Cancer Immunol Immunother; 2007 Apr;56(4):527-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient.
  • Based on the detection of spontaneous immune responses in cancer patients with cancer of different origin, Bcl-X(L) was recently described as a highly interesting tumor antigen recognized by CD8 positive cytotoxic T lymphocytes.
  • To further characterize Bcl-X(L) as a tumor antigen we isolated and expanded Bcl-X(L) specific T cells from the peripheral blood of a breast cancer patient hosting a strong Bcl-X(L) specific T cell response.
  • We describe that HLA-A2 restricted Bcl-X(L) specific T cell clones very efficiently lyse peptide pulsed T2 cells.
  • Furthermore, tumor cell lines of different origin, i.e., breast cancer, colon cancer, and melanoma, are efficiently lysed in an HLA-dependent manner.
  • Finally, ex vivo-isolated leukemia cells, but not non-malignant B and T cells are killed by Bcl-X(L) specific T cells.
  • Our data underline Bcl-X(L) as an universal tumor antigen widely applicable in specific anticancer immunotherapy.
  • [MeSH-major] Antigens, Neoplasm / immunology. Breast Neoplasms / immunology. Neoplasms / immunology. T-Lymphocytes, Cytotoxic / immunology. bcl-X Protein / immunology
  • [MeSH-minor] Clone Cells. Cytotoxicity, Immunologic. Female. Flow Cytometry. HLA-A2 Antigen. Humans. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16850344.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / HLA-A2 Antigen; 0 / bcl-X Protein
  •  go-up   go-down


18. Takada E, Hata K, Mizuguchi J: Requirement for JNK-dependent upregulation of BimL in anti-IgM-induced apoptosis in murine B lymphoma cell lines WEHI-231 and CH31. Exp Cell Res; 2006 Nov 15;312(19):3728-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Requirement for JNK-dependent upregulation of BimL in anti-IgM-induced apoptosis in murine B lymphoma cell lines WEHI-231 and CH31.
  • The cross-linking of B cell receptor (BCR) undergoes growth arrest, accompanied by apoptosis, in the CH31 and WEHI-231 B lymphoma cells, a model representing primary immature B cells.
  • In unstimulated cells, BimL protein was complexed with Bcl-x(L) and changed the partner to associate with Bax on the mitochondrial membrane after ligation of BCR, leading to initiation of apoptotic processes.
  • Retroviral transduction of BimL into WEHI-231 cells overexpressing dominant-negative form of JNK1 (dnJNK1) resulted in a comparable level of apoptotic cells to control cells, whereas the BimL-mediated apoptosis was partially prevented by Bcl-x(L).
  • [MeSH-major] Apoptosis Regulatory Proteins / genetics. JNK Mitogen-Activated Protein Kinases / metabolism. Lymphoma, B-Cell / metabolism. Membrane Proteins / genetics. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Animals. Antibodies, Anti-Idiotypic / administration & dosage. Apoptosis / immunology. Base Sequence. Biological Transport, Active. Cell Line, Tumor. DNA Primers / genetics. Immunoglobulin M. Mice. Protein Isoforms / genetics. Protein Isoforms / metabolism. Receptors, Antigen, B-Cell / metabolism. Recombinant Proteins / genetics. Recombinant Proteins / metabolism. Transduction, Genetic. Up-Regulation. bcl-2-Associated X Protein / metabolism. bcl-X Protein / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17007835.001).
  • [ISSN] 0014-4827
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Apoptosis Regulatory Proteins; 0 / Bax protein, mouse; 0 / Bcl-2-like protein 11; 0 / Bcl2l1 protein, mouse; 0 / DNA Primers; 0 / Immunoglobulin M; 0 / Membrane Proteins; 0 / Protein Isoforms; 0 / Proto-Oncogene Proteins; 0 / Receptors, Antigen, B-Cell; 0 / Recombinant Proteins; 0 / bcl-2-Associated X Protein; 0 / bcl-X Protein; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases
  •  go-up   go-down


19. Klemke CD, Goerdt S, Schrama D, Becker JC: New insights into the molecular biology and targeted therapy of cutaneous T-cell lymphomas. J Dtsch Dermatol Ges; 2006 May;4(5):395-406
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New insights into the molecular biology and targeted therapy of cutaneous T-cell lymphomas.
  • Cutaneous T-cell lymphoma is an extra-nodal non-Hodgkin lymphoma of mature T cells.
  • These tumor cells home to and persist in the skin,producing a broad spectrum of clinical entities.
  • Recent results of basic research on tumor biology and tumor immunology as well as molecular genetics of cutaneous T-cell lymphoma have fostered the development of new therapeutic approaches.
  • Several clinical trials testing these targeted therapies have shown encouraging results.
  • This article provides an overview of recent research developments and therapeutic strategies for cutaneous T-cell lymphoma.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Drug Delivery Systems / trends. Genetic Therapy / trends. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / physiopathology. Skin Neoplasms / drug therapy. Skin Neoplasms / physiopathology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16686607.001).
  • [ISSN] 1610-0379
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 90
  •  go-up   go-down


20. Filippi AR, Franco P, Galliano M, Ricardi U: Peripheral blood complete remission after splenic irradiation in mantle-cell lymphoma with 11q22-23 deletion and ATM inactivation. Radiat Oncol; 2006;1:35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral blood complete remission after splenic irradiation in mantle-cell lymphoma with 11q22-23 deletion and ATM inactivation.
  • Mantle Cell Lymphoma (MCL) is a well-known histological and clinical subtype of B-cell non-Hodgkin's Lymphomas.
  • It is usually characterized by an aggressive disease course, presenting with advanced stage disease at diagnosis and with low response rates to therapy.
  • We herein report a case of MCL with splenomegaly and peripheral blood involvement as main clinical features.
  • Mainly advocated mechanisms responsible for this phenomenon are considered direct radiation-induced apoptotic cell death, immune modulation via proportional changes of lymphocyte subsets due to known differences in intrinsic radiosensitivity and a radiation-induced cytokine release.
  • The peculiar intrinsic radiosensitivity pattern of lymphoid cells could probably be explained by well-defined individual genetic and molecular features.
  • In this context, among NHLs, MCL subtype has the highest rate of ATM (Ataxia Teleangiectasia Mutated) inactivation.
  • While the ATM gene is thought to play a key-role in detecting radiation-induced DNA damage (especially Double Strand Breaks), recent in vitro data support the hypothesis that ATM loss may actually contribute to the radiosensitivity of MCL cells.
  • [MeSH-major] Cell Cycle Proteins / genetics. Chromosome Deletion. Chromosomes, Human, Pair 11. DNA-Binding Proteins / genetics. Lymphoma, Mantle-Cell / genetics. Lymphoma, Mantle-Cell / radiotherapy. Protein-Serine-Threonine Kinases / genetics. Spleen / radiation effects. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • University of Turin Instituional Repository AperTO. Full Text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 2001 Mar;58(3):235-46 [11230883.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2773-8 [10706620.001]
  • [Cites] Eur J Cancer. 2002 Feb;38(3):401-8 [11818206.001]
  • [Cites] Am J Clin Pathol. 2002 Feb;117(2):237-45 [11863220.001]
  • [Cites] Am J Clin Oncol. 2003 Apr;26(2):178-83 [12714892.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5372-7 [12697903.001]
  • [Cites] Oncogene. 2003 Sep 11;22(39):7905-12 [12970738.001]
  • [Cites] Tumori. 1982 Dec 31;68(6):511-4 [6820205.001]
  • [Cites] Acta Haematol. 1983;70(1):59-62 [6408868.001]
  • [Cites] Radiother Oncol. 1985 Aug;4(1):45-54 [3898236.001]
  • [Cites] Int J Radiat Biol Relat Stud Phys Chem Med. 1985 Dec;48(6):943-61 [3877700.001]
  • [Cites] Cancer. 1986 Sep 15;58(6):1204-7 [2427184.001]
  • [Cites] Am J Hematol. 1989 Mar;30(3):188-9 [2916562.001]
  • [Cites] Eur J Haematol. 1991 Apr;46(4):202-4 [2015875.001]
  • [Cites] Br J Haematol. 1990 Oct;76(2):305-6 [2094335.001]
  • [Cites] Eur J Cancer. 1992;28A(10):1729-34 [1389495.001]
  • [Cites] Am J Hematol. 1994 Jun;46(2):65-71 [8172197.001]
  • [Cites] Br J Radiol. 1995 Sep;68(813):997-1003 [7496700.001]
  • [Cites] Leuk Lymphoma. 1997 Jul;26(3-4):395-8 [9322903.001]
  • [Cites] Semin Hematol. 1999 Apr;36(2):115-27 [10319380.001]
  • [Cites] Blood Rev. 1999 Sep;13(3):163-70 [10527268.001]
  • [Cites] Cancer Treat Rev. 2005 May;31(3):159-72 [15923088.001]
  • [Cites] Lancet Oncol. 2005 Jul;6(7):520-8 [15992701.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6409-14 [16155027.001]
  • [Cites] Mutat Res. 2006 May 11;597(1-2):113-8 [16413041.001]
  • [Cites] Blood. 1999 Nov 1;94(9):3262-4 [10556216.001]
  • [Cites] Blood. 2002 Jan 1;99(1):238-44 [11756177.001]
  • (PMID = 16956411.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC1569379
  • [General-notes] NLM/ Original DateCompleted: 20070726
  •  go-up   go-down


21. Reid-Nicholson M, Kavuri S, Ustun C, Crawford J, Nayak-Kapoor A, Ramalingam P: Plasmablastic lymphoma: Cytologic findings in 5 cases with unusual presentation. Cancer; 2008 Oct 25;114(5):333-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma: Cytologic findings in 5 cases with unusual presentation.
  • BACKGROUND: Plasmablastic lymphoma (PBL) is a rare form of non-Hodgkin lymphoma that was once believed to occur primarily in the oral cavity of human immunodeficiency virus-positive individuals.
  • The presence of the following was evaluated: cellularity, plasmablastic cells, background necrosis (BN), single-cell necrosis (SCN), lymphoglandular bodies (LGB), tingible-body macrophages (TBM), 3-dimensional clusters/sheets, and cytoplasmic vacuoles.
  • Two patients had the acquired immunodeficiency syndrome and 3 had second non-PBL related malignancies including endometrial carcinoma, lung adenocarcinoma, and small lymphocytic lymphoma.
  • The most common cytologic features were hypercellularity (80%), plasmablastic cells (73%), SCN (73%), BN (87%), and LGB (66%).
  • These include hypercellular specimens with abundant plasmablastic cells, LGB, SCN, and BN.
  • However, although these findings may suggest PBL, a definitive diagnosis requires adjunctive studies including immunohistochemistry and flow cytometry.
  • [MeSH-major] Lymphoma, Non-Hodgkin / metabolism. Lymphoma, Non-Hodgkin / pathology

  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18683216.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Okur FV, Krance R: Stem cell transplantation in childhood non-Hodgkin's lymphomas. Curr Hematol Malig Rep; 2010 Oct;5(4):192-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stem cell transplantation in childhood non-Hodgkin's lymphomas.
  • Despite the high cure rates achieved with intensified primary therapies for childhood non-Hodgkin's lymphomas (NHL), the prognosis for children with relapsed or refractory disease is poor.
  • Dose intensification followed by stem cell transplantation has been used in these circumstances and may provide a curative treatment option for these patients, but the number of children treated using this approach is relatively small and its effectiveness has been difficult to judge.
  • We summarize the current experience for stem cell transplantation in childhood NHL and offer our recommendations.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Child. Clinical Trials as Topic. Humans. Lymphoma, B-Cell / therapy. Lymphoma, Large-Cell, Anaplastic / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 Feb 15;105(4):1622-31 [15507526.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):899-908 [8164040.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2172-6 [15169805.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2927-36 [11387366.001]
  • [Cites] Blood. 2000 Jan 15;95(2):416-21 [10627444.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):359-72 [7844597.001]
  • [Cites] Blood. 2006 May 15;107(10):4047-52 [16424389.001]
  • [Cites] Int J Hematol. 2006 Jan;83(1):66-73 [16443556.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):825-31 [10071273.001]
  • [Cites] Ann Oncol. 1997;8 Suppl 1:37-42 [9187427.001]
  • [Cites] Ann Oncol. 2000 Jan;11(1):53-8 [10690387.001]
  • [Cites] Br J Haematol. 2006 Apr;133(2):176-82 [16611309.001]
  • [Cites] Br J Haematol. 2006 Mar;132(5):594-7 [16445832.001]
  • [Cites] Blood. 2005 Feb 1;105(3):948-58 [15486066.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):491-9 [16421426.001]
  • [Cites] Am J Clin Pathol. 2004 Apr;121(4):496-506 [15080301.001]
  • [Cites] Semin Oncol. 2009 Oct;36(5):381-418 [19835736.001]
  • [Cites] Haematologica. 2007 Nov;92(11):1533-48 [18024402.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1252-61 [8648381.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3913-21 [10339500.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):509-17 [9053472.001]
  • [Cites] Bone Marrow Transplant. 2003 Aug;32(3):317-24 [12858205.001]
  • [Cites] Bone Marrow Transplant. 1999 Mar;23(5):437-42 [10100556.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1024-32 [8501488.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2736-43 [17138821.001]
  • [Cites] Bone Marrow Transplant. 2002 May;29(9):769-75 [12040475.001]
  • [Cites] Ann Oncol. 1999 Dec;10(12):1419-32 [10643532.001]
  • [Cites] Ann Oncol. 2006 Jan;17(1):123-30 [16236753.001]
  • [Cites] Biol Blood Marrow Transplant. 2010 Feb;16(2):223-30 [19800015.001]
  • [Cites] Bone Marrow Transplant. 1995 Mar;15(3):353-9 [7599558.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] Br J Haematol. 2001 Sep;114(4):741-60 [11564061.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2921-30 [9376572.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3363-9 [19433688.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):39-49 [16173961.001]
  • [Cites] Blood. 2008 Jan 15;111(2):537-43 [17971487.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1560-6 [17957029.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Blood. 2004 Feb 1;103(3):777-83 [12907446.001]
  • [Cites] Br J Haematol. 2009 Jan;144(1):24-40 [19087093.001]
  • [Cites] Leukemia. 2005 Jun;19(6):945-52 [15800666.001]
  • [Cites] Rev Prat. 1993 Sep 1;43(13):1665-8 [8303185.001]
  • [Cites] Bone Marrow Transplant. 2005 Sep;36(5):437-41 [15980879.001]
  • [Cites] Ann Hematol. 2006 Nov;85(11):787-94 [16932891.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2476-82 [12456505.001]
  • [Cites] J Clin Oncol. 2009 Oct 20;27(30):5056-61 [19738127.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1624-30 [15178574.001]
  • [Cites] Bone Marrow Transplant. 2003 Apr;31(8):667-78 [12692607.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1283-91 [12973853.001]
  • [Cites] Blood. 2007 Oct 15;110(8):2838-45 [17609424.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):897-906 [12610191.001]
  • [Cites] Pediatr Blood Cancer. 2008 Sep;51(3):369-74 [18493992.001]
  • [Cites] Leukemia. 2007 Dec;21(12):2563-6 [17597802.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3699-706 [11389005.001]
  • [Cites] Cancer. 2005 Nov 15;104(10):2133-40 [16211546.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2240-7 [15800314.001]
  • [Cites] Br J Haematol. 2006 Jun;133(6):634-7 [16704438.001]
  • (PMID = 20661786.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


23. Diao LP, Yu XM, Gao YH, Li Y, Liu HS, Liu LH, Zhou RM, Wang N, Wu LL, Wang SJ: Association of VEGF genetic polymorphisms with the clinical characteristics of non-Hodgkin's lymphoma. J Cancer Res Clin Oncol; 2009 Nov;135(11):1473-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of VEGF genetic polymorphisms with the clinical characteristics of non-Hodgkin's lymphoma.
  • We investigated the possible associations of two polymorphisms (-2578C/A and +936C/T) in the VEGF gene with the clinicopathologic parameters for patients with non-Hodgkin's lymphoma (NHL).
  • RESULTS: The -2578A allele was significantly associated with less frequent clinical staging III, IV and bone marrow involvement (The odds ratio (OR) 0.59; 95% confidence interval (CI) 0.43-0.82; and OR 0.66; 95% CI 0.48-0.91, respectively).
  • The TT genotype of the +936C/T polymorphism was significantly associated with less frequent T cell histological type, clinical staging III, IV and bone marrow involvement (OR 0.25; 95% CI 0.07-0.89; OR 0.37; 95% CI 0.15-0.89; and OR 0.31; 95% CI 0.10-0.96, respectively).
  • The +936 T allele was marginally associated with less frequent bone marrow involvement and with Clinical staging III, IV (OR 0.71; 95% CI 0.49-1.01; and OR 0.70; 95% CI 0.49-1.00, respectively).
  • None of the evaluated genotypes of -2578C/A was significantly associated with the gender, age, tumor size, B symptoms and immunohistological subtype.
  • [MeSH-major] Lymphoma, Non-Hodgkin / genetics. Vascular Endothelial Growth Factor A / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Genotype. Humans. Male. Middle Aged. Neoplasm Staging. Polymorphism, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3647-53 [15897560.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Mar;134(3):381-7 [17694324.001]
  • [Cites] Eur Urol. 2007 Oct;52(4):1147-55 [17287073.001]
  • [Cites] J Cancer Res Clin Oncol. 2007 Oct;133(10):787-91 [17564725.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 May;62(2):105-18 [17188504.001]
  • [Cites] Nucleic Acids Res. 1988 Feb 11;16(3):1215 [3344216.001]
  • [Cites] Gynecol Oncol. 2007 May;105(2):385-9 [17289129.001]
  • [Cites] Endocr Rev. 1997 Feb;18(1):4-25 [9034784.001]
  • [Cites] Clin Cancer Res. 2007 Feb 1;13(3):898-901 [17289883.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] J Surg Oncol. 2006 Dec 1;94(7):624-30 [17111394.001]
  • [Cites] J Vasc Res. 2000 Nov-Dec;37(6):443-8 [11146397.001]
  • [Cites] Cytokine. 2000 Aug;12(8):1232-5 [10930302.001]
  • [Cites] Semin Oncol. 2005 Feb;32(1 Suppl 1):S36-43 [15786024.001]
  • [Cites] Leuk Lymphoma. 2007 Mar;48(3):584-95 [17454603.001]
  • [Cites] Leuk Lymphoma. 2003 Dec;44(12):2089-93 [14959852.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1148-52 [16775174.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2002 Dec;10(4):316-21 [12607599.001]
  • [Cites] Lung Cancer. 2004 Dec;46(3):293-8 [15541813.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3369-72 [12067976.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):154-61 [15671540.001]
  • [Cites] Cancer Res. 2003 Feb 15;63(4):812-6 [12591731.001]
  • [Cites] Ann Diagn Pathol. 2003 Feb;7(1):1-8 [12616467.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3712-8 [11090051.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):571-5 [15767331.001]
  • [Cites] Genes Immun. 2002 Jun;3(4):229-32 [12058259.001]
  • [Cites] Urology. 2005 Jan;65(1):70-5 [15667866.001]
  • [Cites] Int J Cancer. 2003 Sep 10;106(4):468-71 [12845639.001]
  • (PMID = 19649652.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


24. CpG 7909: PF 3512676, PF-3512676. Drugs R D; 2006;7(5):312-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CpG 7909, acting through the TLR9 receptor present in B cells and plasmacytoid dendritic cells, stimulates human B-cell proliferation, enhances antigen-specific antibody production and induces interferon-alpha production, interleukin-10 secretion and natural killer cell activity.
  • In 2002, GlaxoSmithKline (GSK) was granted a worldwide, non-exclusive licence to Coley's CpG immunostimulatory oligonucleotides, including CpG 7909 [VaxImmune], for their use as adjuvants for cancer vaccines.
  • A phase I/II trial in patients with NHL has also been conducted in 24 patients with relapsed or refractory disease at the University of Iowa.
  • These trials are evaluating CpG 7909 in combination with chemotherapy versus chemotherapy alone as a first-line treatment for patients with advanced (stage IIIb or IV) non-small-cell lung cancer (NSCLC).
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Oligodeoxyribonucleotides / administration & dosage. Oligodeoxyribonucleotides / adverse effects
  • [MeSH-minor] Adjuvants, Immunologic / administration & dosage. Adjuvants, Immunologic / adverse effects. Anthrax Vaccines / administration & dosage. Anthrax Vaccines / adverse effects. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Clinical Trials, Phase I as Topic. Humans. Rituximab. Toll-Like Receptor 9 / agonists

  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16922592.001).
  • [ISSN] 1174-5886
  • [Journal-full-title] Drugs in R&D
  • [ISO-abbreviation] Drugs R D
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Anthrax Vaccines; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Oligodeoxyribonucleotides; 0 / ProMune; 0 / TLR9 protein, human; 0 / Toll-Like Receptor 9; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 14
  •  go-up   go-down


25. Khan F, Bauer F, Gazi G, Bilgrami S: Regression of large B-cell non-Hodgkin's lymphoma of stomach with HAART: case report and review. Leuk Lymphoma; 2006 Apr;47(4):750-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of large B-cell non-Hodgkin's lymphoma of stomach with HAART: case report and review.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Stomach Neoplasms / drug therapy


26. Xie XT, Jiang SY, Li BS, Yang LL: [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine]. Zhonghua Er Ke Za Zhi; 2008 Apr;46(4):276-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: It has been reported that high-dose cytarabine (HD-AraC) was very effective for childhood hematological malignancies, especially for improving the long-term survival of high-risk acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and T-cell lymphoid malignancies (T-ALL, T-cell non-Hodgkin's lymphoma).
  • METHODS: The drug levels of Ara-C in plasma and cerebrospinal fluid were detected with HPLC while HD-AraC was used, the expression of deoxycytidine kinase (dCK) and cytidine deaminase (CDA) mRNA in human leukemia cell lines and the bone marrow cells were investigated in 48 cases of childhood hematological malignancies with RT-PCR methods, and the relationship between the expression of these enzymes mRNA and the outcome of the patients was analyzed. RESULTS:.
  • There were no significant differences in expressions of dCK in T-ALL and B lineage ALL. (3) In vitro study found that the expressions of dCK and CDA mRNA did not change in leukemia cell lines incubated at different doses and times of Ara-C.
  • [MeSH-minor] Child. Cytidine Deaminase / genetics. Deoxycytidine Kinase / genetics. Gene Expression. Humans. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / metabolism. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / genetics. Lymphoma, Non-Hodgkin / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19099730.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; EC 2.7.1.74 / Deoxycytidine Kinase; EC 3.5.4.5 / Cytidine Deaminase
  •  go-up   go-down


27. Yamamoto R, Hashiguchi K, Iwai A, Satoh S, Hanaoka N, Okudaira K, Inoue T, Miyazaki J, Matsuzaki K, Tsuzuki Y, Kawaguchi A, Nagao S, Itoh K, Miura S, Hatano B: [A case of secondary non-Hodgkin's lymphoma of the colon after the treatment for Hodgkin's disease]. Nihon Shokakibyo Gakkai Zasshi; 2005 Jan;102(1):53-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of secondary non-Hodgkin's lymphoma of the colon after the treatment for Hodgkin's disease].
  • [MeSH-major] Colonic Neoplasms / etiology. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / etiology. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Female. Humans. Peripheral Blood Stem Cell Transplantation. Prednisone / administration & dosage. Procarbazine / administration & dosage. Radiotherapy Dosage. Remission Induction. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15682817.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; COPP protocol
  •  go-up   go-down


28. Andréasson U, Ek S, Merz H, Rosenquist R, Andersen N, Jerkeman M, Dictor M, Borrebaeck CA: B cell lymphomas express CX3CR1 a non-B cell lineage adhesion molecule. Cancer Lett; 2008 Feb 8;259(2):138-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B cell lymphomas express CX3CR1 a non-B cell lineage adhesion molecule.
  • To study the differential expression of cell membrane-bound receptors and their potential role in growth and/or survival of the tumor cells, highly purified follicular lymphoma cells were analyzed, using gene expression analysis, and compared to non-malignant B cell populations.
  • Filtering the genome for overexpressed genes coding for cell membrane-bound proteins/receptors resulted in a hit list of 27 identified genes.
  • Among these, we have focused on the aberrant over expression of CX3CR1, in different types of B cell lymphoma, as compared to non-malignant B cells.
  • We show that CX3CR1, which normally is not expressed on B cells, is expressed both at the mRNA and protein level in several subtypes of lymphoma.
  • CX3CR1 has also shown to be involved in the homing to specific tissues that express the ligand, CX3CL1, in breast and prostate cancer and may thus be involved in dissemination of lymphoma.
  • [MeSH-major] B-Lymphocytes / immunology. Lymphoma, Follicular / immunology. Lymphoma, Mantle-Cell / immunology. Palatine Tonsil / immunology. Receptors, Chemokine / analysis
  • [MeSH-minor] Cell Separation. Flow Cytometry. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Humans. Oligonucleotide Array Sequence Analysis. RNA, Messenger / analysis

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18060687.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / CX3CR1 protein, human; 0 / RNA, Messenger; 0 / Receptors, Chemokine
  •  go-up   go-down


29. Hara T, Omura-Minamisawa M, Chao C, Nakagami Y, Ito M, Inoue T: Bcl-2 inhibitors potentiate the cytotoxic effects of radiation in Bcl-2 overexpressing radioresistant tumor cells. Int J Radiat Oncol Biol Phys; 2005 Feb 1;61(2):517-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2 inhibitors potentiate the cytotoxic effects of radiation in Bcl-2 overexpressing radioresistant tumor cells.
  • PURPOSE: Bcl-2, an inhibitor of apoptosis frequently shows elevated expression in human tumors, thus resulting in resistance to radiation therapy.
  • Therefore, inhibiting Bcl-2 function may enhance the radiosensitivity of tumor cells.
  • Tetrocarcin A (TC-A) and bcl-2 antisense oligonucleotides exhibit antitumor activity by inhibiting Bcl-2 function and transcription, respectively.
  • We investigated whether these antitumor agents would enhance the cytotoxic effects of radiation in tumor cells overexpressing Bcl-2.
  • METHODS AND MATERIALS: We used HeLa/bcl-2 cells, a stable Bcl-2-expressing cell line derived from wild-type HeLa (HeLa/wt) cells.
  • Cells were incubated with TC-A and bcl-2 antisense oligonucleotides for 24 h after irradiation, and cell viability was then determined.
  • Apoptotic cells were quantified by flow cytometric assay.
  • RESULTS: The HeLa/bcl-2 cells were more resistant to radiation than HeLa/wt cells.
  • At concentrations that are not inherently cytotoxic, both TC-A and bcl-2 antisense oligonucleotides increased the cytotoxic effects of radiation in HeLa/bcl-2 cells, but not in HeLa/wt cells.
  • However, in HeLa/bcl-2 cells, additional treatment with TC-A in combination with radiation did not significantly increase apoptosis.
  • CONCLUSIONS: The present results suggest that TC-A and bcl-2 antisense oligonucleotides reduce radioresistance of tumor cells overexpressing Bcl-2.
  • Therefore, a combination of radiotherapy and Bcl-2 inhibitors may prove to be a useful therapeutic approach for treating tumors that overexpress Bcl-2.
  • [MeSH-major] Aminoglycosides / pharmacology. Apoptosis. Oligonucleotides, Antisense / pharmacology. Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors. Radiation Tolerance / drug effects. Radiation-Sensitizing Agents / pharmacology
  • [MeSH-minor] Analysis of Variance. Cell Survival / drug effects. Cell Survival / radiation effects. HeLa Cells / drug effects. HeLa Cells / metabolism. HeLa Cells / radiation effects. Humans. RNA, Messenger / antagonists & inhibitors. Tumor Stem Cell Assay

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667975.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Oligonucleotides, Antisense; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / Radiation-Sensitizing Agents; 73666-84-9 / tetrocarcin A
  •  go-up   go-down


30. Vose JM: Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach. Hematol Oncol; 2006 Jun;24(2):47-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach.
  • In patients with B-cell lymphomas, particularly indolent lymphoma, the use of passive immunotherapy, such as the anti-CD20 monoclonal antibody rituximab, has made an impressive impact on patient outcome.
  • Personalized immunotherapy, a method that triggers the immune system to mount a response against tumor cells, has shown promising results in early clinical trials in hematologic malignancies.
  • Currently, 3 large phase III studies are evaluating the efficacy and safety of personalized immunotherapy in patients with follicular lymphoma.
  • It is hoped that the results of these studies will lead to the incorporation of this promising approach into the standard treatment of patients with lymphoma.
  • [MeSH-major] Cancer Vaccines. Hodgkin Disease / immunology. Immunotherapy / methods
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. Humans

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16447298.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cancer Vaccines; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  • [Number-of-references] 64
  •  go-up   go-down


31. Kvansakul M, Yang H, Fairlie WD, Czabotar PE, Fischer SF, Perugini MA, Huang DC, Colman PM: Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. Cell Death Differ; 2008 Oct;15(10):1564-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands.
  • Some viruses express proteins homologous in sequence and function to mammalian pro-survival Bcl-2 proteins.
  • Anti-apoptotic F1L expressed by vaccinia virus is essential for survival of infected cells, but it bears no discernable sequence homology to proteins other than its immediate orthologues in related pox viruses.
  • Here we report that the crystal structure of F1L reveals a Bcl-2-like fold with an unusual N-terminal extension.
  • Structural comparison of F1L with other Bcl-2 family members reveals a novel sequence signature that redefines the BH4 domain as a structural motif present in both pro- and anti-apoptotic Bcl-2 members, including viral Bcl-2-like proteins.
  • [MeSH-major] Protein Structure, Quaternary. Protein Structure, Tertiary. Proto-Oncogene Proteins c-bcl-2 / chemistry. Viral Proteins / chemistry. Viral Proteins / metabolism


32. Paoluzzi L, Gonen M, Bhagat G, Furman RR, Gardner JR, Scotto L, Gueorguiev VD, Heaney ML, Manova K, O'Connor OA: The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood; 2008 Oct 1;112(7):2906-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Overexpression of antiapoptotic members of the Bcl-2 family is observed in approximately 80% of B-cell lymphomas, contributing to intrinsic and acquired drug resistance.
  • ABT-737 is a BH3-only mimetic and potent inhibitor of the antiapoptotic Bcl-2 family members Bcl-2, Bcl-X(L), and Bcl-w.
  • In vitro, ABT-737 exhibited concentration-dependent cytotoxicity against a broad panel of lymphoma cell lines including mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL).
  • ABT-737 showed synergism when combined with the proteasome inhibitors bortezomib or carfilzomib in select lymphoma cell lines and induced potent mitochondrial membrane depolarization and apoptosis when combined with either.
  • ABT-737 plus bortezomib also induced significant apoptosis in primary samples of MCL, DLBCL, and chronic lymphocytic leukemia (CLL) but no significant cytotoxic effect was observed in peripheral blood mononuclear cells from healthy donors.
  • Collectively, these data suggest that ABT-737 alone or in combination with a proteasome inhibitor represents a novel and potentially important platform for the treatment of B-cell malignancies.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Biphenyl Compounds / pharmacology. Enzyme Inhibitors / pharmacology. Lymphoma / enzymology. Lymphoma / pathology. Molecular Mimicry / drug effects. Nitrophenols / pharmacology. Proteasome Inhibitors. Sulfonamides / pharmacology
  • [MeSH-minor] Animals. Boronic Acids / pharmacology. Bortezomib. Cell Death / drug effects. Cell Line, Tumor. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm / drug effects. Drug Synergism. Health. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukocytes, Mononuclear / drug effects. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Mantle-Cell / pathology. Membrane Potential, Mitochondrial / drug effects. Mice. Microscopy, Confocal. Piperazines / pharmacology. Proto-Oncogene Proteins c-bcl-2 / metabolism. Pyrazines / pharmacology. Tissue Donors. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18591385.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABT-737; 0 / Antineoplastic Agents; 0 / Biphenyl Compounds; 0 / Boronic Acids; 0 / Enzyme Inhibitors; 0 / Nitrophenols; 0 / Piperazines; 0 / Proteasome Inhibitors; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Pyrazines; 0 / Sulfonamides; 69G8BD63PP / Bortezomib
  •  go-up   go-down


33. Takakuwa T, Miyauchi A, Aozasa K: Aberrant somatic hypermutations in thyroid lymphomas. Leuk Res; 2009 May;33(5):649-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant somatic hypermutations in thyroid lymphomas.
  • To determine a possible role of aberrant somatic hypermutation (ASHM) in the pathogenesis of thyroid lymphoma (TL), mutational status of genes affected by ASHM, including c-MYC, PIM-1, PAX-5 and RhoH/TTF, was analyzed.
  • Tumor specimens from 33 patients with thyroid B-cell lymphoma and 14 with chronic lymphocytic thyroiditis (CLTH), an autoimmune thyroiditis known to provide a basis for TL development, was examined.
  • Occurrence of ASHM in PIM-1, RhoH/TTF, and c-MYC was a constant finding in follicular lymphoma (FL) (all of 11 cases) but not so frequent in diffuse large B-cell lymphoma (DLBCL) (4 (33.3%) of 12 cases) and Marginal zone B-cell lymphoma (MZBCL) (1 (10.0%) of 10 cases).
  • [MeSH-major] Lymphoma, Non-Hodgkin / genetics. Mutation. Thyroid Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19019431.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


34. Chang PM, Chen PM, Hsieh SL, Tzeng CH, Liu JH, Chiou TJ, Wang WS, Yen CC, Gau JP, Yang MH: Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome. Int J Oncol; 2008 Sep;33(3):549-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome.
  • It is regarded as a decoy receptor released from tumor cells to escape host immune response by neutralizing the cytotoxic and immunomodulatory effects of FasL, LIGHT and TL1A.
  • Overexpression of DcR3 has been observed in several human malignancies; however, only limited information exists on the role of DcR3 in non-Hodgkin lymphoma especially for B-cell origin.
  • In the current study, the expression profile of DcR3 was analyzed by RT-PCR and immunohistochemistry (IHC) in a set of lymphoma cell lines including T-cell and B-cell lymphomas.
  • The result demonstrated that overexpression of DcR3 was detected in most T-cell lymphoma cells, which was consistent with previous reports.
  • Interestingly, overexpression of DcR3 was also detected both in the B-cell lymphoma cell lines and diffuse large B cell lymphoma (DLBCL) patients.
  • An in vitro study showed that neutralization of DcR3 increased the percentage of doxorubicin-mediated apoptosis in two B-cell lymphoma cell lines, which indicated the possibility of DcR3 mediated chemo-resistance in B-cell lymphomas.
  • We suggest that overexpression of DcR3 is associated with a worse prognosis in DLBCL and the possible mechanism may act through the increase of chemo-resistance of lymphoma cells.
  • [MeSH-major] Biomarkers, Tumor / analysis. Drug Resistance, Neoplasm / genetics. Lymphoma, Large B-Cell, Diffuse / metabolism. Receptors, Tumor Necrosis Factor, Member 6b / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Gene Expression. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymphoma, T-Cell / metabolism. Lymphoma, T-Cell / mortality. Lymphoma, T-Cell / pathology. Male. Middle Aged. Prednisone / therapeutic use. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18695885.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Tumor Necrosis Factor, Member 6b; 0 / TNFRSF6B protein, human; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


35. Utkan G, Tek I, Kocer M, Muallaoglu S, Durnal AG, Arslan UY, Celenkoglu G, Tokluoglu S, Alkis N: Blood viscosity in patients with diffuse large B cell non-Hodgkin's lymphoma. Exp Oncol; 2006 Dec;28(4):326-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blood viscosity in patients with diffuse large B cell non-Hodgkin's lymphoma.
  • The aim of the study was to evaluate blood viscosity as possible marker of disease progression in patients with newly diagnosed non-Hodgkin's lymphoma (NHL).
  • [MeSH-major] Blood Viscosity. Lymphoma, B-Cell / blood. Lymphoma, Large B-Cell, Diffuse / blood

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17285120.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  •  go-up   go-down


36. Hirose A, Yamane T, Nakajima Y, Manabe M, Kanashima H, Hagihara K, Sakamoto E, Nakamae M, Terada Y, Kosaka S, Aoyama Y, Sakamoto C, Kumura T, Koh KR, Hirai M, Ohta K, Nakao Y, Mugitani A, Teshima H, Hino M: [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma]. Gan To Kagaku Ryoho; 2005 Dec;32(13):2059-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma].
  • To evaluate the results of high-dose chemotherapy (HDT) and autologous hematopoietic stem cell transplantation (ASCT) in patients with diffuse B-cell aggressive non-Hodgkin's lymphoma(NHL).
  • The 5-year probability of disease-free survival for patients in the low-risk group and in the high-risk group was 68.8% and 60.0%,respectively (p = 0.9 6).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Transplantation, Autologous
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Nitrosourea Compounds / administration & dosage. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16352929.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Nitrosourea Compounds; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; RYH2T97J77 / ranimustine
  •  go-up   go-down


37. Hajdu M, Kopper L, Sebestyén A: Notch-regulation upon Dll4-stimulation of TGFb-induced apoptosis and gene expression in human B-cell non-Hodgkin lymphomas. Scand J Immunol; 2010 Jan;71(1):29-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notch-regulation upon Dll4-stimulation of TGFb-induced apoptosis and gene expression in human B-cell non-Hodgkin lymphomas.
  • Notch-signalling has been implicated as a pathogenetic factor and a therapeutical target in T-cell leukaemias and in some lymphomas of B-cell origin.
  • Our aim was to investigate the role of Notch-signalling in apoptosis regulation in human non-Hodgkin B-cell lymphoma (B-NHL) cell lines and in primary chronic lymhocytic leukaemia (CLL) cells using Delta-like 4 (Dll4) ligand mediated Notch activation and gamma-secretase inhibitor (GSI) mediated Notch inhibition in vitro.
  • Modulation of Notch-signalling by itself did not change the rate of apoptosis in B-NHL cell lines and in CLL cells.
  • TGFb-induced apoptosis was decreased - but not completely abolished - by GSI in TGFb-sensitive cell lines, but resistance to the apoptotic effects of TGFb were not reversed by Notch activation or inhibition.
  • We identified Hairy/Enhancer of Split (HES)-1 as a TGFb target gene in selected - TGFb-sensitive - B-NHL cell lines.
  • [MeSH-major] Apoptosis / drug effects. Intercellular Signaling Peptides and Proteins / pharmacology. Lymphoma, B-Cell / pathology. Receptors, Notch / physiology. Transforming Growth Factor beta / pharmacology
  • [MeSH-minor] Amyloid Precursor Protein Secretases / antagonists & inhibitors. Basic Helix-Loop-Helix Transcription Factors / genetics. Cell Line, Tumor. Dipeptides / pharmacology. Gene Expression Regulation, Neoplastic / drug effects. Homeodomain Proteins / genetics. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Repressor Proteins / genetics. Signal Transduction

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20017807.001).
  • [ISSN] 1365-3083
  • [Journal-full-title] Scandinavian journal of immunology
  • [ISO-abbreviation] Scand. J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DLL4 protein, human; 0 / Dipeptides; 0 / HEY2 protein, human; 0 / Homeodomain Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester; 0 / Receptors, Notch; 0 / Repressor Proteins; 0 / Transforming Growth Factor beta; 149348-15-2 / HES1 protein, human; EC 3.4.- / Amyloid Precursor Protein Secretases
  •  go-up   go-down


38. Cypel M, Belfort R Jr, Moraes N, Muccioli C: [Primary intraocular B-cell lymphoma: case report]. Arq Bras Oftalmol; 2007 Jul-Aug;70(4):709-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary intraocular B-cell lymphoma: case report].
  • [Transliterated title] Linfoma intra-ocular primário de células tipo B: relato de caso.
  • Ocular non-Hodgkin's lymphoma is a rare condition that can involve the retina, the vitreous and the optic nerve.
  • It can occur alone or can be associated with lymphoma of the central nervous system and a frequent manifestation is a posterior uveitis of difficult treatment.
  • This kind of ocular tumor is difficult and a challenge to diagnosis.
  • We describe a case of non-Hodgkin's intraocular B-cell lymphoma in a 47-year-old woman who had a posterior uveitis as the first manifestation.
  • We emphasize the importance of a careful investigation and of the general clinical examination since this is the most common type in the eye.
  • We expect to call the attention to this disease that many times appears in an unspecific form with unspecific symptoms.
  • [MeSH-major] Eye Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis
  • [MeSH-minor] Female. Humans. Lymphoma, Non-Hodgkin / diagnosis. Middle Aged. Uveitis / diagnosis

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17906772.001).
  • [ISSN] 0004-2749
  • [Journal-full-title] Arquivos brasileiros de oftalmologia
  • [ISO-abbreviation] Arq Bras Oftalmol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


39. Lin P, Jetly R, Lennon PA, Abruzzo LV, Prajapati S, Medeiros LJ: Translocation (18;22)(q21;q11) in B-cell lymphomas: a report of 4 cases and review of the literature. Hum Pathol; 2008 Nov;39(11):1664-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocation (18;22)(q21;q11) in B-cell lymphomas: a report of 4 cases and review of the literature.
  • Follicular lymphomas characteristically carry t(14;18)(q32;q21) which results in IGH-BCL-2 fusion.
  • Variant translocations that juxtapose the BCL-2 gene with the immunoglobulin kappa (2p11) and lambda (22q11) light chain genes are rare.
  • We report 4 cases of B-cell lymphoma/leukemia associated with t(18;22)(q21;q11).
  • Three cases were classified as chronic lymphocytic leukemia, and one as follicular lymphoma based on morphology and immunophenotype.
  • Fluorescence in situ hybridization analysis was performed on all 4 cases using a BCL-2 breakapart probe.
  • The BCL-2 gene was rearranged in all cases.
  • These cases illustrate that t(18;22)(q21;q11) is more commonly observed in chronic lymphocytic leukemia and may represent either an initial or secondary genetic event.
  • [MeSH-major] Chromosomes, Human, Pair 18. Chromosomes, Human, Pair 22. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymphoma, B-Cell / genetics
  • [MeSH-minor] Aged. Fatal Outcome. Female. Gene Rearrangement, B-Lymphocyte. Genes, bcl-2. Humans. Male. Middle Aged. Translocation, Genetic

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656237.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


40. Autorino R, Lamendola MG, De Sio M, Di Trolio RA, Ferraraccio F, Di Lorenzo G: A complete response with rituximab in metastatic diffuse large B-cell lymphoma of the testis: case report. Int J Immunopathol Pharmacol; 2007 Apr-Jun;20(2):401-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A complete response with rituximab in metastatic diffuse large B-cell lymphoma of the testis: case report.
  • Primary testicular lymphoma is an uncommon testicular tumour.
  • We present a case of a primary non-Hodgkin lymphoma of the testis, describing its clinical and pathological features and discussing our treatment strategy.
  • Light microscopy demonstrated the classic appearance of a diffuse large B-cell lymphoma.
  • The immunohistochemical study showed tumour cells intensively positive for CD45, Ki67 and CD20.
  • No evidence of extra-testicular involvement by lymphoma was found.
  • At 6 months, a TC-PET showed a clinical relapse in lung and abdominal lymphonodes, while clinical examination demonstrated a single, indolent and erythematous nodule in the left foot.
  • The histologic analysis confirmed diagnosis of CD-20 positive B-cell lymphoma.
  • After 3 months a complete response was observed in all sites of disease.
  • The patient was free from disease at 12 months follow-up.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antineoplastic Agents / pharmacology. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Testicular Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17624254.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


41. Meyer J, Delay J, Bienzle D: Clinical, laboratory, and histopathologic features of equine lymphoma. Vet Pathol; 2006 Nov;43(6):914-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical, laboratory, and histopathologic features of equine lymphoma.
  • Clinical, laboratory and tissue findings from 37 horses with lymphoma were investigated.
  • Tumor cell morphology was heterogeneous in 17 tumors, and 8 tumors had marked histiocytic and multinucleated giant cell infiltrates.
  • Extensive necrosis or focal fibrosis was present in 22 and 4 lymphomas, respectively.
  • Staining of tumor sections with antibodies against CD3 and CD79alpha molecules resulted in classification of T-cell (n = 26) or B-cell (n = 7) origin.
  • Most T-cell tumors comprised small to medium CD3(+) lymphocytes, whereas 5 of 7 B-cell tumors were infiltrated by numerous small T lymphocytes and classified as T-cell-rich B-cell lymphoma.
  • Fresh tumor cells from 6 horses bound antibodies reactive with equine CD4, CD5, CD8, CD21, or major histocompatibility class II molecules, confirming T-cell (n = 5) or B-cell origin (n = 1).
  • These findings suggest that T-cell lymphoma is more common than B-cell lymphoma in horses and that inflammation, possibly from tumor cytokine production, is frequent.
  • [MeSH-major] Horse Diseases / pathology. Lymphoma / veterinary

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17099148.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Chang CM, Schroeder JC, Huang WY, Dunphy CH, Baric RS, Olshan AF, Dorsey KC, Dent GA, Cerhan JR, Lynch CF, Rothman N, Cantor KP, Blair A: Non-Hodgkin lymphoma (NHL) subtypes defined by common translocations: utility of fluorescence in situ hybridization (FISH) in a case-control study. Leuk Res; 2010 Feb;34(2):190-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin lymphoma (NHL) subtypes defined by common translocations: utility of fluorescence in situ hybridization (FISH) in a case-control study.
  • We used fluorescence in situ hybridization (FISH) assays to identify t(14;18) translocations in archival paraffin-embedded tumor sections from non-Hodgkin lymphoma (NHL) cases enrolled in a population-based study. t(14;18) was identified in 54% of 152 cases, including 39% of diffuse large cell lymphomas (26 of 66 cases) and 84% of follicular lymphomas (36 of 43 cases).
  • Eighty-seven percent of t(14;18)-positive cases and 57% of t(14;18)-negative cases expressed bcl-2.
  • FISH assays detected twice as many t(14;18)-positive follicular lymphomas as PCR assays.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • [Cites] Cancer Genet Cytogenet. 2003 May;143(1):73-9 [12742158.001]
  • [Cites] Arch Pathol Lab Med. 2008 Aug;132(8):1355-61 [18684042.001]
  • [Cites] Int J Hematol. 2003 Aug;78(2):154-9 [12953811.001]
  • [Cites] Cancer. 2003 Dec 25;99(6):385-93 [14681948.001]
  • [Cites] Pathology. 2004 Feb;36(1):19-44 [14757555.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Apr 1;150(1):22-6 [15041219.001]
  • [Cites] Am J Pathol. 2004 Jul;165(1):159-66 [15215171.001]
  • [Cites] Histopathology. 2004 Nov;45(5):501-10 [15500654.001]
  • [Cites] J Natl Cancer Inst. 1987 Apr;78(4):675-8 [3470542.001]
  • [Cites] J Natl Cancer Inst. 1987 Jun;78(6):1137-44 [3473254.001]
  • [Cites] Am J Public Health. 1988 May;78(5):570-1 [3354743.001]
  • [Cites] Cancer Res. 1990 Oct 15;50(20):6585-91 [2208120.001]
  • [Cites] Arch Environ Health. 1991 Mar-Apr;46(2):70-4 [2006896.001]
  • [Cites] Leuk Res. 1991;15(5):305-14 [2046383.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5522s-5528s [1394167.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5529s-5540s [1394168.001]
  • [Cites] Am J Ind Med. 1993 Feb;23(2):301-12 [8427258.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):963-9 [8622046.001]
  • [Cites] Blood Cells Mol Dis. 1998 Mar;24(1):62-72 [9616042.001]
  • [Cites] Cancer Sci. 2005 Feb;96(2):77-82 [15723651.001]
  • [Cites] Leukemia. 2005 Jun;19(6):1058-63 [15815725.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1067-73 [16006802.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3179-82 [16101124.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):421-9 [16191511.001]
  • [Cites] Eur J Haematol. 2006 Apr;76(4):284-93 [16519699.001]
  • [Cites] Cancer. 2006 Jun 25;108(3):198-204 [16671111.001]
  • [Cites] Mod Pathol. 2006 Aug;19(8):1027-33 [16680153.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1363-9 [16621961.001]
  • [Cites] Hum Pathol. 2007 Feb;38(2):365-72 [17134735.001]
  • [Cites] Am J Epidemiol. 2007 Mar 15;165(6):652-9 [17204518.001]
  • [Cites] Leuk Res. 2008 May;32(5):737-42 [17964648.001]
  • [Cites] Cancer Causes Control. 2008 Oct;19(8):859-67 [18386141.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5456s-5462s; discussion 5462s-5464s [1394154.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Jan;27(1):85-94 [10564590.001]
  • [Cites] Arch Pathol Lab Med. 1999 Dec;123(12):1189-207 [10583924.001]
  • [Cites] Br J Haematol. 2001 May;113(2):383-90 [11380403.001]
  • [Cites] Epidemiology. 2001 Nov;12(6):701-9 [11679800.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2285-90 [11895757.001]
  • [Cites] Cancer Causes Control. 2002 Mar;13(2):159-68 [11936822.001]
  • [Cites] Leukemia. 2003 Jan;17(1):255-9 [12529690.001]
  • [Cites] J Mol Diagn. 2003 Aug;5(3):168-75 [12876207.001]
  • (PMID = 19505720.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES010126; United States / NCI NIH HHS / CA / R21 CA107966-01; United States / NICHD NIH HHS / HD / R24 HD050924; United States / NCI NIH HHS / CA / R03 CA71617-01; United States / NIEHS NIH HHS / ES / P30ES10126; United States / NCI NIH HHS / CA / CA107966-01
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2
  • [Other-IDs] NLM/ NIHMS157999; NLM/ PMC2815151
  •  go-up   go-down


43. Westphal D, Ledgerwood EC, Hibma MH, Fleming SB, Whelan EM, Mercer AA: A novel Bcl-2-like inhibitor of apoptosis is encoded by the parapoxvirus ORF virus. J Virol; 2007 Jul;81(13):7178-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel Bcl-2-like inhibitor of apoptosis is encoded by the parapoxvirus ORF virus.
  • Apoptotic cell death forms part of the host defense against virus infection.
  • We tested orf virus, a member of the poxvirus family, for the ability to inhibit apoptosis and found that orf virus-infected cells were fully resistant to UV-induced changes in cell morphology, caspase activation, and DNA fragmentation.
  • These features are comparable to the antiapoptotic properties of the mitochondrial regulator Bcl-2.
  • Furthermore, bioinformatic analyses revealed sequence and secondary-structure similarities to Bcl-2 family members, including characteristic residues of all four Bcl-2 homology domains.
  • Consistent with this, the viral protein inhibited the UV-induced activation of the proapoptotic Bcl-2 family members Bax and Bak.
  • ORFV125 is the first parapoxvirus apoptosis inhibitor to be identified, and we propose that it is a new antiapoptotic member of the Bcl-2 family.
  • [MeSH-minor] Apoptosis. Caspases / metabolism. DNA Fragmentation / radiation effects. Enzyme Activation / genetics. Enzyme Activation / radiation effects. HeLa Cells. Humans. JNK Mitogen-Activated Protein Kinases / metabolism. Mitochondria / metabolism. Protein Structure, Secondary. Protein Structure, Tertiary. Ultraviolet Rays. bcl-2 Homologous Antagonist-Killer Protein / genetics. bcl-2 Homologous Antagonist-Killer Protein / metabolism. bcl-2-Associated X Protein / genetics. bcl-2-Associated X Protein / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 May 15;60(10):2666-72 [10825139.001]
  • [Cites] J Virol. 2004 Jan;78(1):353-66 [14671117.001]
  • [Cites] J Gen Virol. 2000 Nov;81(Pt 11):2803-11 [11038395.001]
  • [Cites] Protein Sci. 2000 Dec;9(12):2528-34 [11206074.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3012-7 [11248023.001]
  • [Cites] Mol Biol Cell. 2002 May;13(5):1615-25 [12006657.001]
  • [Cites] Curr Opin Microbiol. 2002 Aug;5(4):395-402 [12160859.001]
  • [Cites] Genes Dev. 2002 Oct 1;16(19):2465-78 [12368257.001]
  • [Cites] J Gen Virol. 2000 Apr;81(Pt 4):1087-97 [10725436.001]
  • [Cites] J Virol. 2000 Apr;74(8):3815-31 [10729156.001]
  • [Cites] J Exp Med. 2000 May 1;191(9):1487-98 [10790424.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 1;1644(2-3):83-94 [14996493.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 1;1644(2-3):95-105 [14996494.001]
  • [Cites] J Virol. 2004 Jul;78(13):7097-111 [15194786.001]
  • [Cites] Science. 2004 Jul 30;305(5684):626-9 [15286356.001]
  • [Cites] Arch Virol. 1982;71(1):43-55 [6279055.001]
  • [Cites] Nucleic Acids Res. 1987 Sep 11;15(17):7192 [2821498.001]
  • [Cites] Arch Virol. 1988;101(3-4):255-9 [3178493.001]
  • [Cites] J Virol. 1994 Dec;68(12):7728-37 [7966562.001]
  • [Cites] Nature. 1996 May 23;381(6580):335-41 [8692274.001]
  • [Cites] Cell. 1996 Jul 12;86(1):147-57 [8689682.001]
  • [Cites] Science. 1997 Feb 14;275(5302):983-6 [9020082.001]
  • [Cites] Oncogene. 1997 Jan 30;14(4):405-14 [9053837.001]
  • [Cites] Virology. 1997 Mar 3;229(1):193-200 [9123861.001]
  • [Cites] Biochem J. 1998 Jan 1;329 ( Pt 1):95-9 [9405280.001]
  • [Cites] Virology. 1998 May 10;244(2):365-96 [9601507.001]
  • [Cites] Virus Genes. 1998;17(2):107-15 [9857983.001]
  • [Cites] Trends Microbiol. 1999 Apr;7(4):160-5 [10217831.001]
  • [Cites] Curr Opin Cell Biol. 2004 Dec;16(6):647-52 [15530776.001]
  • [Cites] J Virol. 2005 Jan;79(2):1084-98 [15613337.001]
  • [Cites] Bioinformatics. 2005 Apr 1;21(7):951-60 [15531603.001]
  • [Cites] Cancer Biol Ther. 2005 Feb;4(2):139-63 [15725726.001]
  • [Cites] Biochem J. 2005 Jul 1;389(Pt 1):83-9 [15727562.001]
  • [Cites] FEBS Lett. 2005 Jul 4;579(17):3503-7 [15949801.001]
  • [Cites] J Virol. 2005 Nov;79(22):14031-43 [16254338.001]
  • [Cites] Curr Opin Cell Biol. 2005 Dec;17(6):617-25 [16243507.001]
  • [Cites] J Virol. 2006 Feb;80(3):1140-51 [16414991.001]
  • [Cites] Virus Res. 2006 Mar;116(1-2):146-58 [16274827.001]
  • [Cites] Cell Death Differ. 2006 Sep;13(9):1423-33 [16676004.001]
  • [Cites] Cell Death Differ. 2006 Oct;13(10):1651-62 [16439990.001]
  • [Cites] J Biol Chem. 2006 Dec 22;281(51):39728-39 [17074758.001]
  • [Cites] Mol Cell. 2007 Mar 23;25(6):933-42 [17386268.001]
  • [Cites] Oncogene. 2000 May 4;19(19):2286-95 [10822379.001]
  • [Cites] J Cell Biol. 2003 Jan 6;160(1):53-64 [12515824.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2432-7 [12591950.001]
  • [Cites] Cell Death Differ. 2003 Jan;10 Suppl 1:S68-76 [12655348.001]
  • [Cites] EMBO J. 2003 Apr 1;22(7):1497-507 [12660157.001]
  • [Cites] Bioessays. 2003 Sep;25(9):888-96 [12938178.001]
  • [Cites] J Cell Biol. 2003 Sep 1;162(5):877-87 [12952938.001]
  • [Cites] Immunity. 2003 Sep;19(3):341-52 [14499110.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14345-50 [14610284.001]
  • [Cites] J Virol. 2004 Jan;78(1):168-77 [14671098.001]
  • [Cites] Trends Cell Biol. 2000 Sep;10(9):369-77 [10932094.001]
  • (PMID = 17475653.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Inhibitor of Apoptosis Proteins; 0 / Viral Proteins; 0 / bcl-2 Homologous Antagonist-Killer Protein; 0 / bcl-2-Associated X Protein; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC1933275
  •  go-up   go-down


44. Horning SJ, Younes A, Jain V, Kroll S, Lucas J, Podoloff D, Goris M: Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol; 2005 Feb 1;23(4):712-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab.
  • PURPOSE: To determine overall response (OR) and complete response (CR) rates, response duration, progression-free (PFS) and overall survival and safety with the tositumomab and iodine-131 tositumomab ((131)I tositumomab) therapeutic regimen in patients with indolent, follicular large-cell, or transformed B-cell lymphoma, progressive after rituximab.
  • CONCLUSION: (131)I tositumomab is effective in CD20-positive lymphoma progressive after rituximab, with a 65% OR rate and median PFS of 24.5 months for responders.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, B-Cell / radiotherapy. Radioimmunotherapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15613695.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / iodine-131 anti-B1 antibody; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


45. Ascani S, Massone C, Ferrara G, Rongioletti F, Papini M, Pileri S, Cerroni L: CD4-negative variant of CD4+/CD56+ hematodermic neoplasm: description of three cases. J Cutan Pathol; 2008 Oct;35(10):911-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD4-negative variant of CD4+/CD56+ hematodermic neoplasm: description of three cases.
  • BACKGROUND: CD4+/CD56+ hematodermic neoplasm (HN) (blastic natural killer (NK)-cell lymphoma) is a rare entity characterized by dense, monomorphous infiltrates of medium-sized cells with blastic appearance and a characteristic immunophenotype (positivity for CD4, CD56 and CD123).
  • The term 'CD4+/CD56+ hematodermic neoplasm' adopted in the World Health Organization-European Organization for Research and Treatment of Cancer classification of cutaneous lymphomas may be misleading and should probably be revised in the light of all data published in the literature.
  • [MeSH-major] Antigens, CD4 / metabolism. Antigens, CD56 / metabolism. Killer Cells, Natural / pathology. Lymphoma, Non-Hodgkin / pathology. Skin Neoplasms / pathology


46. Xiao W, Li L, Zhou R, Xiao R, Wang Y, Ji X, Wu M, Wang L, Huang W, Zheng X, Tan X, Chen L, Xiong T, Xiong J, Jin Y, Tan J, He Y: EBV-induced human CD8(+) NKT cells synergise CD4(+) NKT cells suppressing EBV-associated tumours upon induction of Th1-bias. Cell Mol Immunol; 2009 Oct;6(5):367-79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV-induced human CD8(+) NKT cells synergise CD4(+) NKT cells suppressing EBV-associated tumours upon induction of Th1-bias.
  • CD8(+) natural killer T (NKT) cells from EBV-associated tumour patients are quantitatively and functionally impaired.
  • EBV-induced CD8(+) NKT cells drive syngeneic T cells into a Th1-bias response to suppress EBV-associated malignancies.
  • IL-4-biased CD4(+) NKT cells do not affect either syngeneic T cell cytotoxicity or Th cytokine secretion.
  • Circulating mDC1 cells from patients with EBV-associated malignancies impair the production of IFN-gamma by CD8(+) NKT cells.
  • In this study, we have established a human-thymus-SCID chimaera model to further investigate the underlying mechanism of EBV-induced CD8(+) NKT cells in suppressing EBV-associated malignancies.
  • In the human-thymus-SCID chimera, EBV-induced CD8(+) NKT cells suppress EBV-associated malignancies in a manner dependent on the Th1-bias response and syngeneic CD3(+) T cells.
  • However, adoptive transfer with CD4(+) NKT cells alone inhibits T cell immunity.
  • Interestingly, CD4(+) NKT cells themselves secrete high levels of IL-2, enhancing the persistence of adoptively transferred CD8(+) NKT cells and T cells, thereby leading to a more pronounced T cell anti-tumour response in chimaeras co-transferred with CD4(+) and CD8(+) NKT cells.
  • Thus, immune reconstitution with EBV-induced CD4(+) and CD8(+) NKT cells synergistically enhances T cell tumour immunity, providing a potential prophylactic and therapeutic treatment for EBV-associated malignancies.
  • [MeSH-major] Antigens, CD8 / immunology. Cytotoxicity, Immunologic. Epstein-Barr Virus Infections / immunology. Herpesvirus 4, Human / immunology. Hodgkin Disease / immunology. Hodgkin Disease / therapy. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / therapy. Nasopharyngeal Neoplasms / immunology. Nasopharyngeal Neoplasms / therapy. Natural Killer T-Cells / immunology. Th1 Cells / immunology
  • [MeSH-minor] Adoptive Transfer. Animals. Antigens, CD4 / immunology. Cell Line, Tumor. Chimera. Humans. Interferon-gamma / metabolism. Interleukin-2 / metabolism. Interleukin-4 / immunology. Lymphocyte Activation. Mice. Mice, SCID. T-Lymphocyte Subsets / immunology. T-Lymphocyte Subsets / metabolism

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cell Mol Immunol. 2011 Jul;8(4):368
  • (PMID = 19887050.001).
  • [ISSN] 2042-0226
  • [Journal-full-title] Cellular & molecular immunology
  • [ISO-abbreviation] Cell. Mol. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Antigens, CD8; 0 / Interleukin-2; 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC4003220
  •  go-up   go-down


47. Hariprasad R, Kumar L, Bhatla DM, Kukreja M, Papaiah S: Primary uterine lymphoma: report of 2 cases and review of literature. Am J Obstet Gynecol; 2006 Jul;195(1):308-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary uterine lymphoma: report of 2 cases and review of literature.
  • Primary uterine non-Hodgkin's lymphoma is a rare malignancy.
  • We here describe 2 patients who presented with cervical growth, stage IE, diffuse large B cell histology.
  • They achieved complete clinical and radiological response.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Radiotherapy Dosage. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16813759.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 30
  •  go-up   go-down


48. Trümper L, Zwick C, Ziepert M, Hohloch K, Schmits R, Mohren M, Liersch R, Bentz M, Graeven U, Wruck U, Hoffmann M, Metzner B, Hasenclever D, Loeffler M, Pfreundschuh M, German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL): Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens. Ann Oncol; 2008 Mar;19(3):538-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens.
  • BACKGROUND: To determine the maximum tolerated dose of a bi- and tri-weekly combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone plus etoposide (CHOEP) regimen without stem-cell support.
  • PATIENTS AND METHODS: Randomized phase I/II multicenter four-level (cyclophosphamide: 1000-1200-1400-1600 mg/m2; doxorubicin: 55-60-65-70 mg/m2; etoposide: 375-450-525-600 mg/m2) dose escalation study with CHOEP-14 and CHOEP-21 in young patients (18-60 years) with newly diagnosed aggressive non-Hodgkin's lymphoma.

  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212092.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


49. Al-Abbadi MA, Hattab EM, Tarawneh MS, Amr SS, Orazi A, Ulbright TM: Primary testicular diffuse large B-cell lymphoma belongs to the nongerminal center B-cell-like subgroup: A study of 18 cases. Mod Pathol; 2006 Dec;19(12):1521-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary testicular diffuse large B-cell lymphoma belongs to the nongerminal center B-cell-like subgroup: A study of 18 cases.
  • The most common type of primary testicular lymphoma is diffuse large B-cell type, which has the potential for aggressive clinical behavior.
  • Diffuse large B-cell lymphoma can be further subclassified into two major prognostic categories: germinal center B-cell-like and nongerminal center B-cell-like.
  • Such distinction is made possible using the immunohistochemical expression of CD10, Bcl-6 and MUM1.
  • The aim of this study was to stratify primary testicular lymphoma of the diffuse large B-cell type according to this scheme.
  • Immunohistochemical stains for CD10, Bcl-6 and MUM1 were performed on 18 cases of primary testicular lymphoma of diffuse large B-cell type.
  • Subclassification was carried out as previously described where CD10 and/or Bcl-6 positivity and negativity for MUM1 were considered indicative of germinal center B-cell-like type and the opposite expression as nongerminal center B-cell-like type.
  • Of 18 cases, 16 (89%) were found to belong to the nongerminal center B-cell-like type.
  • Two cases (11%) were classified as germinal center B-cell-like type; one had a CD10-positive, Bcl-6-positive and MUM1-negative profile, and the other was CD10 negative, Bcl-6 positive and MUM1 negative.
  • We conclude that most (89%) primary testicular lymphomas of the diffuse large B-cell type belong to the nongerminal center B-cell-like subgroup and have high proliferative activity.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Non-Hodgkin / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. DNA-Binding Proteins / analysis. Humans. Immunoenzyme Techniques. Interferon Regulatory Factors / analysis. Male. Middle Aged. Neoplasm Staging. Neprilysin / analysis. Prognosis. Survival Rate. Testis / chemistry. Testis / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16998463.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Interferon Regulatory Factors; 0 / interferon regulatory factor-4; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


50. Kohlhof JK, Driemel O, Müller-Richter UD: [Re-re-relapse of a MALT lymphoma of the conjunctiva]. Klin Monbl Augenheilkd; 2008 Aug;225(8):727-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Re-re-relapse of a MALT lymphoma of the conjunctiva].
  • BACKGROUND: The MALT lymphoma (mucosa-associated lymphoid-like tissue lymphomas) is a rare entity and belongs to the low-grade non-Hodgkin (NHL) lymphomas.
  • In some cases a MALT lymphoma of the conjunctiva is misdiagnosed as chronic conjunctivitis.
  • Mostly a MALT lymphoma of the conjunctiva can be cured by radiation and has a good prognosis.
  • The medical history revealed treatment for a MALT lymphoma 4 years previously and a relapse 3 years previously.
  • CLINICAL COURSE: To confirm the diagnosis a biopsy was done.
  • The histological examination demonstrated a relapse of the MALT lymphoma.
  • CONCLUSION: This case shows that a relapse of the MALT lymphoma may arise although the previous tumour and its relapse were resected totally.
  • [MeSH-major] Conjunctival Neoplasms / diagnosis. Lymphoma, B-Cell, Marginal Zone / diagnosis. Neoplasm Recurrence, Local / diagnosis

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18712659.001).
  • [ISSN] 1439-3999
  • [Journal-full-title] Klinische Monatsblätter für Augenheilkunde
  • [ISO-abbreviation] Klin Monbl Augenheilkd
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


51. Li B, Shi S, Qian W, Zhao L, Zhang D, Hou S, Zheng L, Dai J, Zhao J, Wang H, Guo Y: Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Res; 2008 Apr 1;68(7):2400-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite the effectiveness of the anti-CD20 monoclonal antibody (mAb) Rituximab (C2B8) in the treatment of B-cell lymphoma, its efficacy remains variable and often modest.
  • Unfortunately, all the current anti-CD20 mAbs effective in CDC are relatively inactive in signaling cell death and vice versa.
  • TetraMcAbs, with a molecular mass only 25 kDa higher than native divalent antibodies (DiMcAb), were shown not only to be as effective in mediating CDC and antibody-dependent cellular cytotoxicity against B-lymphoma cells as DiMcAbs but also to have antiproliferative and apoptosis-inducing activity markedly superior to that of DiMcAbs.
  • Interestingly, whereas 2F2 and C2B8 were equally effective in inducing cell growth arrest and apoptosis, the functions of their tetravalent versions, 2F2(ScFvHL)(4)-Fc and C2B8(ScFvHL)(4)-Fc, were significantly different.
  • Immunotherapeutic studies further showed that 2F2(ScFvHL)(4)-Fc was far more effective in prolonging the survival of severe combined immunodeficient mice bearing systemic Daudi or Raji tumors than C2B8, 2F2, and C2B8(ScFvHL)(4)-Fc, suggesting that it might be a promising therapeutic agent for B-cell lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antigens, CD30 / immunology. Antineoplastic Agents / pharmacology. Burkitt Lymphoma / therapy. Lymphoma, B-Cell / therapy
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Murine-Derived. CHO Cells. Cell Line, Tumor. Cricetinae. Cricetulus. Female. Humans. Lymphoma, T-Cell / immunology. Lymphoma, T-Cell / therapy. Mice. Mice, Inbred BALB C. Mice, Inbred ICR. Mice, SCID. Rituximab. Xenograft Model Antitumor Assays

  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18381448.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD30; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


52. Ci W, Polo JM, Melnick A: B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma. Curr Opin Hematol; 2008 Jul;15(4):381-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma.
  • PURPOSE OF REVIEW: The B-cell lymphoma 6 transcriptional repressor is the most commonly involved oncogene in B-cell lymphomas.
  • Sustained expression of B-cell lymphoma 6 causes malignant transformation of germinal center B cells.
  • Understanding the mechanism of action of B-cell lymphoma 6 is crucial for the study of how aberrant transcriptional programming leads to lymphomagenesis and development of targeted antilymphoma therapy.
  • RECENT FINDINGS: Identification of B-cell lymphoma 6 target genes indicates a critical role for B-cell lymphoma 6 in facilitating a state of physiological genomic instability required for germinal center B cells to undergo affinity maturation, and suggests its contribution to several additional cellular functions.
  • The discovery of several layers of counterregulatory mechanisms reveals how B cells can control and fine-tune the potentially lymphomagenic actions of B-cell lymphoma 6.
  • From the biochemical standpoint, B-cell lymphoma 6 can regulate distinct biological pathways through different cofactors.
  • This observation explains how the biological actions of B-cell lymphoma 6 can be physiologically controlled through separate mechanisms and affords the means for improved therapeutic targeting.
  • The fact that patients with B-cell lymphoma 6-dependent lymphoma can be identified on the basis of gene signatures suggests that therapeutic trials of B-cell lymphoma 6 inhibitors could be personalized to these individuals.
  • SUMMARY: B-cell lymphoma 6 plays a fundamental role in lymphomagenesis and is an excellent therapeutic target for development of improved antilymphoma therapeutic regimens.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2004 Dec 2;432(7017):635-9 [15577913.001]
  • [Cites] Blood Cells Mol Dis. 2008 Jul-Aug;41(1):95-9 [18346918.001]
  • [Cites] Nat Med. 2004 Dec;10(12):1329-35 [15531890.001]
  • [Cites] J Immunol. 2005 Jan 1;174(1):205-14 [15611242.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):28-40 [15671525.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1851-61 [15550490.001]
  • [Cites] Cancer Cell. 2005 May;7(5):445-55 [15894265.001]
  • [Cites] Nat Immunol. 2005 Oct;6(10):1054-60 [16142238.001]
  • [Cites] Mol Immunol. 2006 May;43(12):1965-71 [16423395.001]
  • [Cites] Oncogene. 2006 Apr 6;25(15):2223-33 [16331266.001]
  • [Cites] Mol Cell Biol. 2006 Sep;26(18):6880-9 [16943429.001]
  • [Cites] Oncogene. 2007 Jan 11;26(2):224-33 [16819511.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Cancer Invest. 2000;18(4):356-65 [10808372.001]
  • [Cites] Genes Dev. 2000 Jul 15;14(14):1810-23 [10898795.001]
  • [Cites] J Exp Med. 2000 Dec 18;192(12):1841-8 [11120780.001]
  • [Cites] Nat Immunol. 2000 Sep;1(3):214-20 [10973278.001]
  • [Cites] Nature. 2001 Jul 19;412(6844):341-6 [11460166.001]
  • [Cites] Science. 2007 Jan 26;315(5811):528-31 [17185562.001]
  • [Cites] Mol Cell. 2003 Dec;12(6):1551-64 [14690607.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1454-63 [14551142.001]
  • [Cites] J Immunol. 2004 Jul 15;173(2):1158-65 [15240705.001]
  • [Cites] Cell. 2004 Oct 1;119(1):75-86 [15454082.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14198-203 [15375218.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5257-68 [8652841.001]
  • [Cites] Science. 1997 Apr 25;276(5312):589-92 [9110977.001]
  • [Cites] Nat Genet. 1997 Jun;16(2):161-70 [9171827.001]
  • [Cites] Nature. 2007 Mar 1;446(7131):83-7 [17268470.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3207-12 [17360630.001]
  • [Cites] J Exp Med. 2007 Apr 16;204(4):819-30 [17403935.001]
  • [Cites] Mol Cell Proteomics. 2007 May;6(5):820-34 [17296600.001]
  • [Cites] Nat Immunol. 2007 Jul;8(7):705-14 [17558410.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5439-49 [17694085.001]
  • [Cites] J Pathol. 2007 Sep;213(1):106-15 [17573669.001]
  • [Cites] Blood. 2007 Sep 15;110(6):2067-74 [17545502.001]
  • [Cites] Cancer Cell. 2007 Sep;12(3):280-92 [17785208.001]
  • [Cites] Nat Immunol. 2007 Oct;8(10):1132-9 [17828269.001]
  • [Cites] Eur J Cell Biol. 2007 Oct;86(10):581-9 [17651861.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2332-43 [17625604.001]
  • [Cites] Nat Genet. 2008 Jan;40(1):108-12 [18066064.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1515-23 [17951530.001]
  • [Cites] J Pathol. 2008 Mar;214(4):498-507 [18189332.001]
  • [Cites] Nature. 2008 Feb 14;451(7180):841-5 [18273020.001]
  • [Cites] Mol Cell. 2008 Feb 15;29(3):384-91 [18280243.001]
  • [Cites] Mol Cell Biol. 2008 Apr;28(7):2175-86 [18212045.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3701-13 [18160665.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3361-9 [18451163.001]
  • [Cites] Leuk Lymphoma. 2008 May;49(5):874-82 [18452090.001]
  • [Cites] Blood. 2004 Dec 15;104(13):4088-96 [15331443.001]
  • (PMID = 18536578.001).
  • [ISSN] 1531-7048
  • [Journal-full-title] Current opinion in hematology
  • [ISO-abbreviation] Curr. Opin. Hematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA104348-05; United States / NCI NIH HHS / CA / R01 CA104348; United States / NCI NIH HHS / CA / R01 CA104348-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-6
  • [Number-of-references] 51
  • [Other-IDs] NLM/ NIHMS126312; NLM/ PMC2748732
  •  go-up   go-down


53. Benmiloud S, Steffens M, Beauloye V, de Wandeleer A, Devogelaer JP, Brichard B, Vermylen C, Maiter D: Long-term effects on bone mineral density of different therapeutic schemes for acute lymphoblastic leukemia or non-Hodgkin lymphoma during childhood. Horm Res Paediatr; 2010;74(4):241-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term effects on bone mineral density of different therapeutic schemes for acute lymphoblastic leukemia or non-Hodgkin lymphoma during childhood.
  • METHODS: Bone mineral density (BMD) was evaluated at lumbar spine (LS), total hip and femoral neck in 89 patients (44 men) more than 5 years after remission of childhood acute lymphoblastic leukemia (ALL) or non-Hodgkin lymphoma (NHL).
  • A multivariate analysis showed independent significant influences of male gender at LS (p < 0.001) and of type of treatment and dexamethasone at the hip (p < 0.05).
  • [MeSH-major] Antineoplastic Agents / adverse effects. Bone Density / drug effects. Bone Density / radiation effects. Lymphoma, Non-Hodgkin / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


54. Nemet AY, Deckel Y, Kourt G: Orbital invasion of frontal sinus lymphoma. Orbit; 2006 Jun;25(2):149-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital invasion of frontal sinus lymphoma.
  • Paranasal sinus lymphoma is an uncommon malignancy and is often difficult to diagnose.
  • Early diagnosis is essential for effective treatment.
  • Ophthalmological symptoms and signs occur early in the disease process due to the close proximity of the orbit to the paranasal sinuses.
  • We report a case of frontal sinus lymphoma that presented as a superior-nasal orbital mass in an 84 year old man.
  • Histology revealed diffuse large B cell non Hodgkin's lymphoma.
  • [MeSH-major] Frontal Sinus / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Orbit / pathology. Paranasal Sinus Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Humans. Male. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Orbital lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16754228.001).
  • [ISSN] 0167-6830
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


55. Walls KC, Ghosh AP, Ballestas ME, Klocke BJ, Roth KA: bcl-2/Adenovirus E1B 19-kd interacting protein 3 (BNIP3) regulates hypoxia-induced neural precursor cell death. J Neuropathol Exp Neurol; 2009 Dec;68(12):1326-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] bcl-2/Adenovirus E1B 19-kd interacting protein 3 (BNIP3) regulates hypoxia-induced neural precursor cell death.
  • In addition to producing neuron death, HI causes death of neural precursor cells (NPCs) in the developing brain.
  • To characterize the molecular pathways that regulate hypoxia-induced death of NPCs, we treated a mouse neural stem cell line (C17.2 cells) and fibroblastic growth factor II-expanded primary NPCs derived from wild-type or gene-disrupted mice, with oxygen glucose deprivation or the hypoxia mimetics desferrioxamine or cobalt chloride.
  • Neural precursor cells undergoing hypoxia exhibited time- and concentration-dependent caspase-3 activation and cell death, which was significantly reduced by treatment with a broad caspase inhibitor or protein synthesis inhibition.
  • Oxygen glucose deprivation or hypoxia-mimetic exposure also resulted in increased hypoxia-inducible factor alpha and bcl-2/adenovirus E1B 19-kd interacting protein 3 (BNIP3) expression.
  • BNIP3 shRNA treatment failed to affect hypoxia-induced caspase-3 activation but inhibited cell death and nuclear translocation of apoptosis-inducing factor, indicating that BNIP3 is an important regulator of caspase-independent NPC death after hypoxia.
  • These studies demonstrate that hypoxia activates both caspase-dependent and -independent NPC death pathways that are critically regulated by multiple Bcl-2 family members.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1999 Nov 12;274(46):32631-7 [10551817.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2008 Nov;295(5):H2025-31 [18790835.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(15):5454-68 [10891486.001]
  • [Cites] FEBS Lett. 2001 Feb 23;491(1-2):85-90 [11226425.001]
  • [Cites] Science. 2001 Apr 20;292(5516):464-8 [11292862.001]
  • [Cites] Science. 2001 Apr 20;292(5516):468-72 [11292861.001]
  • [Cites] EMBO Rep. 2001 Jul;2(7):615-20 [11454738.001]
  • [Cites] Cell. 2001 Oct 5;107(1):43-54 [11595184.001]
  • [Cites] Science. 2004 Feb 13;303(5660):1010-4 [14963330.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 1;1644(2-3):189-203 [14996503.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4286-93 [15205343.001]
  • [Cites] Anat Embryol (Berl). 1990;181(3):195-213 [2186664.001]
  • [Cites] Cell. 1992 Jan 10;68(1):33-51 [1732063.001]
  • [Cites] Science. 1995 Oct 6;270(5233):96-9 [7569956.001]
  • [Cites] Nature. 1998 Mar 26;392(6674):405-8 [9537326.001]
  • [Cites] J Biol Chem. 1999 Jan 1;274(1):7-10 [9867803.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):597-609 [15607964.001]
  • [Cites] Neuroscience. 2005;131(1):55-65 [15680691.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):980-91 [15592527.001]
  • [Cites] FASEB J. 2005 Aug;19(10):1308-10 [15941769.001]
  • [Cites] Cell. 2005 Sep 23;122(6):927-39 [16179260.001]
  • [Cites] Apoptosis. 2006 Jan;11(1):67-77 [16374551.001]
  • [Cites] Cell Death Differ. 2006 Oct;13(10):1727-39 [16514420.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Jan;66(1):66-74 [17204938.001]
  • [Cites] Cell Death Differ. 2007 Apr;14(4):775-84 [17039248.001]
  • [Cites] Cell Biochem Biophys. 2007;47(1):11-20 [17406056.001]
  • [Cites] Stroke. 2007 May;38(5):1606-13 [17379825.001]
  • [Cites] Free Radic Biol Med. 2007 Jul 1;43(1):117-27 [17561100.001]
  • [Cites] Biochem J. 2007 Aug 1;405(3):407-15 [17447897.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1741-8 [17635954.001]
  • [Cites] Mol Cell Biol. 2007 Sep;27(17):6229-42 [17576813.001]
  • [Cites] J Clin Invest. 2007 Oct;117(10):2825-33 [17909626.001]
  • [Cites] Autophagy. 2007 Nov-Dec;3(6):616-9 [17786027.001]
  • [Cites] J Neurochem. 2007 Nov;103(3):1121-31 [17711427.001]
  • [Cites] Autophagy. 2008 Feb;4(2):195-204 [18059169.001]
  • [Cites] J Biol Chem. 2008 Apr 18;283(16):10892-903 [18281291.001]
  • [Cites] FASEB J. 2008 Aug;22(8):2662-75 [18375543.001]
  • [Cites] J Biol Chem. 2000 Jan 14;275(2):1439-48 [10625696.001]
  • (PMID = 19915483.001).
  • [ISSN] 1554-6578
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / P30 NS047466; United States / NINDS NIH HHS / NS / NS047466-05; United States / NINDS NIH HHS / NS / R01 NS035107-11; United States / NINDS NIH HHS / NS / R01 NS041962; United States / NINDS NIH HHS / NS / P30 NS057098; United States / NINDS NIH HHS / NS / P30 NS047466-05; United States / NINDS NIH HHS / NS / R01 NS041962-06; United States / NINDS NIH HHS / NS / NS57098; United States / NINDS NIH HHS / NS / R01 NS035107; United States / NINDS NIH HHS / NS / NS057098-04; United States / NINDS NIH HHS / NS / NS35107; United States / NINDS NIH HHS / NS / NS035107-11; United States / NINDS NIH HHS / NS / NS47466; United States / NINDS NIH HHS / NS / NS41962; United States / NINDS NIH HHS / NS / NS041962-06; United States / NINDS NIH HHS / NS / P30 NS057098-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BNip3 protein, mouse; 0 / Enzyme Inhibitors; 0 / Membrane Proteins; 0 / Mitochondrial Proteins; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ NIHMS161285; NLM/ PMC2791349
  •  go-up   go-down


56. Vose JM, Bierman PJ, Loberiza FR, Lynch JC, Bociek GR, Weisenburger DD, Armitage JO: Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index. Biol Blood Marrow Transplant; 2008 Jan;14(1):36-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index.
  • Although results of autologous stem cell transplantation (SCT) for recurrent follicular non-Hodgkin lymphoma (NHL) have been previously reported, the long-term results and evaluation of prognostic factors in a large patient population receiving this therapy are difficult to find in the literature.
  • At the time of transplantation, 88 of the patients (35%) had a Follicular Lymphoma International Prognostic Index (FLIPI) score of low risk, 87 (35%) had an intermediate-risk FLIPI score, 37 (15%) had a high-risk FLIPI score, and 36 (15%) had at least 1 missing value, preventing calculation of the FLIPI score.
  • In addition, the use of a transplantation regimen including a monoclonal antibody decreased the relative risk of progressive lymphoma.
  • These data suggest that transplantation earlier in the course of the disease for patients with follicular lymphoma with use of a monoclonal antibody-based regimen may lead to improved outcomes.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Hematopoietic Stem Cell Transplantation / adverse effects. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Follicular / therapy. Severity of Illness Index
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Disease-Free Survival. Female. Humans. Longitudinal Studies. Male. Middle Aged. Risk Assessment. Transplantation Conditioning / adverse effects. Transplantation Conditioning / methods. Transplantation, Autologous / adverse effects. Transplantation, Autologous / methods. Treatment Outcome. Whole-Body Irradiation / adverse effects


57. Henrich M, Hecht W, Weiss AT, Reinacher M: A new subgroup of immunoglobulin heavy chain variable region genes for the assessment of clonality in feline B-cell lymphomas. Vet Immunol Immunopathol; 2009 Jul 15;130(1-2):59-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new subgroup of immunoglobulin heavy chain variable region genes for the assessment of clonality in feline B-cell lymphomas.
  • In human medicine, PCR-amplification of the complementarity determining region 3 of the immunoglobulin heavy chain genes followed by polyacrylamide gel electrophoresis (PAGE) is an accepted method to assess clonality in B-cell lymphomas and thereby facilitates the differentiation of neoplasias from benign hyperplasias or reactive infiltrates.
  • To generate a basis for the development of a PCR-based assay for the assessment of clonality in feline B-cell lymphomas we analyzed 28 transcripts (cDNA) of the feline immunoglobulin heavy chain variable region genes (IGHV).
  • With these four sets of primers, the assay was able to detect monoclonality in 7/10 (70%) cats with histologically and immunohistochemically diagnosed B-cell lymphomas.
  • The use of a PCR-based assay in combination with standard techniques for the diagnosis of feline lymphoma is helpful and the characterization of the additional subgroup of feline variable regions genes puts this assay on a broader basis.
  • [MeSH-major] Cat Diseases / immunology. Cat Diseases / pathology. Immunoglobulin Heavy Chains / genetics. Immunoglobulin Variable Region / genetics. Lymphoma, B-Cell / veterinary
  • [MeSH-minor] Amino Acid Sequence. Animals. Cats. Clone Cells. Molecular Sequence Data. Plasmids / genetics. RNA, Neoplasm / chemistry. RNA, Neoplasm / genetics. Random Amplified Polymorphic DNA Technique / veterinary. Sequence Alignment. Sequence Analysis, DNA

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19243841.001).
  • [ISSN] 1873-2534
  • [Journal-full-title] Veterinary immunology and immunopathology
  • [ISO-abbreviation] Vet. Immunol. Immunopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; 0 / RNA, Neoplasm
  •  go-up   go-down


58. Bremer E, ten Cate B, Samplonius DF, Mueller N, Wajant H, Stel AJ, Chamuleau M, van de Loosdrecht AA, Stieglmaier J, Fey GH, Helfrich W: Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists. Cancer Res; 2008 Jan 15;68(2):597-604
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical efficacy of the CD20-specific chimeric monoclonal antibody rituximab is significantly hampered by intrinsic or acquired resistance to therapy.
  • The resultant fusion protein, designated scFvRit:sFasL, potently induced CD20-restricted apoptosis in a panel of malignant B-cell lines (10 of 11) and primary patient-derived malignant B cells (two of two non-Hodgkin lymphoma and five of six B cell chronic lymphocytic leukemia).
  • ScFvRit:sFasL lacked activity toward normal human B cells and also lacked systemic toxicity in nude mice with no elevation of aspartate aminotransferase and alanine aminotransferase levels or liver caspase-3 activity.
  • In conclusion, scFvRit:sFasL efficiently activates CD20 and Fas-apoptotic signaling and may be useful for the elimination of malignant B cells.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fas Ligand Protein / agonists. Genetic Therapy. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Lymphoma, Non-Hodgkin / therapy. Recombinant Fusion Proteins / genetics. Recombinant Fusion Proteins / therapeutic use
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Murine-Derived. Apoptosis / drug effects. Apoptosis / genetics. B-Lymphocytes / drug effects. CHO Cells. Cricetinae. Cricetulus. Female. Humans. Male. Rituximab. Signal Transduction / drug effects. Signal Transduction / genetics. Single-Chain Antibodies. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18199557.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Recombinant Fusion Proteins; 0 / Single-Chain Antibodies; 0 / scFvRit-sFasL protein, human; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


59. Weng Y, Gao ZF, Liu K, Zhang WJ, Ke XY, Li M: [Factors affecting the prognosis of diffuse large B-cell lymphoma in Chinese]. Zhonghua Nei Ke Za Zhi; 2005 Sep;44(9):681-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Factors affecting the prognosis of diffuse large B-cell lymphoma in Chinese].
  • OBJECTIVE: To study the correlation between clinical prognosis and clinicopathologic features, origin and cell proliferous index of diffuse large B-cell lymphoma (DLBCL) in China.
  • Immunohistochemistry stain was used to check the expression of CD(45)RO, CD(3), CD(20), CD(79)a, CD(45)RA, Ki-67, p53 and bcl-6.
  • 23 patients 38.3% died during follow-up, the longest survival period lasting 108 months.16 died in the first year after establishment of diagnosis (16/23, 69.6%).
  • Ki-67, p53, bcl-6 were expressed in some cases (48/53, 90.6%; 26/46, 56.5%; 21/41, 51.2%).
  • The expression of bcl-6 protein was somewhat related with prognosis (P = 0.0049), but the expression of p53 was not (P = 0.5948).
  • Most of the cases died in the first year after establishment of diagnosis.
  • IPI can be used to predict the clinical outcome.
  • The expression of bcl-6 protein was somewhat related with clinical prognosis, but that of p53 was not.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Proliferation. Child. China. DNA-Binding Proteins / metabolism. Female. Follow-Up Studies. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Prognosis. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202261.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


60. Yun SJ, Lee KH, Yang DW, Lee JB, Kim SJ, Lee SC, Won YH: Primary cutaneous spindle cell B-cell lymphoma with multiple figurate erythema-like manifestation. J Cutan Pathol; 2009 Jan;36(1):49-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous spindle cell B-cell lymphoma with multiple figurate erythema-like manifestation.
  • Spindle-shaped cells with elongated, twisted nuclei containing dispersed chromatin were also seen.
  • Immunohistochemical analysis showed that all of the cells were strongly positive for CD20, CD21, CD79a and CD45, while they were negative for CD3, CD5, CD10, CD23, CD35, CD43, CD45RO and CD68.
  • The spindle cells were also negative for smooth-muscle actin, desmin, S-100 and CD34.
  • They consistently expressed nuclear bcl-6, but did not express bcl-2, multiple myeloma-1 and p16.
  • We diagnosed him with primary cutaneous spindle cell B-cell lymphoma (PCSBCL) and treated him with six cycles of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab (R-CHOP) chemotherapy; his skin lesions disappeared completely.
  • Immunohistochemical profiles suggest that PCSBCL is a variant of primary cutaneous follicle center lymphoma.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19125734.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


61. Cho DG, Cho KD, Jo MS: Thoracoscopic direct suture repair of thoracic duct injury after thoracoscopic mediastinal surgery. Surg Laparosc Endosc Percutan Tech; 2007 Feb;17(1):60-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report herein a case of postoperative chylothorax managed successfully by early thoracoscopic direct suture repair of the site of chylous leak that developed after the thoracoscopic resection of mediastinal mass and surrounding fat with ectopic thymus in a patient with persistent myasthenia gravis with non-Hodgkin lymphoma.
  • [MeSH-major] Lymphoma, B-Cell / surgery. Mediastinal Neoplasms / surgery. Suture Techniques. Thoracic Duct / injuries. Thoracoscopy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17318061.001).
  • [ISSN] 1530-4515
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L, Dummer R, Duvic M, Hoppe RT, Pimpinelli N, Rosen ST, Vermeer MH, Whittaker S, Willemze R, European Organization for Research and Treatment of Cancer, International Society for Cutaneous Lymphoma: European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood; 2008 Sep 1;112(5):1600-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas.
  • Primary cutaneous B-cell lymphomas (CBCL) represent approximately 20% to 25% of all primary cutaneous lymphomas.
  • With the advent of the World Health Organization-European Organization for Research and Treatment of Cancer (EORTC) Consensus Classification for Cutaneous Lymphomas in 2005, uniform terminology and classification for this rare group of neoplasms were introduced.
  • However, staging procedures and treatment strategies still vary between different cutaneous lymphoma centers, which may be because consensus recommendations for the management of CBCL have never been published.
  • Based on an extensive literature search and discussions within the EORTC Cutaneous Lymphoma Group and the International Society for Cutaneous Lymphomas, the present report aims to provide uniform recommendations for the management of the 3 main groups of CBCL.
  • Despite these limitations, there was consensus among the members of the multidisciplinary expert panel that these recommendations reflect the state-of-the-art management as currently practiced in major cutaneous lymphoma centers.
  • They may therefore contribute to uniform staging and treatment and form the basis for future clinical trials in patients with a CBCL.
  • [MeSH-major] Lymphoma, B-Cell / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Humans. Interferon Type I / administration & dosage. Lyme Disease / complications. Lyme Disease / drug therapy. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy. Neoplasm Staging / methods. Radiotherapy Dosage. Recombinant Proteins. Rituximab

  • Genetic Alliance. consumer health - Cutaneous B-Cell Lymphomas.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18567836.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Interferon Type I; 0 / Recombinant Proteins; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 123
  •  go-up   go-down


63. Arnaoutakis K, Oo TH: Bronchus-associated lymphoid tissue lymphomas. South Med J; 2009 Dec;102(12):1229-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bronchus-associated lymphoid tissue lymphomas.
  • BACKGROUND: : Bronchus-associated Lymphoid Tissue (BALT) lymphomas are a rare type of extranodal marginal zone lymphomas.
  • They comprise 1% of lymphomas and more than two-thirds of all primary non-Hodgkin lymphoma (NHL) of the lung.
  • BALT lymphomas arise from the bronchus-associated lymphoid tissue.
  • METHODS: This report describes five cases of BALT lymphoma and discusses the pathogenesis, diagnosis, prognosis and treatment of BALT lymphomas.
  • DISCUSSION: BALT lymphomas are associated with chronic inflammation, and they are often asymptomatic.
  • [MeSH-major] Bronchial Neoplasms / diagnosis. Bronchial Neoplasms / therapy. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Immunotherapy / methods. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20016430.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Leonard JP, Friedberg JW, Hagemeister FB, Levine AM: Combination treatment approaches and novel therapies for lymphoma. Clin Adv Hematol Oncol; 2007 Aug;5(8 Suppl 12):4-20; quiz 1 p following 20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination treatment approaches and novel therapies for lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Antibodies, Anti-Idiotypic / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Bendamustine Hydrochloride. Boronic Acids / therapeutic use. Bortezomib. Cancer Vaccines / immunology. Cancer Vaccines / therapeutic use. Cytokines / therapeutic use. Humans. Immunologic Factors / therapeutic use. Nitrogen Mustard Compounds / therapeutic use. Pyrazines / therapeutic use. Rituximab. Stem Cell Transplantation

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Bendamustine .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18154235.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Boronic Acids; 0 / Cancer Vaccines; 0 / Cytokines; 0 / Immunologic Factors; 0 / Nitrogen Mustard Compounds; 0 / Pyrazines; 357613-77-5 / galiximab; 4F4X42SYQ6 / Rituximab; 69G8BD63PP / Bortezomib; 981Y8SX18M / Bendamustine Hydrochloride
  • [Number-of-references] 112
  •  go-up   go-down


65. Fuchs O, Provaznikova D, Kocova M, Kostecka A, Cvekova P, Neuwirtova R, Kobylka P, Cermak J, Brezinova J, Schwarz J, Markova J, Salaj P, Klamova H, Maaloufova J, Lemez P, Novakova L, Benesova K: CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma. Blood Cells Mol Dis; 2008 May-Jun;40(3):401-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma.
  • CEBPA mutations were found in 14/152 (9.2%) of acute myeloid leukemia (AML) patients' samples, 6/143 (4.2%) of MDS patients' samples, 2/56 (3.6%) of non-Hodgkin's lymphoma (NHL) patients' samples and 2/39 (5.1%) of multiple myeloma (MM) patients' samples.
  • No C/EBPalpha mutations were detected in healthy donors (41 individuals).
  • [MeSH-major] CCAAT-Enhancer-Binding Proteins / genetics. Leukemia, Myeloid, Acute / genetics. Lymphoma, Non-Hodgkin / genetics. Multiple Myeloma / genetics. Mutation. Myelodysplastic Syndromes / genetics. Polymorphism, Genetic


66. Watanuki J, Hatakeyama K, Sonoki T, Tatetsu H, Yoshida K, Fujii S, Mizutani M, Abo T, Kurimoto M, Matsuoka H, Matsuno F, Nakakuma H: Bone marrow large B cell lymphoma bearing cyclin D3 expression: clinical, morphologic, immunophenotypic, and genotypic analyses of seven patients. Int J Hematol; 2009 Sep;90(2):217-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow large B cell lymphoma bearing cyclin D3 expression: clinical, morphologic, immunophenotypic, and genotypic analyses of seven patients.
  • We report seven large B cell lymphoma patients showing the involvement of tumor cells with cyclin D3 (CCND3) expression in bone marrow (BM) at the initial diagnosis.
  • The tumor cells were divided into those with a lymphoplasmacytoid or blastoid appearance.
  • Six cases were confirmed to express CD5 antigen on tumor cells.
  • Further studies are required to determine whether CCND3 expression is associated with a unique subset of diffuse large B cell lymphoma.
  • [MeSH-major] B-Lymphocytes / physiology. Bone Marrow Cells / physiology. Cyclins / genetics. Genotype. Lymphoma, Large B-Cell, Diffuse / genetics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1995 Mar;48(3):189-93 [7730473.001]
  • [Cites] Br J Haematol. 2000 Dec;111(3):826-34 [11122144.001]
  • [Cites] Blood. 2002 Feb 1;99(3):815-21 [11806981.001]
  • [Cites] Blood. 2001 Jul 1;98(1):217-23 [11418483.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1570-80 [18725575.001]
  • [Cites] Int J Hematol. 2008 Oct;88(3):299-303 [18758895.001]
  • [Cites] Int J Hematol. 2008 Dec;88(5):536-42 [18972186.001]
  • [Cites] Blood. 2003 Oct 15;102(8):3003-9 [12842981.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):804-15 [15728813.001]
  • [Cites] J Clin Pathol. 1992 Sep;45(9):770-5 [1401205.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2837-44 [11675358.001]
  • [Cites] Br J Haematol. 2007 Feb;136(3):351 [17233843.001]
  • [Cites] Br J Haematol. 1991 Mar;77(3):301-10 [2012754.001]
  • [Cites] Am J Clin Pathol. 2007 May;127(5):762-9 [17439835.001]
  • [Cites] Mt Sinai J Med. 2003 Mar;70(2):133-8 [12634906.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2205-11 [17657714.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13931-6 [8943038.001]
  • [Cites] Blood. 2008 Jun 15;111(12 ):5683-90 [18391076.001]
  • [Cites] Rinsho Ketsueki. 2002 Oct;43(10):943-8 [12462031.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3451-61 [17170124.001]
  • [Cites] N Engl J Med. 1999 Nov 11;341(20):1520-9 [10559454.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D781-4 [16381979.001]
  • [Cites] Cell. 2000 Sep 1;102(5):553-63 [11007474.001]
  • [Cites] Br J Haematol. 1999 Aug;106(2):477-85 [10460609.001]
  • [Cites] Br J Haematol. 1989 Oct;73(2):199-204 [2479409.001]
  • [Cites] Int J Hematol. 1996 Jan;63(1):71-6 [8713579.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8265-72 [16322284.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 [9254694.001]
  • [Cites] J Exp Med. 2007 Mar 19;204(3):633-43 [17353367.001]
  • [Cites] Leukemia. 2002 May;16(5):937-9 [11986957.001]
  • (PMID = 19639271.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / CCND3 protein, human; 0 / Cyclin D3; 0 / Cyclins
  •  go-up   go-down


67. Tari A, Asaoku H, Kashiwado K, Yoshino T, Kitadai Y, Tanaka S, Fujihara M: Predictive value of endoscopy and endoscopic ultrasonography for regression of gastric diffuse large B-cell lymphomas after Helicobacter pylori eradication. Dig Endosc; 2009 Oct;21(4):219-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of endoscopy and endoscopic ultrasonography for regression of gastric diffuse large B-cell lymphomas after Helicobacter pylori eradication.
  • BACKGROUND: Some gastric diffuse large B-cell lymphomas have been reported to regress completely after the successful eradication of Helicobacter pylori.
  • The aim of this study was to investigate the clinical characteristics of gastric diffuse large B-cell lymphomas without any detectable mucosa-associated lymphoid tissue (MALT) lymphoma that went into complete remission after successful H. pylori eradication.
  • PATIENTS AND METHODS: We examined the effect of H. pylori eradication in 15 H. pylori-positive gastric diffuse large B-cell lymphoma patients without any evidence of an associated MALT lymphoma (clinical stage I by the Lugano classification) by endoscopic examination including biopsies, endoscopic ultrasonography, computed tomography, and bone marrow aspiration.
  • RESULTS: H. pylori eradication was successful in all the patients and complete remission was achieved in four patients whose clinical stage was I.
  • CONCLUSION: In gastric diffuse large B-cell lymphomas without a concomitant MALT lymphoma but associated with H. pylori infection, only superficial cases and lesions limited to the shallow portion of the submucosa regressed completely after successful H. pylori eradication.
  • The endoscopic appearance and the rating of the depth of invasion by endosonography are both valuable for predicting the efficacy of H. pylori eradication in treating gastric diffuse large B-cell lymphomas.
  • [MeSH-major] Endoscopy. Endosonography. Helicobacter Infections / drug therapy. Helicobacter pylori. Lymphoma, Large B-Cell, Diffuse / diagnosis. Stomach Neoplasms / diagnosis


68. Tuma J: [CME ultrasound diagnosis. Nodes in the groin. Low malignancy B-cell lymphoma, particularly follicular lymphoma, WHO grade 2]. Praxis (Bern 1994); 2008 Aug 27;97(17):957-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CME ultrasound diagnosis. Nodes in the groin. Low malignancy B-cell lymphoma, particularly follicular lymphoma, WHO grade 2].
  • [Transliterated title] CME-Sonographie 23/Auflösung. Knoten in der Leiste. Niedrig malignes Non-Hodgkin- Lymphom der-Zell-Reihe, insbesondere follikuläres Lymphom, WHO-Grad 2.
  • [MeSH-major] Lymphatic Diseases / etiology. Lymphatic Diseases / ultrasonography. Lymphoma, B-Cell / ultrasonography. Lymphoma, Follicular / ultrasonography
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Lymph Nodes / ultrasonography

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18777781.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


69. Roychoudhury P, Ghosh U, Bhattacharyya NP, Chaudhuri K: Activation of mitochondrial promoter P(H)-binding protein in a radio-resistant Chinese hamster cell strain associated with Bcl-2. Biochem Biophys Res Commun; 2006 Nov 17;350(2):272-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of mitochondrial promoter P(H)-binding protein in a radio-resistant Chinese hamster cell strain associated with Bcl-2.
  • Previously, we have shown that up regulation of mitochondrial genes ND1, ND4, and COX1 transcribed from the heavy strand promoter (P(H)) has been increased in a radio-resistant cell strain designated as M5 in comparison with the parental Chinese hamster V79 cells.
  • These genes are also up regulated in Chinese hamster V79 cells VB13 that express exogenous human Bcl2.
  • In the present study, the expression of the gene ND6 that is expressed from the light strand promoter (P(L)) was found to be similar in both the cell lines, as determined by RT-PCR.
  • To test the possibility that this differential expression of mitochondrial genes under these two promoters was mediated by differences in proteins' affinity to interact with these promoters, we have carried out electrophoretic mobility shift assay (EMSA) using mitochondrial cell extracts from these two cell lines.
  • Our result of these experiments revealed that two different proteins formed complex with the synthetic promoters and higher amount of protein from M5 cell extracts interacted with the P(H) promoter in comparison to that observed with cell extracts from Chinese hamster V79 cells.
  • These results showed that differential mitochondrial gene expression observed earlier in the radio-resistant M5 cells was due to enhanced interaction proteins with the promoters P(H) and mediated by the expression of Bcl2.
  • [MeSH-major] DNA-Binding Proteins / metabolism. Genes, Mitochondrial. Mitochondrial Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Radiation Tolerance
  • [MeSH-minor] Animals. Cell Line. Cricetinae. Cricetulus. Electrophoretic Mobility Shift Assay. Gamma Rays. Gene Expression Regulation, Enzymologic. Humans. Male. Mitochondria / enzymology. Mitochondria / radiation effects. NADH Dehydrogenase / biosynthesis. NADH Dehydrogenase / genetics. Promoter Regions, Genetic. Protein Subunits / biosynthesis. Protein Subunits / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17007815.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Mitochondrial Proteins; 0 / Protein Subunits; 0 / Proto-Oncogene Proteins c-bcl-2; EC 1.6.99.3 / NADH Dehydrogenase
  •  go-up   go-down


70. Schulze-Bergkamen H, Ehrenberg R, Hickmann L, Vick B, Urbanik T, Schimanski CC, Berger MR, Schad A, Weber A, Heeger S, Galle PR, Moehler M: Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells. World J Gastroenterol; 2008 Jun 28;14(24):3829-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells.
  • AIM: To explore the role of Bcl-x(L) and Myeloid cell leukaemia (Mcl)-1 for the apoptosis resistance of colorectal carcinoma (CRC) cells towards current treatment modalities.
  • METHODS: Bcl-x(L) and Mcl-1 mRNA and protein expression were analyzed in CRC cell lines as well as human CRC tissue by Western blot, quantitative PCR and immunohistochemistry.
  • Bcl-x(L) and Mcl-1 protein expression was knocked down or increased in CRC cell lines by applying specific siRNAs or expression plasmids, respectively.
  • After modulation of protein expression, CRC cells were treated with chemotherapeutic agents, an antagonistic epidermal growth factor receptor (EGFR1) antibody, an EGFR1 tyrosine kinase inhibitor, or with the death receptor ligand TRAIL.
  • Apoptosis induction and cell viability were analyzed.
  • RESULTS: Here we show that in human CRC tissue and various CRC cell lines both Bcl-x(L) and Mcl-1 are expressed.
  • Bcl-x(L) expression was higher in CRC tissue than in surrounding non-malignant tissue, both on protein and mRNA level.
  • Mcl-1 mRNA expression was significantly lower in malignant tissues.
  • Viability rates of CRC cells were significantly decreased after knock down of Bcl-x(L) expression, and, to a lower extent, after knock down of Mcl-1 expression.
  • Furthermore, cells with reduced Bcl-x(L) or Mcl-1 expression was more sensitive towards oxaliplatin- and irinotecan-induced apoptosis, and in the case of Bcl-x(L) also towards 5-FU-induced apoptosis.
  • On the other hand, upregulation of Bcl-x(L) by transfection of an expression plasmid decreased chemotherapeutic drug-induced apoptosis.
  • EGF treatment clearly induced Bcl-x(L) and Mcl-1 expression in CRC cells.
  • Apoptosis induction upon EGFR1 blockage by cetuximab or PD168393 was increased by inhibiting Mcl-1 and Bcl-x(L) expression.
  • More strikingly, CD95- and TRAIL-induced apoptosis was increased by Bcl-x(L) knock down.
  • CONCLUSION: Our data suggest that Bcl-x(L) and, to a lower extent, Mcl-1, are important anti-apoptotic factors in CRC.
  • Specific downregulation of Bcl-x(L) is a promising approach to sensitize CRC cells towards chemotherapy and targeted therapy.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Proto-Oncogene Proteins c-bcl-2 / metabolism. bcl-X Protein / metabolism
  • [MeSH-minor] Antigens, CD95 / metabolism. Camptothecin / analogs & derivatives. Camptothecin / pharmacology. Cell Line, Tumor. Cell Survival / drug effects. Fluorouracil / pharmacology. Humans. Myeloid Cell Leukemia Sequence 1 Protein. Organoplatinum Compounds / pharmacology. RNA, Messenger / metabolism. Receptor, Epidermal Growth Factor / antagonists & inhibitors. TNF-Related Apoptosis-Inducing Ligand / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Colorectal cancer 1.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 1999 Feb;5(2):157-63 [9930862.001]
  • [Cites] Dig Dis Sci. 1998 Dec;43(12):2641-8 [9881495.001]
  • [Cites] Oncogene. 1999 Aug 19;18(33):4654-62 [10467412.001]
  • [Cites] Mol Cancer Ther. 2005 Mar;4(3):451-6 [15767554.001]
  • [Cites] Jpn J Clin Oncol. 2005 Aug;35(8):453-63 [16024531.001]
  • [Cites] Cancer Biol Ther. 2005 Mar;4(3):267-76 [15753661.001]
  • [Cites] Int J Oncol. 2006 Jan;28(1):25-32 [16327976.001]
  • [Cites] J Hepatol. 2006 Jan;44(1):151-7 [16289418.001]
  • [Cites] J Biol Chem. 2006 Apr 14;281(15):10153-63 [16478725.001]
  • [Cites] Clin Cancer Res. 2006 Apr 15;12(8):2640-6 [16638878.001]
  • [Cites] Semin Oncol. 2006 Aug;33(4):369-85 [16890793.001]
  • [Cites] Oncogene. 2006 Aug 24;25(37):5145-54 [16636678.001]
  • [Cites] BMC Cancer. 2006;6:232 [17014711.001]
  • [Cites] FEBS Lett. 2006 Dec 11;580(28-29):6565-9 [17113582.001]
  • [Cites] Oncogene. 2007 Feb 26;26(9):1324-37 [17322918.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2226-35 [17404107.001]
  • [Cites] Curr Top Med Chem. 2007;7(10):961-5 [17508927.001]
  • [Cites] Pathology. 2007 Jun;39(3):334-8 [17558861.001]
  • [Cites] Cancer Cell. 2007 Jul;12(1):66-80 [17613437.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(7-8):1462-75 [17403612.001]
  • [Cites] Anticancer Agents Med Chem. 2007 Sep;7(5):492-503 [17896910.001]
  • [Cites] Expert Opin Ther Targets. 2007 Oct;11(10):1299-314 [17907960.001]
  • [Cites] Genes Dev. 2000 Jan 1;14(1):23-7 [10640272.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(8):2687-95 [10733571.001]
  • [Cites] Nat Med. 2000 May;6(5):513-9 [10802706.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2547-55 [10873111.001]
  • [Cites] Science. 2000 Nov 3;290(5493):989-92 [11062132.001]
  • [Cites] J Clin Pathol. 2002 Mar;55(3):206-11 [11896073.001]
  • [Cites] Leukemia. 2002 Apr;16(4):444-54 [11960321.001]
  • [Cites] Nature. 2002 Jul 11;418(6894):244-51 [12110901.001]
  • [Cites] Genes Dev. 2003 Jun 15;17(12):1475-86 [12783855.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):5118-25 [12941843.001]
  • [Cites] Lancet. 2003 Oct 25;362(9393):1401-3 [14585643.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):37-49 [14749125.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):1110-3 [14871845.001]
  • [Cites] Semin Oncol. 2004 Feb;31(1):90-119 [14970941.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3517-24 [15150106.001]
  • [Cites] Carcinogenesis. 2004 Oct;25(10):1867-77 [15205359.001]
  • [Cites] Nature. 1987 May 28-Jun 3;327(6120):293-7 [3587348.001]
  • [Cites] J Immunol Methods. 1991 Jun 3;139(2):271-9 [1710634.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3516-20 [7682708.001]
  • [Cites] Cell. 1994 Aug 26;78(4):539-42 [8069905.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):237-41 [7812951.001]
  • [Cites] Cancer Res. 1996 May 15;56(10):2422-7 [8625322.001]
  • [Cites] Exp Cell Res. 1998 Apr 10;240(1):107-21 [9570926.001]
  • [Cites] Br J Cancer. 1998 Oct;78(8):1035-42 [9792147.001]
  • [Cites] Clin Cancer Res. 1996 Jul;2(7):1215-9 [9816290.001]
  • [Cites] J Clin Invest. 1999 Jul;104(2):155-62 [10411544.001]
  • (PMID = 18609706.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Antineoplastic Agents; 0 / BCL2L1 protein, human; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Organoplatinum Compounds; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / bcl-X Protein; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC2721439
  •  go-up   go-down


71. Marín García D, Cárdenas Lafuente F, Utrilla Ayala Mdel C, Galán Jurado MV, Jiménez Martín JJ, García Ordóñez MA: [Primary diffuse large B-cell lymphoma of the rectum simulating a rectal adenocarcinoma]. Gastroenterol Hepatol; 2010 Feb;33(2):92-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary diffuse large B-cell lymphoma of the rectum simulating a rectal adenocarcinoma].
  • [Transliterated title] Linfoma de tipo B difuso de células grandes primario rectal que simula un adenocarcinoma de recto.
  • Colorectal lymphoma is an extremely infrequent entity, representing less than 0.5% of all primary colorectal neoplasms.
  • Colorectal localization accounts for 15-20% of all gastrointestinal lymphomas, after the stomach and small intestine.
  • Because the symptoms are non-specific, this disease is usually diagnosed in the advanced stages.
  • Dawson's criteria are highly useful in the differential diagnosis between primary colorectal involvement and gastrointestinal tract involvement secondary to systemic lymphoma, which is important due to the distinct prognosis and treatment of these entities.
  • We report the case of a B-cell non-Hodgkin's lymphoma that was difficult to diagnose and was treated with R-CHOP polychemotherapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Rectal Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonoscopy. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Doxorubicin / therapeutic use. Humans. Immunohistochemistry. Male. Meta-Analysis as Topic. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Prognosis. Radiography, Abdominal. Rectum / pathology. Tomography, X-Ray Computed. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier España, S.L. All rights reserved.
  • (PMID = 19875198.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


72. Niwa K, Onogi K, Yun W, Hirose Y, Tamaya T: Primary lymphoma of the uterine corpus: an unusual location for a common disease--case report. Eur J Gynaecol Oncol; 2007;28(6):522-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the uterine corpus: an unusual location for a common disease--case report.
  • A case of a primary uterine corpus lymphoma in a 75-year-old woman is described.
  • Immunohistochemical studies showed diffuse large B-cell type one.
  • Primary lymphoma of the uterine corpus is considered to be an unusual location for a common disease.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Uterine Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18179154.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


73. Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM: Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood; 2006 May 1;107(9):3639-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma.
  • Most non-Hodgkin lymphomas (NHLs) are of B-cell origin, but the tumor tissue can be variably infiltrated with T cells.
  • In the present study, we have identified a subset of CD4(+)CD25(+) T cells with high levels of CTLA-4 and Foxp3 (intratumoral T(reg) cells) that are overrepresented in biopsy specimens of B-cell NHL (median of 17% in lymphoma biopsies, 12% in inflammatory tonsil, and 6% in tumor-free lymph nodes; P = .001).
  • We found that these CD4(+)CD25(+) T cells suppressed the proliferation and cytokine (IFN-gamma and IL-4) production of infiltrating CD4(+)CD25(-) T cells in response to PHA stimulation.
  • PD-1 was found to be constitutively and exclusively expressed on a subset of infiltrating CD4(+)CD25(-) T cells, and B7-H1 could be induced on intratumoral CD4(+)CD25(+) T cells in B-cell NHL.
  • Anti-B7-H1 antibody or PD-1 fusion protein partly restored the proliferation of infiltrating CD4(+)CD25(-) T cells when cocultured with intratumoral T(reg) cells.
  • Finally, we found that CCL22 secreted by lymphoma B cells is involved in the chemotaxis and migration of intratumoral T(reg) cells that express CCR4, but not CCR8.
  • Taken together, our results suggest that T(reg) cells are highly represented in the area of B-cell NHL and that malignant B cells are involved in the recruitment of these cells into the area of lymphoma.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 1999 May 1;162(9):5317-26 [10228007.001]
  • [Cites] J Immunol. 2004 Jan 15;172(2):834-42 [14707053.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1467-73 [15746048.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Jun;5(3):477-85 [16001955.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6358-63 [16155020.001]
  • [Cites] J Immunol. 2005 Oct 1;175(7):4180-3 [16177055.001]
  • [Cites] J Exp Med. 2001 Sep 17;194(6):847-53 [11560999.001]
  • [Cites] Immunol Rev. 2001 Aug;182:18-32 [11722621.001]
  • [Cites] Nat Immunol. 2001 Dec;2(12):1126-32 [11702067.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8643-6 [11751377.001]
  • [Cites] J Immunol. 2002 May 1;168(9):4272-6 [11970966.001]
  • [Cites] Nat Rev Immunol. 2002 Jun;2(6):389-400 [12093005.001]
  • [Cites] J Exp Med. 2002 Jul 15;196(2):237-46 [12119348.001]
  • [Cites] Adv Immunol. 2003;81:331-71 [14711059.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1755-62 [14604957.001]
  • [Cites] Semin Immunol. 2004 Apr;16(2):81-8 [15036231.001]
  • [Cites] Semin Immunol. 2004 Apr;16(2):89-98 [15036232.001]
  • [Cites] J Immunol. 2004 Jul 15;173(2):1444-53 [15240741.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • [Cites] J Immunol. 1995 Aug 1;155(3):1151-64 [7636184.001]
  • [Cites] Int Immunol. 1998 Dec;10(12):1969-80 [9885918.001]
  • [Cites] J Immunol. 1999 Nov 15;163(10):5211-8 [10553041.001]
  • [Cites] J Exp Med. 2000 Jul 17;192(2):295-302 [10899916.001]
  • [Cites] J Exp Med. 2000 Jul 17;192(2):303-10 [10899917.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):720-6 [11157023.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4766-72 [11406550.001]
  • [Cites] Nat Immunol. 2001 Sep;2(9):816-22 [11526392.001]
  • [Cites] J Exp Med. 2001 Sep 3;194(5):629-44 [11535631.001]
  • [Cites] J Exp Med. 2001 Sep 17;194(6):823-32 [11560997.001]
  • [Cites] J Exp Med. 2002 Jul 15;196(2):247-53 [12119349.001]
  • [Cites] J Exp Med. 2002 Jul 15;196(2):255-60 [12119350.001]
  • [Cites] J Exp Med. 2002 Aug 5;196(3):379-87 [12163566.001]
  • [Cites] J Immunol. 2002 Sep 1;169(5):2756-61 [12193750.001]
  • [Cites] Curr Opin Immunol. 2002 Dec;14(6):771-8 [12413528.001]
  • [Cites] J Allergy Clin Immunol. 2002 Nov;110(5):693-702 [12417876.001]
  • [Cites] J Exp Med. 2002 Nov 18;196(10):1335-46 [12438424.001]
  • [Cites] J Immunol. 2002 Dec 1;169(11):6210-7 [12444126.001]
  • [Cites] J Clin Invest. 2003 Feb;111(3):363-70 [12569162.001]
  • [Cites] Science. 2003 Feb 14;299(5609):1057-61 [12522256.001]
  • [Cites] Nat Immunol. 2003 Apr;4(4):330-6 [12612578.001]
  • [Cites] Nat Immunol. 2003 Apr;4(4):337-42 [12612581.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):1089-99 [12942579.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4404-8 [14555512.001]
  • [Cites] Curr Opin Immunol. 2003 Dec;15(6):690-6 [14630204.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3128-33 [10397255.001]
  • (PMID = 16403912.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA92104; United States / NCI NIH HHS / CA / CA97274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD274; 0 / Antigens, Surface; 0 / Apoptosis Regulatory Proteins; 0 / CD274 protein, human; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor; 0 / Receptors, Interleukin-2; 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC1895773
  •  go-up   go-down


74. Kocjan G: Best Practice No 185. Cytological and molecular diagnosis of lymphoma. J Clin Pathol; 2005 Jun;58(6):561-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Best Practice No 185. Cytological and molecular diagnosis of lymphoma.
  • With the advances in molecular pathology, the cell as a morphological and functional unit has become essential in the diagnosis of lymphoma.
  • Conventional staining, preparation, and interpretation of cells, as seen in fine needle aspiration cytology (FNAC), often used as a first line investigation of lymphadenopathy, is being supplemented with an array of immunocytochemical and molecular analyses, aimed not only at a more precise disease definition, but also at recognising factors that can predict prognosis and response to treatment.
  • Accepting the pitfalls of conventional cytomorphology, this review looks at molecular changes characteristic to particular lymphomas and explores the currently available technology for their detection, with particular reference to cytological material.
  • Future protocols for the diagnosis and management of patients with lymphadenopathy should include FNAC as an initial investigation, followed by immunocytochemistry and molecular investigations.
  • Tissue biopsy, the conventional method of diagnosis, may be avoided in selected cases.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Biopsy, Fine-Needle. Chromosome Aberrations. Diagnosis, Differential. Gene Expression Profiling / methods. Humans. Nucleic Acid Hybridization / methods. Polymerase Chain Reaction / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2000 Jan;27(1):85-94 [10564590.001]
  • [Cites] Arch Pathol Lab Med. 1999 Dec;123(12):1189-207 [10583924.001]
  • [Cites] Cytopathology. 1999 Oct;10(5):291-7 [10588346.001]
  • [Cites] Cancer. 1999 Dec 25;87(6):325-45 [10603186.001]
  • [Cites] Am J Clin Pathol. 2000 May;113(5):688-99 [10800402.001]
  • [Cites] Nature. 2000 Nov 9;408(6809):216-21 [11089977.001]
  • [Cites] N Engl J Med. 2004 Aug 26;351(9):856-7 [15329421.001]
  • [Cites] Blood. 1992 Oct 1;80(7):1781-7 [1356511.001]
  • [Cites] Blood. 1992 Nov 15;80(10):2594-9 [1384792.001]
  • [Cites] Blood. 1993 Oct 15;82(8):2289-95 [8400281.001]
  • [Cites] Oncogene. 1993 Dec;8(12):3447-57 [8247550.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Am J Pathol. 1994 Jun;144(6):1312-9 [8203469.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Acta Cytol. 1995 Mar-Apr;39(2):180-6 [7887065.001]
  • [Cites] Diagn Mol Pathol. 1995 Mar;4(1):25-31 [7735552.001]
  • [Cites] Blood. 1996 Dec 1;88(11):4110-7 [8943844.001]
  • [Cites] Cytopathology. 1997 Apr;8(2):114-21 [9134337.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Monogr Pathol. 1997;(39):118-33 [9249823.001]
  • [Cites] Diagn Mol Pathol. 1997 Jun;6(3):154-60 [9276187.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1680-7 [9473234.001]
  • [Cites] Cancer Genet Cytogenet. 2003 May;143(1):73-9 [12742158.001]
  • [Cites] Cancer. 2003 Jun 15;97(12):2960-71 [12784330.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4944-51 [12595313.001]
  • [Cites] Cytopathology. 2003 Aug;14(4):186-90 [12873310.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6 [12900505.001]
  • [Cites] Br J Haematol. 2003 Sep;122(5):745-59 [12930384.001]
  • [Cites] Arch Pathol Lab Med. 2003 Sep;127(9):1148-60 [12946230.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3681-95 [11090048.001]
  • [Cites] Eur J Haematol. 2001 Feb;66(2):100-6 [11168517.001]
  • [Cites] Mol Diagn. 2000 Dec;5(4):287-99 [11172493.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2098-104 [11264177.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Apr 1;126(1):26-33 [11343775.001]
  • [Cites] Mod Pathol. 2001 May;14(5):472-81 [11353059.001]
  • [Cites] Cytopathology. 2001 Jun;12(3):157-67 [11380557.001]
  • [Cites] J Clin Pathol. 2001 Jul;54(7):565-7 [11429433.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2001 Aug 20;60(2):135-40 [11518591.001]
  • [Cites] Mol Diagn. 2001 Sep;6(3):161-8 [11571709.001]
  • [Cites] Blood. 2002 Jan 15;99(2):716-8 [11781262.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] Diagn Mol Pathol. 2002 Mar;11(1):47-57 [11854602.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):794-801 [11895911.001]
  • [Cites] Hematol J. 2000;1(1):53-66 [11920170.001]
  • [Cites] Breast Cancer Res. 2002;4(3):R3 [12052255.001]
  • [Cites] Semin Oncol. 2002 Jun;29(3):258-63 [12063678.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Methods Mol Biol. 2002;204:143-53 [12397796.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2363-7 [12424193.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):185-97 [12620412.001]
  • [Cites] Br J Haematol. 2003 Apr;121(1):49-56 [12670331.001]
  • [Cites] Diagn Cytopathol. 2003 Apr;28(4):191-5 [12672094.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1777-85 [12724484.001]
  • [Cites] Acta Cytol. 2004 Mar-Apr;48(2):119-26 [15085740.001]
  • [Cites] Diagn Cytopathol. 2004 May;30(5):332-40 [15108231.001]
  • [Cites] Eur J Hum Genet. 2004 Jun;12(6):423 [15162123.001]
  • [Cites] Leuk Lymphoma. 2003;44 Suppl 3:S13-20 [15202520.001]
  • [Cites] Am J Pathol. 2004 Jul;165(1):159-66 [15215171.001]
  • [Cites] Diagn Cytopathol. 2004 Jul;31(1):23-30 [15236260.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3046-52 [15284254.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):644-53 [15286744.001]
  • [Cites] Am J Hematol. 2003 Sep;74(1):78-84 [12949897.001]
  • [Cites] Leuk Lymphoma. 2003 Aug;44(8):1385-94 [12952233.001]
  • [Cites] Exp Hematol. 2003 Sep;31(9):784-8 [12962724.001]
  • [Cites] Acta Cytol. 2003 Sep-Oct;47(5):744-8 [14526672.001]
  • [Cites] Semin Hematol. 2003 Oct;40(4):296-307 [14582080.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] Histopathology. 2003 Dec;43(6):509-28 [14636252.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5980-7 [14676123.001]
  • [Cites] Cancer. 2003 Dec 25;99(6):385-93 [14681948.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Mod Pathol. 2004 Jan;17(1):131-5 [14657953.001]
  • [Cites] J Exp Med. 2004 Jan 5;199(1):59-68 [14707115.001]
  • [Cites] Lancet. 2004 Jan 10;363(9403):105-11 [14726163.001]
  • [Cites] Hematol J. 2004;5(1):69-76 [14745433.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):474-83 [14752070.001]
  • [Cites] Pathology. 2004 Feb;36(1):19-44 [14757555.001]
  • [Cites] Semin Immunol. 1998 Apr;10(2):133-42 [9618759.001]
  • [Cites] Cancer. 1998 Aug 25;84(4):252-61 [9723601.001]
  • [Cites] Diagn Mol Pathol. 1998 Aug;7(4):209-14 [9917131.001]
  • [Cites] Cell. 1999 Jan 8;96(1):35-45 [9989495.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3601-9 [10339464.001]
  • [Cites] Diagn Cytopathol. 1999 Aug;21(2):98-104 [10425046.001]
  • [Cites] Diagn Cytopathol. 1999 Oct;21(4):240-9 [10495316.001]
  • [Cites] J Clin Lab Anal. 1999;13(5):224-8 [10494131.001]
  • (PMID = 15917402.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 90
  • [Other-IDs] NLM/ PMC1770685
  •  go-up   go-down


75. Luo RF, Zhao S, Tibshirani R, Myklebust JH, Sanyal M, Fernandez R, Gratzinger D, Marinelli RJ, Lu ZS, Wong A, Levy R, Levy S, Natkunam Y: CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. Hum Pathol; 2010 Feb;41(2):271-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas.
  • CD81 is a tetraspanin cell surface protein that regulates CD19 expression in B lymphocytes and enables hepatitis C virus infection of human cells.
  • Immunohistologic analysis in normal hematopoietic tissue showed strong staining for CD81 in normal germinal center B cells, a cell type in which its increased expression has not been previously recognized.
  • High-dimensional flow cytometry analysis of normal hematopoietic tissue confirmed that among B- and T-cell subsets, germinal center B cells showed the highest level of CD81 expression.
  • In more than 800 neoplastic tissue samples, its expression was also found in most non-Hodgkin lymphomas.
  • Staining for CD81 was rarely seen in multiple myeloma, Hodgkin lymphoma, or myeloid leukemia.
  • In hierarchical cluster analysis of diffuse large B-cell lymphoma, staining for CD81 was most similar to other germinal center B cell-associated markers, particularly LMO2.
  • By flow cytometry, CD81 was expressed in diffuse large B-cell lymphoma cells independent of the presence or absence of CD10, another germinal center B-cell marker.
  • The detection of CD81 in routine biopsy samples and its differential expression in lymphoma subtypes, particularly diffuse large B-cell lymphoma, warrant further study to assess CD81 expression and its role in the risk stratification of patients with diffuse large B-cell lymphoma.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] J Immunol. 2002 Dec 15;169(12):6691-5 [12471100.001]
  • [Cites] Leuk Lymphoma. 2003 Jul;44(7):1113-20 [12916862.001]
  • [Cites] J Immunol. 2003 Oct 15;171(8):4062-72 [14530327.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] PLoS Biol. 2004 Apr;2(4):E108 [15094809.001]
  • [Cites] N Engl J Med. 2004 Apr 29;350(18):1828-37 [15115829.001]
  • [Cites] Mod Pathol. 2001 Jul;14(7):686-94 [11455001.001]
  • [Cites] Int J Cancer. 2000 Jul 20;89(4):313-24 [10956404.001]
  • [Cites] J Pathol. 2000 Aug;191(4):452-61 [10918222.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Immunity. 1997 Feb;6(2):107-18 [9047233.001]
  • [Cites] Science. 1998 Oct 30;282(5390):938-41 [9794763.001]
  • [Cites] Nat Rev Immunol. 2005 Feb;5(2):136-48 [15688041.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1851-61 [15550490.001]
  • [Cites] Blood. 2005 May 15;105(10):3979-86 [15677569.001]
  • [Cites] J Virol. 2005 Jul;79(13):8079-89 [15956553.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5027-33 [15955905.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18544-9 [16339892.001]
  • [Cites] J Clin Oncol. 2006 Feb 20;24(6):995-1007 [16418498.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1636-42 [17038524.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1378-83 [18042694.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D871-7 [17989087.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):447-54 [18086797.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5509-14 [18445689.001]
  • [Cites] J Immunol. 2008 Jul 1;181(1):174-85 [18566382.001]
  • (PMID = 20004001.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA034233; United States / NCI NIH HHS / CA / CA34233; United States / NCI NIH HHS / CA / P01 CA034233-21; United States / NCI NIH HHS / CA / CA034233-21; United States / NCI NIH HHS / CA / CA33399; United States / NCI NIH HHS / CA / R37 CA033399
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD81; 0 / CD81 protein, human
  • [Other-IDs] NLM/ NIHMS139240; NLM/ PMC2813949
  •  go-up   go-down


76. Chan WK, Au WY, Wong CY, Liang R, Leung AY, Kwong YL, Khong PL: Metabolic activity measured by F-18 FDG PET in natural killer-cell lymphoma compared to aggressive B- and T-cell lymphomas. Clin Nucl Med; 2010 Aug;35(8):571-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic activity measured by F-18 FDG PET in natural killer-cell lymphoma compared to aggressive B- and T-cell lymphomas.
  • PURPOSE: We aim to compare the metabolic activity by F-18 fluorodeoxyglucose (FDG) uptake across the various histologic subtypes of non-Hodgkin lymphoma (NHL) in a single center, with particular interest in the natural killer (NK)-cell lymphoma subtype for which literature is scarce because of the rarity of these lymphomas in Western populations.
  • Mean SUV(max) of 4 major groups of NHL; aggressive B-cell (n = 63), indolent B-cell (n = 31), NK-cell (n = 14) and aggressive T-cell lymphoma (n = 9), was compared using one-way analysis of variance.
  • RESULTS: SUV(max) (mean +/- standard deviation) of NK-cell lymphoma (9.2 +/- 4.5) was significantly lower than aggressive B-cell lymphoma (14.1 +/- 6.4) (P = 0.013), similar to aggressive T-cell lymphoma (7.6 +/- 3.9) and significantly higher than that of indolent B-cell lymphoma (5.3 +/- 3.1) (P = 0.039).
  • Although NK-cell lymphomas demonstrate high metabolic activity, SUV(max) is significantly lower than its aggressive B-cell counterparts.
  • This may reflect the large amount of coagulative necrosis and inflammatory component of the tumor, and the relatively slower tumor growth rate compared with aggressive B-cell lymphomas.
  • [MeSH-major] Fluorodeoxyglucose F18. Killer Cells, Natural / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / radionuclide imaging. Lymphoma, T-Cell / metabolism. Lymphoma, T-Cell / radionuclide imaging. Positron-Emission Tomography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20631501.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


77. Anderson LA, Gadalla S, Morton LM, Landgren O, Pfeiffer R, Warren JL, Berndt SI, Ricker W, Parsons R, Engels EA: Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer; 2009 Jul 15;125(2):398-405
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Logistic regression was used to derive odds ratios (ORs) comparing the prevalence of autoimmune conditions in cases and controls, by lymphoid malignancy subtype, adjusted for gender, age at malignancy/selection, year of malignancy/selection, race and number of physician claims.
  • The strongest associations observed by non-Hodgkin lymphoma (NHL) subtypes were diffuse large B-cell lymphoma with rheumatoid arthritis (OR 1.4, 95%CI 1.2-1.5) and Sjögren syndrome (2.0, 1.5-2.8); T-cell lymphoma with hemolytic anemia (9.7, 4.3-22), psoriasis (3.1, 2.5-4.0), discoid lupus erythematosus (4.4, 2.3-8.4) and celiac disease (5.0, 2.4-14.
  • ); and marginal zone lymphoma with Sjögren syndrome (6.6, 4.6-9.5), systemic lupus erythematosus (2.8, 1.7-4.7) and hemolytic anemia (7.4, 3.1-18).
  • Hodgkin lymphoma was associated with systemic lupus erythematosus (3.5, 1.9-6.7).
  • Several autoimmune conditions were associated with increased risk of lymphoid neoplasms, especially NHLs of diffuse large B-cell, marginal zone and T-cell subtypes.
  • [MeSH-major] Autoimmune Diseases / epidemiology. Lymphoma / complications. Population Surveillance

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published 2009 UICC.
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):791-4 [11309323.001]
  • [Cites] Ann Oncol. 2001 Jun;12(6):853-8 [11484964.001]
  • [Cites] J Invest Dermatol. 2001 Dec;117(6):1531-7 [11886519.001]
  • [Cites] Med Oncol. 2007;24(4):469-71 [17917102.001]
  • [Cites] Arthritis Rheum. 2008 Mar;58(3):657-66 [18311836.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3388-94 [18239085.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]
  • [Cites] Annu Rev Med. 2005;56:29-44 [15660500.001]
  • [Cites] Blood. 2000 May 1;95(9):2786-92 [10779422.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):497-502 [11054684.001]
  • [Cites] Scand J Rheumatol. 2002;31(2):66-71 [12109649.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-3-18 [12187163.001]
  • [Cites] Nat Rev Immunol. 2002 Sep;2(9):647-55 [12209133.001]
  • [Cites] J Assoc Physicians India. 2002 Sep;50:1186-8 [12516708.001]
  • [Cites] Arthritis Rheum. 2003 Apr;48(4):963-70 [12687538.001]
  • [Cites] Cancer Causes Control. 2004 May;15(4):419-28 [15141141.001]
  • [Cites] Cancer. 2004 Aug 15;101(4):790-5 [15305411.001]
  • [Cites] Am J Med Sci. 1978 Jan-Feb;275(1):93-8 [665715.001]
  • [Cites] Br J Cancer. 1989 May;59(5):810-3 [2736218.001]
  • [Cites] Cancer. 1993 Feb 1;71(3):745-50 [8431855.001]
  • [Cites] BMJ. 1998 Jul 18;317(7152):180-1 [9665898.001]
  • [Cites] Ann Intern Med. 1999 Apr 6;130(7):591-601 [10189330.001]
  • [Cites] Gut. 2005 Jan;54(1):54-9 [15591504.001]
  • [Cites] Clin Chem Lab Med. 2005;43(10):1158-63 [16197314.001]
  • [Cites] Arch Intern Med. 2005 Nov 14;165(20):2337-44 [16287762.001]
  • [Cites] Am J Epidemiol. 2005 Dec 15;162(12):1153-61 [16251389.001]
  • [Cites] Blood. 2006 Jan 1;107(1):265-76 [16150940.001]
  • [Cites] J Natl Cancer Inst. 2006 Jan 4;98(1):51-60 [16391371.001]
  • [Cites] Arthritis Rheum. 2006 Mar;54(3):692-701 [16508929.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3095-8 [16395700.001]
  • [Cites] Korean J Intern Med. 2006 Mar;21(1):46-9 [16646565.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] J Invest Dermatol. 2006 Oct;126(10):2194-201 [16741509.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 20;98(18):1321-30 [16985251.001]
  • [Cites] Eur J Cancer. 2006 Nov;42(17):3028-33 [16945522.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2069-77 [17119030.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):405-8 [17337643.001]
  • [Cites] Rheumatology (Oxford). 2007 May;46(5):830-2 [17255135.001]
  • [Cites] Leuk Lymphoma. 2007 Jun;48(6):1139-49 [17577777.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Clin Rheumatol. 2007 Sep;26(9):1491-4 [17297594.001]
  • [Cites] Nat Clin Pract Rheumatol. 2007 Oct;3(10):561-9 [17906611.001]
  • [Cites] J Clin Epidemiol. 2000 Dec;53(12):1258-67 [11146273.001]
  • [Cites] J Leukoc Biol. 2001 Mar;69(3):331-9 [11261778.001]
  • [Cites] Dermatologica. 1989;178(4):221-4 [2767291.001]
  • [Cites] Cancer. 1992 Dec 1;70(11):2592-6 [1423186.001]
  • [Cites] J Natl Cancer Inst. 1993 Feb 17;85(4):307-11 [8426374.001]
  • (PMID = 19365835.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010150-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS81238; NLM/ PMC2692814
  •  go-up   go-down


78. Sumida T, Kitadai Y, Masuda H, Shinagawa K, Tanaka M, Kodama M, Kuroda T, Hiyama T, Tanaka S, Nakayama H, Yoshihara M, Yoshino T, Chayama K: Rapid progression of Epstein-Barr-virus-positive gastric diffuse large B-cell lymphoma during chemoradiotherapy: a case report. Clin J Gastroenterol; 2008 Oct;1(3):105-109
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid progression of Epstein-Barr-virus-positive gastric diffuse large B-cell lymphoma during chemoradiotherapy: a case report.
  • Biopsy specimens showed diffuse infiltration of large atypical lymphoid cells in which Epstein-Barr virus (EBV) was detected by in situ hybridization.
  • Diffuse large B-cell lymphoma (DLBCL), stage II1, was diagnosed.
  • Partial remission was achieved by chemotherapy, but the disease progressed rapidly during radiotherapy.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):16-26 [12502924.001]
  • [Cites] Surgery. 1997 May;121(5):501-5 [9142147.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2444-51 [15941916.001]
  • [Cites] Br J Haematol. 2001 Jun;113(3):814-21 [11380475.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):44-50 [15213617.001]
  • [Cites] N Engl J Med. 1998 Jul 2;339(1):21-6 [9647875.001]
  • [Cites] Cancer Sci. 2007 Sep;98(9):1281-7 [17627615.001]
  • [Cites] Leuk Lymphoma. 2001 May;41(5-6):669-73 [11378585.001]
  • [Cites] Am J Clin Pathol. 2007 Oct;128(4):579-84 [17875508.001]
  • [Cites] Cancer Sci. 2005 Jun;96(6):349-52 [15958057.001]
  • [Cites] Cancer Sci. 2006 Feb;97(2):163-6 [16441428.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):29-34 [11801537.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(13):2306-11 [9038614.001]
  • [Cites] Br J Haematol. 2000 Oct;111(1):239-46 [11091207.001]
  • [Cites] Ann Oncol. 1997;8 Suppl 1:85-8 [9187438.001]
  • [Cites] Leuk Lymphoma. 1995 Apr;17(3-4):321-6 [8580802.001]
  • (PMID = 26193647.001).
  • [ISSN] 1865-7257
  • [Journal-full-title] Clinical journal of gastroenterology
  • [ISO-abbreviation] Clin J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Chemoradiotherapy / Diffuse large B-cell lymphoma / Epstein-Barr virus
  •  go-up   go-down


79. Honeychurch J, Glennie MJ, Illidge TM: Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells. Cancer Res; 2005 Aug 15;65(16):7493-501
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells.
  • We therefore assessed the efficacy of combining anti-CD40 mAb, known to elicit CTL responses against murine lymphoma models with the commonly used cytotoxic drug, cyclophosphamide.
  • In vivo tracking experiments reveal that pretreatment with cyclophosphamide leads to diminished CTL expansion, as well as an increased number of CD11b+ cells that display an activated phenotype.
  • These latter cells are able to inhibit T-cell proliferation, at least in part via production of nitric oxide, but do not induce T-cell apoptosis.
  • Furthermore, adoptive transfer of the induced CD11b+ cells is sufficient to inhibit anti-CD40 therapy in tumor-bearing recipients.
  • We have shown that the timing of cyclophosphamide relative to mAb administration is critical to the therapeutic outcome, and although the combination can improve survival, cyclophosphamide given prior to immunotherapy may generate a population of myeloid cells that can interfere with CTL responses and compromise the therapeutic outcome.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antigens, CD11b / immunology. Antigens, CD40 / immunology. Cyclophosphamide / pharmacology. Immunosuppressive Agents / pharmacology. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16103104.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD11b; 0 / Antigens, CD40; 0 / Immunosuppressive Agents; 31C4KY9ESH / Nitric Oxide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


80. Chowdhury M, Endo M, Chiba T, Kudara N, Oana S, Sato K, Akasaka R, Tomita K, Fujiwara S, Mizutani T, Sugai T, Takikawa Y, Suzuki K: Characterization of follicular lymphoma in the small intestine using double-balloon endoscopy. Gastroenterol Res Pract; 2009;2009:835258
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of follicular lymphoma in the small intestine using double-balloon endoscopy.
  • Follicular lymphomas occur rarely in the gastrointestinal tract, representing only 1-3% of all gastrointestinal tract B-cell non-Hodgkin lymphomas.
  • We describe endoscopic analysis of 3 cases of follicular lymphoma in the small intestine using double-balloon endoscopy.
  • These cases are the first follicular lymphomas in the small intestine evaluated using narrow-band imaging or Fuji Intelligent Chromo Endoscopy to be reported.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1979 Aug;44(2):645-51 [383259.001]
  • [Cites] Chin Med J (Engl). 2008 Jun 5;121(11):977-82 [18706244.001]
  • [Cites] Mod Pathol. 1992 Nov;5(6):631-3 [1285443.001]
  • [Cites] Am J Pathol. 1992 May;140(5):1089-95 [1374590.001]
  • [Cites] Am J Pathol. 1992 Jun;140(6):1327-35 [1376556.001]
  • [Cites] Am J Surg Pathol. 1992 Jul;16(7):637-40 [1530105.001]
  • [Cites] Semin Hematol. 1988 Apr;25(2 Suppl 2):11-6 [2456618.001]
  • [Cites] Cancer Treat Rep. 1981 May-Jun;65(5-6):413-8 [7016324.001]
  • [Cites] Hematol Oncol. 1995 May-Jun;13(3):153-63 [7622145.001]
  • [Cites] J Surg Oncol. 1995 Sep;60(1):41-9 [7666666.001]
  • [Cites] Mod Pathol. 1994 Jun;7(5):560-4 [7937722.001]
  • [Cites] Ann Oncol. 1994 May;5(5):397-400 [8075046.001]
  • [Cites] Gastroenterology. 1994 Apr;106(4):846-58 [8143991.001]
  • [Cites] J Clin Gastroenterol. 1994 Mar;18(2):99-104 [8189031.001]
  • [Cites] Am J Surg Pathol. 1996 May;20(5):627-40 [8619427.001]
  • [Cites] Histopathology. 1996 Jun;28(6):487-95 [8803592.001]
  • [Cites] Histopathology. 1995 Dec;27(6):501-8 [8838329.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):7-16 [8978336.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1587-94 [9193357.001]
  • [Cites] Am J Clin Pathol. 1997 Sep;108(3):302-7 [9291459.001]
  • [Cites] Cancer. 1997 Dec 15;80(12):2311-20 [9404709.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):688-93 [10800987.001]
  • [Cites] Blood. 2000 Jul 15;96(2):410-9 [10887100.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3861-73 [11559724.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):216-24 [11812943.001]
  • [Cites] Ann Oncol. 2003 Apr;14(4):623-9 [12649111.001]
  • [Cites] Semin Oncol. 2003 Feb;30(1 Suppl 2):16-20 [12652460.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2 Suppl 4):66-71 [15124137.001]
  • [Cites] Histopathology. 2005 Nov;47(5):467-78 [16241994.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E26-7 [17285496.001]
  • [Cites] Dig Dis Sci. 2007 Apr;52(4):1031-5 [17353993.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E86-7 [17440873.001]
  • [Cites] Intern Med. 2007;46(11):705-9 [17541220.001]
  • [Cites] Endoscopy. 2008 Apr;40(4):343-6 [18067068.001]
  • [Cites] Endoscopy. 2008 Sep;40 Suppl 2:E8-9 [18278712.001]
  • [Cites] J Clin Pathol. 1992 Nov;45(11):1018-22 [1280654.001]
  • (PMID = 19901998.001).
  • [ISSN] 1687-630X
  • [Journal-full-title] Gastroenterology research and practice
  • [ISO-abbreviation] Gastroenterol Res Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2773429
  •  go-up   go-down


81. Terrano DT, Upreti M, Chambers TC: Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol Cell Biol; 2010 Feb;30(3):640-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis.
  • Despite detailed knowledge of the components of the spindle assembly checkpoint, a molecular explanation of how cells die after prolonged spindle checkpoint activation, and thus how microtubule inhibitors and other antimitotic drugs ultimately elicit their lethal effects, has yet to emerge.
  • Mitotically arrested cells typically display extensive phosphorylation of two key antiapoptotic proteins, Bcl-x(L) and Bcl-2, and evidence suggests that phosphorylation disables their antiapoptotic activity.
  • In this report, evidence is presented that cyclin-dependent kinase 1 (CDK1)/cyclin B catalyzes mitotic-arrest-induced Bcl-x(L)/Bcl-2 phosphorylation.
  • When mitosis is prolonged in the absence of microtubule inhibition, Bcl-x(L) and Bcl-2 become highly phosphorylated.
  • Transient overexpression of nondegradable cyclin B1 caused apoptotic death, which was blocked by a phosphodefective Bcl-x(L) mutant but not by a phosphomimetic Bcl-x(L) mutant, confirming Bcl-x(L) as a key target of proapoptotic CDK1 signaling.
  • These findings suggest a model whereby a switch in the duration of CDK1 activation, from transient during mitosis to sustained during mitotic arrest, dramatically increases the extent of Bcl-x(L)/Bcl-2 phosphorylation, resulting in inactivation of their antiapoptotic function.
  • Thus, phosphorylation of antiapoptotic Bcl-2 proteins acts as a sensor for CDK1 signal duration and as a functional link coupling mitotic arrest to apoptosis.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2003 Mar 13;538(1-3):41-7 [12633850.001]
  • [Cites] J Biol Chem. 2008 Dec 19;283(51):35517-25 [18974096.001]
  • [Cites] Cell. 1995 Jan 27;80(2):179-85 [7834738.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4507-11 [7753834.001]
  • [Cites] Cancer Res. 1997 Jan 1;57(1):130-5 [8988053.001]
  • [Cites] Eur J Biochem. 1997 Jan 15;243(1-2):527-36 [9030781.001]
  • [Cites] Curr Opin Cell Biol. 1997 Dec;9(6):807-14 [9425345.001]
  • [Cites] Cell Growth Differ. 1998 Jan;9(1):23-9 [9438385.001]
  • [Cites] Mol Cell Biol. 1998 Jun;18(6):3509-17 [9584191.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3331-8 [9699663.001]
  • [Cites] J Biol Chem. 1998 Nov 13;273(46):30777-84 [9804855.001]
  • [Cites] Mol Cell. 1998 Nov;2(5):581-91 [9844631.001]
  • [Cites] J Cell Biol. 1999 Mar 8;144(5):891-901 [10085289.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):4797-802 [10220373.001]
  • [Cites] Mol Cell Biol. 1999 Dec;19(12):8469-78 [10567572.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):21661-7 [10766756.001]
  • [Cites] Cell. 2000 Aug 4;102(3):279-91 [10975519.001]
  • [Cites] J Biol Chem. 2000 Sep 29;275(39):29980-5 [10913135.001]
  • [Cites] Cell. 2000 Oct 13;103(2):239-52 [11057897.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6403-7 [11103805.001]
  • [Cites] Neoplasia. 2001 Jan-Feb;3(1):70-9 [11326318.001]
  • [Cites] Curr Biol. 2001 Jun 5;11(11):R431-5 [11516665.001]
  • [Cites] Oncogene. 2001 Sep 27;20(43):6172-80 [11593425.001]
  • [Cites] Nat Cell Biol. 2002 Aug;4(8):556-64 [12134156.001]
  • [Cites] Cancer Cell. 2002 Jul;2(1):43-54 [12150824.001]
  • [Cites] Cell Death Differ. 2002 Dec;9(12):1287-93 [12478465.001]
  • [Cites] Dev Cell. 2004 Nov;7(5):637-51 [15525526.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):316-23 [15549093.001]
  • [Cites] Oncogene. 2005 Jan 6;24(1):107-17 [15531923.001]
  • [Cites] Cancer Cell. 2005 Jul;8(1):7-12 [16023594.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 11;103(28):10660-5 [16818887.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 May;8(5):379-93 [17426725.001]
  • [Cites] Mol Cell. 2007 Apr 27;26(2):301-10 [17466630.001]
  • [Cites] J Cell Biol. 2007 Nov 19;179(4):671-85 [18025303.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Jan;9(1):47-59 [18097445.001]
  • [Cites] Nat Rev Cancer. 2008 Feb;8(2):121-32 [18202696.001]
  • [Cites] Cell Cycle. 2008 May 15;7(10):1449-61 [18418077.001]
  • [Cites] Apoptosis. 2003 Oct;8(5):413-50 [12975575.001]
  • (PMID = 19917720.001).
  • [ISSN] 1098-5549
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109821; United States / NCI NIH HHS / CA / CA-109821
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Tubulin Modulators; 0 / bcl-X Protein; 5V9KLZ54CY / Vinblastine; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.22 / CDC2 Protein Kinase; EC 2.7.12.2 / MAP Kinase Kinase 4
  • [Other-IDs] NLM/ PMC2812246
  •  go-up   go-down


82. Singh F, Weinberg JM: Partial remission of psoriasis following rituximab therapy for non-Hodgkin lymphoma. Cutis; 2005 Sep;76(3):186-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Partial remission of psoriasis following rituximab therapy for non-Hodgkin lymphoma.
  • Rituximab, a human-mouse, chimeric, monoclonal antibody that targets the B-cell CD20 antigen and causes rapid and specific B-cell depletion, is indicated for the treatment of low-grade or follicular, relapsed or refractory, CD20+ B-cell, non-Hodgkin lymphoma (NHL).
  • We report the case of a middle-aged woman with psoriasis who experienced a partial sustained remission of her psoriasis after treatment with rituximab for NHL and discuss potential pathophysiologic mechanisms for this unexpected effect in a condition known to be mediated by T cells.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Psoriasis / drug therapy


83. Pan J, Huang H, Sun L, Fang B, Yeung SC: Bcl-2-associated X protein is the main mediator of manumycin a-induced apoptosis in anaplastic thyroid cancer cells. J Clin Endocrinol Metab; 2005 Jun;90(6):3583-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2-associated X protein is the main mediator of manumycin a-induced apoptosis in anaplastic thyroid cancer cells.
  • We previously demonstrated that the combination of paclitaxel and manumycin A, a farnesyltransferase inhibitor, enhanced apoptosis of anaplastic thyroid cancer (ATC) cells.
  • We also found that manumycin induced translocation of Bcl-2-associated X protein (Bax), another possible mediator of cytochrome c release, from the cytosol to the mitochondria.
  • Using a binary adenoviral vector system, we found that overexpression of Bax enhanced manumycin-induced apoptosis of ATC cells, and the combination of manumycin and overexpression of Bax increased inhibition of ATC xenograft growth in nude mice.
  • Thus, we concluded that manumycin-induced apoptosis in ATC cells was primarily mediated by Bax and that increasing Bax expression may sensitize ATC cells to manumycin.
  • [MeSH-major] Apoptosis / drug effects. Polyenes / toxicity. Proto-Oncogene Proteins c-bcl-2 / physiology. Thyroid Neoplasms / pathology. Thyroid Neoplasms / physiopathology
  • [MeSH-minor] Animals. Carcinoma. Cell Line, Tumor. Enzyme Inhibitors / toxicity. Humans. Mice. Mice, Nude. Mitochondria / drug effects. Mitochondria / pathology. Mitochondria / ultrastructure. Paclitaxel / toxicity. Polyunsaturated Alkamides. Transplantation, Heterologous. bcl-X Protein

  • Genetic Alliance. consumer health - Thyroid cancer, anaplastic.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15769983.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16672
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL2L1 protein, human; 0 / Bcl2l1 protein, mouse; 0 / Enzyme Inhibitors; 0 / Polyenes; 0 / Polyunsaturated Alkamides; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-X Protein; 52665-74-4 / manumycin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


84. Wu LX, La Rose J, Chen L, Neale C, Mak T, Okkenhaug K, Wange R, Rottapel R: CD28 regulates the translation of Bcl-xL via the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway. J Immunol; 2005 Jan 1;174(1):180-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD28 regulates the translation of Bcl-xL via the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway.
  • In concert with the TCR, CD28 promotes T cell survival by regulating the expression of the antiapoptotic protein Bcl-x(L).
  • The mechanism by which CD28 mediates the induction of Bcl-x(L) remains unknown.
  • We show that although signaling through the TCR is sufficient to stimulate transcription of Bcl-x(L) mRNA, CD28, by activating PI3K and mammalian target of rapamycin, provides a critical signal that regulates the translation of Bcl-x(L) transcripts.
  • We observe that CD28 induced 4E-binding protein-1 phosphorylation, an inhibitor of the translational machinery, and that CD28 costimulation directly augmented the translation of a Bcl-x(L) 5'-untranslated region reporter construct.
  • Lastly, costimulation by CD28 shifted the distribution of Bcl-x(L) mRNA transcripts from the pretranslation complex to the translationally active polyribosomes.
  • These results demonstrate that CD28 relieves the translational inhibition of Bcl-x(L) in a PI3K/mammalian target of rapamycin-dependent manner.
  • [MeSH-major] Antigens, CD28 / metabolism. Phosphatidylinositol 3-Kinases / metabolism. Protein Biosynthesis / immunology. Proto-Oncogene Proteins c-bcl-2 / metabolism. T-Lymphocytes / immunology
  • [MeSH-minor] Animals. Antigens, CD3 / immunology. Antigens, CD3 / metabolism. Blotting, Northern. Cell Death / physiology. Cells, Cultured. Chromones / pharmacology. Enzyme Inhibitors / pharmacology. Flow Cytometry. Humans. Immunosuppressive Agents / pharmacology. Interleukin-2 / biosynthesis. Interleukin-2 / immunology. Jurkat Cells. Mice. Mice, Transgenic. Morpholines / pharmacology. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Sirolimus / pharmacology. Transfection. bcl-X Protein

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15611240.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD28; 0 / Antigens, CD3; 0 / BCL2L1 protein, human; 0 / Bcl2l1 protein, mouse; 0 / Chromones; 0 / Enzyme Inhibitors; 0 / Immunosuppressive Agents; 0 / Interleukin-2; 0 / Morpholines; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / bcl-X Protein; 154447-36-6 / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


85. Wang J, Chen C, Lau S, Raghavan RI, Rowsell EH, Said J, Weiss LM, Huang Q: CD3-positive large B-cell lymphoma. Am J Surg Pathol; 2009 Apr;33(4):505-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD3-positive large B-cell lymphoma.
  • It is not uncommon for some B-lineage non-Hodgkin lymphomas (NHLs) to aberrantly coexpress T-cell markers, particularly CD5, as well as CD7, CD2, CD4, and/or CD8 in rare cases.
  • Cases of CD3-positive B-cell NHL, however, have not previously been described in the literature.
  • We present 4 cases of large B-cell lymphoma aberrantly coexpressing T-cell marker CD3 and B-lineage markers as well as demonstrating clonal rearrangement of the immunoglobulin genes but not the gamma T-cell receptor gene.
  • To our knowledge, this represents the first series report of B-cell NHL coexpressing T-lineage-specific marker CD3.
  • The identification of such cases indicates that the use of CD3 antibody alone in paraffin sections may lead to an incorrect determination of cell lineage in some B-cell NHL.
  • Immunohistochemistry using additional cell lineage specific markers or molecular analysis for antigen receptor gene rearrangements are necessary for correct determination of the cell lineage in such cases.
  • [MeSH-major] Antigens, CD3 / analysis. B-Lymphocytes / pathology. Biomarkers, Tumor / analysis. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Aged, 80 and over. Clone Cells. DNA, Neoplasm / analysis. Female. Gene Rearrangement. Genes, Immunoglobulin / genetics. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / isolation & purification. Humans. In Situ Hybridization. Male. Middle Aged. RNA, Viral / analysis. RNA-Binding Proteins / analysis. Ribosomal Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011566.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RNA, Viral; 0 / RNA-Binding Proteins; 0 / Ribosomal Proteins; 135844-68-7 / RPL22 protein, human
  •  go-up   go-down


86. Khosravi A, Anjidani AA: Spontaneous recovery of chylothorax caused by lymphoma. Hematol Oncol Stem Cell Ther; 2009;2(3):431-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous recovery of chylothorax caused by lymphoma.
  • Chylothorax is a rare complication with both traumatic and non-traumatic causes.
  • The most common non-traumatic cause is malignancy, especially lymphoma.
  • We evaluated the case of a patient suffering from a low-grade lymphoma who developed chylothorax that did not respond to chemotherapy and conservative treatment.
  • [MeSH-major] Chylothorax / etiology. Lymphoma, Non-Hodgkin / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20139059.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


87. Dancey JE, Curiel R, Purvis J: Evaluating temsirolimus activity in multiple tumors: a review of clinical trials. Semin Oncol; 2009 Dec;36 Suppl 3:S46-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.
  • Temsirolimus, a novel analog of rapamycin, has shown promising preclinical and early clinical anti-tumor activity in various solid and hematologic tumor types, either alone or in combination with chemotherapy or other targeted agents.
  • Randomized phase III trials have already demonstrated significant clinical benefits of treatment with single-agent temsirolimus in advanced renal cell carcinoma and relapsed and/or refractory mantle cell lymphoma.
  • Other malignancies studied in the phase I and II trial settings include glioblastoma, breast cancer, endometrial cancer, non-Hodgkin lymphomas, and multiple myeloma.
  • This article reviews a comprehensive collection of the clinical trial results reported to date for temsirolimus in various solid and hematologic malignancies, as well as current strategies being tested in ongoing trials.
  • [MeSH-major] Clinical Trials as Topic / methods. Neoplasms / drug therapy. Sirolimus / analogs & derivatives
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Disease Models, Animal. Drug Evaluation, Preclinical. Hematologic Neoplasms / drug therapy. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19963100.001).
  • [ISSN] 1532-8708
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 624KN6GM2T / temsirolimus; W36ZG6FT64 / Sirolimus
  • [Number-of-references] 91
  •  go-up   go-down


88. Lu Y, Prescott J, Sullivan-Halley J, Henderson KD, Ma H, Chang ET, Clarke CA, Horn-Ross PL, Ursin G, Bernstein L: Body size, recreational physical activity, and B-cell non-Hodgkin lymphoma risk among women in the California teachers study. Am J Epidemiol; 2009 Nov 15;170(10):1231-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body size, recreational physical activity, and B-cell non-Hodgkin lymphoma risk among women in the California teachers study.
  • The authors examined body size measurements and recreational physical activity in relation to risk of B-cell non-Hodgkin lymphoma (NHL) in the prospective California Teachers Study.
  • Between 1995 and 2007, 574 women were diagnosed with incident B-cell NHL among 121,216 eligible women aged 22-84 years at cohort entry.
  • Multivariable-adjusted relative risks and 95% confidence intervals were estimated by fitting Cox proportional hazards models for all B-cell NHL combined and for the 3 most common subtypes: diffuse large B-cell lymphoma, follicular lymphoma, and B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma.
  • Height was positively associated with risk of all B-cell NHLs (for >1.70 vs. 1.61-1.65 m, relative risk = 1.50, 95% confidence interval: 1.16, 1.96) and chronic lymphocytic leukemia/small lymphocytic lymphoma (relative risk = 1.93, 95% confidence interval: 1.09, 3.41).
  • Weight and body mass index at age 18 years were positive predictors of B-cell NHL risk overall.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1287-94 [16835325.001]
  • [Cites] Cancer Causes Control. 2007 Aug;18(6):677-85 [17484069.001]
  • [Cites] Soc Sci Med. 2001 Apr;52(8):1269-84 [11281409.001]
  • [Cites] Am J Epidemiol. 2002 Sep 15;156(6):527-35 [12226000.001]
  • [Cites] Cancer Causes Control. 2002 Sep;13(7):625-35 [12296510.001]
  • [Cites] Cancer Causes Control. 2003 Sep;14(7):687-94 [14575367.001]
  • [Cites] Am J Phys Anthropol. 2003;Suppl 37:100-25 [14666535.001]
  • [Cites] Cancer Causes Control. 2004 Feb;15(1):35-43 [14970733.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):779-86 [15159310.001]
  • [Cites] Am J Clin Nutr. 2004 Aug;80(2):447-52 [15277169.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):579-91 [15286738.001]
  • [Cites] Cancer Causes Control. 2006 Feb;17(1):85-93 [16411057.001]
  • [Cites] Int J Cancer. 2006 May 1;118(9):2298-302 [16331621.001]
  • [Cites] JAMA. 2006 Apr 5;295(13):1549-55 [16595758.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Apr;91(4):1382-9 [16434460.001]
  • [Cites] Public Health Nutr. 2006 May;9(3):359-68 [16684388.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jul;91(7):2514-9 [16670160.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 20;91(20):1751-8 [10528026.001]
  • [Cites] Proc Nutr Soc. 2000 Feb;59(1):147-54 [10828184.001]
  • [Cites] Annu Rev Physiol. 2001;63:141-64 [11181952.001]
  • [Cites] Cancer Causes Control. 2001 Jan;12(1):13-21 [11227921.001]
  • [Cites] Epidemiology. 2004 Nov;15(6):746-54 [15475725.001]
  • [Cites] Lancet. 1973 Mar 3;1(7801):481 [4120387.001]
  • [Cites] Arch Dis Child. 1987 May;62(5):495-9 [3606184.001]
  • [Cites] Proc Nutr Soc. 1989 Jul;48(2):303-12 [2678126.001]
  • [Cites] Am J Public Health. 1991 May;81(5):639-42 [2014869.001]
  • [Cites] Blood. 1992 Sep 1;80(5):1207-12 [1515639.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5566s-5569s [1394175.001]
  • [Cites] J Clin Invest. 1993 Aug;92(2):540-8 [8349796.001]
  • [Cites] Blood. 1993 Nov 15;82(10):3005-11 [7693033.001]
  • [Cites] Nature. 1995 Oct 19;377(6550):646-9 [7566179.001]
  • [Cites] World Health Organ Tech Rep Ser. 1995;854:1-452 [8594834.001]
  • [Cites] Endocr Rev. 1997 Apr;18(2):157-79 [9101135.001]
  • [Cites] Med Sci Sports Exerc. 1999 Apr;31(4):566-71 [10211853.001]
  • [Cites] Adv Data. 2004 Oct 27;(347):1-17 [15544194.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):204-12 [15668496.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):210-8 [15687364.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 1;97(11):860-1 [15928310.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4742-54 [16034050.001]
  • [Cites] Br J Cancer. 2005 Oct 3;93(7):811-6 [16160698.001]
  • [Cites] Front Biosci. 2007;12:4997-5029 [17569626.001]
  • [Cites] Obes Rev. 2007 Jul;8(4):307-26 [17578381.001]
  • [Cites] Am J Epidemiol. 2007 Sep 15;166(6):697-708 [17596266.001]
  • [Cites] Endocr Relat Cancer. 2007 Sep;14(3):721-32 [17914102.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):11074-82 [18006854.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):196-203 [18187389.001]
  • [Cites] Int J Cancer. 2008 May 1;122(9):2062-70 [18167059.001]
  • [Cites] Proc Nutr Soc. 2008 May;67(2):128-45 [18412987.001]
  • [Cites] PLoS One. 2008;3(7):e2619 [18612430.001]
  • [Cites] Haematologica. 2008 Nov;93(11):1666-77 [18835833.001]
  • [Cites] Eur J Cancer. 2009 May;45(7):1232-8 [19091543.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Am J Epidemiol. 2009 Aug 1;170(3):297-307 [19478235.001]
  • [Cites] Cancer Causes Control. 2005 Dec;16(10):1203-14 [16215871.001]
  • [Cites] Am J Epidemiol. 2005 Dec 15;162(12):1162-73 [16269580.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 10;103(2):498-503 [16387863.001]
  • (PMID = 19822569.001).
  • [ISSN] 1476-6256
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] ENG
  • [Grant] United States / PHS HHS / / U55/CCR921930-02; United States / NCI NIH HHS / PC / N02-PC-15105; United States / NCI NIH HHS / CA / CA077398-10; United States / NCI NIH HHS / CA / R01 CA077398-10; United States / NCI NIH HHS / PC / N01-PC-35139; United States / NCI NIH HHS / PC / N02 PC015105; United States / NCI NIH HHS / CA / K05 CA136967; United States / NCI NIH HHS / CA / R01 CA077398-11; United States / NCI NIH HHS / CA / R01 CA077398; United States / NCI NIH HHS / CA / R01 CA77398; United States / NCI NIH HHS / CA / N01PC35136; United States / NCI NIH HHS / CA / K05 CA136967-01A1; United States / NCI NIH HHS / CA / N01PC35139; United States / NCI NIH HHS / PC / N01-PC-35136
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2781760
  •  go-up   go-down


89. Yip KW, Shi W, Pintilie M, Martin JD, Mocanu JD, Wong D, MacMillan C, Gullane P, O'Sullivan B, Bastianutto C, Liu FF: Prognostic significance of the Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal cancer. Clin Cancer Res; 2006 Oct 1;12(19):5726-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of the Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal cancer.
  • PURPOSE: Nasopharyngeal cancer (NPC) is a malignant epithelial carcinoma which is intimately associated with EBV.
  • The latent presence of EBV affects the function of p53, Bcl-2, and survivin.
  • We thus investigated the relationship between EBV status, p53, Bcl-2, and survivin in biopsy specimens from patients with primary NPC.
  • The presence of EBV was determined using EBER in situ hybridization, whereas p53, Bcl-2, and survivin were assessed using immunohistochemistry.
  • RESULTS: The majority of NPC specimens in this patient cohort were EBER-positive (64 of 78, or 82%), which in turn, was significantly associated with ethnicity (P = 0.0007), and WHO subtype 2A/2B (P = 0.04).
  • EBER-positive tumors were also associated with p53 (P = 0.002), Bcl-2 (P = 0.04), and nuclear survivin (P = 0.03) expression.
  • For nuclear survivin, patients with either low or high nuclear survivin fared worse than patients with intermediate survivin expression (P = 0.05), suggesting that there is an optimal proportion of survivin-expressing cells for best function and clinical outcome.
  • EBV-positive NPC has strong molecular associations with p53, Bcl-2, and survivin expression.
  • Furthermore, we provide clinical data revealing the potentially dual nature of survivin in predicting clinical outcome.
  • [MeSH-major] Epstein-Barr Virus Infections / metabolism. Gene Expression Regulation, Neoplastic. Microtubule-Associated Proteins / metabolism. Nasopharyngeal Neoplasms / metabolism. Neoplasm Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / virology. DNA, Neoplasm / genetics. Female. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / isolation & purification. Humans. Immunoenzyme Techniques. Inhibitor of Apoptosis Proteins. Male. Middle Aged. Prognosis. Survival Rate

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17020977.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / DNA, Neoplasm; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


90. Gruschkus SK, Lairson D, Dunn JK, Risser J, Du XL: Comparative effectiveness of white blood cell growth factors on neutropenia, infection, and survival in older people with non-Hodgkin's lymphoma treated with chemotherapy. J Am Geriatr Soc; 2010 Oct;58(10):1885-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative effectiveness of white blood cell growth factors on neutropenia, infection, and survival in older people with non-Hodgkin's lymphoma treated with chemotherapy.
  • OBJECTIVES: To determine the effect of colony-stimulating factor (CSF) on incidence of febrile neutropenia, infection, and survival in older people with non-Hodgkin's lymphoma (NHL) treated with chemotherapy.
  • PARTICIPANTS: Thirteen thousand two hundred twenty-three people diagnosed with NHL at age 65 and older (mean age 74.9, range 65-102) in 1992 to 2002 who received chemotherapy within 12 months of diagnosis.
  • These findings substantiate the clinical guidelines for recommending prophylactic CSF in older people with NHL receiving chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Colony-Stimulating Factors / therapeutic use. Infection / epidemiology. Lymphoma, Non-Hodgkin / drug therapy. Neutropenia / epidemiology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010, Copyright the Authors. Journal compilation © 2010, The American Geriatrics Society.
  • (PMID = 20840455.001).
  • [ISSN] 1532-5415
  • [Journal-full-title] Journal of the American Geriatrics Society
  • [ISO-abbreviation] J Am Geriatr Soc
  • [Language] eng
  • [Grant] United States / AHRQ HHS / HS / R01-HS016743
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Colony-Stimulating Factors
  •  go-up   go-down


91. Carozza SE, Li B, Wang Q, Horel S, Cooper S: Agricultural pesticides and risk of childhood cancers. Int J Hyg Environ Health; 2009 Mar;212(2):186-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Agricultural pesticide applications have the potential for significant drift beyond the target spray area and may result in exposure to non-farming residents in surrounding communities.
  • There was an overall pattern of increased risk for germ-cell tumors but the odds ratios were based on few number of exposed cases.
  • There was also some indication of increased risk for non-Hodgkin lymphoma (NHL) and Burkitt lymphoma, but point estimates were imprecise and not statistically significant.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Pesticides.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Environ Health Perspect. 2000 Jan;108(1):5-12 [10622770.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 2007 Jan-Mar;10(1-2):81-99 [18074305.001]
  • [Cites] Cancer. 2000 Dec 1;89(11):2315-21 [11147603.001]
  • [Cites] Environ Health Perspect. 2001 Mar;109(3):299-303 [11333193.001]
  • [Cites] Environ Res. 2001 Oct;87(2):99-107 [11683593.001]
  • [Cites] Leuk Lymphoma. 2001 Aug;42(4):619-29 [11697490.001]
  • [Cites] Environ Health Perspect. 2002 Mar;110(3):319-24 [11882484.001]
  • [Cites] Environ Health Perspect. 2002 May;110(5):549-53 [12003762.001]
  • [Cites] Environ Health Perspect. 2002 Aug;110(8):829-33 [12153767.001]
  • [Cites] J Expo Anal Environ Epidemiol. 2003 Jan;13(1):42-50 [12595883.001]
  • [Cites] Environ Health Perspect. 2004 Apr;112(5):631-5 [15064173.001]
  • [Cites] Int J Cancer. 1987 Nov 15;40(5):620-4 [3679589.001]
  • [Cites] Cancer Causes Control. 1995 May;6(3):187-98 [7612798.001]
  • [Cites] Environ Health Perspect. 1995 Dec;103(12):1126-34 [8747019.001]
  • [Cites] Environ Health Perspect. 1997 Oct;105(10):1068-77 [9349828.001]
  • [Cites] Environ Health Perspect. 1997 Dec;105(12):1344-53 [9405329.001]
  • [Cites] Cancer Causes Control. 1997 May;8(3):420-43 [9498903.001]
  • [Cites] Environ Health Perspect. 1998 Jun;106 Suppl 3:893-908 [9646054.001]
  • [Cites] Epidemiology. 2005 Jan;16(1):93-100 [15613951.001]
  • [Cites] Scand J Work Environ Health. 2005;31 Suppl 1:46-54; discussion 5-7 [16190149.001]
  • [Cites] Am J Epidemiol. 2005 Nov 1;162(9):858-67 [16192347.001]
  • [Cites] Int J Hyg Environ Health. 2006 Jan;209(1):31-40 [16373200.001]
  • [Cites] Environ Health Perspect. 2006 Jun;114(6):893-7 [16759991.001]
  • [Cites] Am J Epidemiol. 2006 Aug 1;164(3):208-11 [16707652.001]
  • [Cites] J Expo Sci Environ Epidemiol. 2006 Sep;16(5):387-96 [16249796.001]
  • [Cites] Int J Occup Med Environ Health. 2006;19(3):152-69 [17252666.001]
  • [Cites] J Agric Saf Health. 2007 Jan;13(1):9-24 [17370910.001]
  • [Cites] Environ Health Perspect. 2007 May;115(5):684-9 [17520053.001]
  • [Cites] Int J Hyg Environ Health. 2007 Oct;210(5):645-57 [17434797.001]
  • [Cites] Environ Res. 2000 Nov;84(3):290-302 [11097803.001]
  • (PMID = 18675586.001).
  • [ISSN] 1618-131X
  • [Journal-full-title] International journal of hygiene and environmental health
  • [ISO-abbreviation] Int J Hyg Environ Health
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA092670-05; United States / NCI NIH HHS / CA / R01 CA092670; United States / NCI NIH HHS / CA / R01 CA092670-05; United States / NCI NIH HHS / CA / R01CA92670
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Agrochemicals; 0 / Pesticides
  • [Other-IDs] NLM/ NIHMS96975; NLM/ PMC2659586
  •  go-up   go-down


92. Baecklund E, Backlin C, Iliadou A, Granath F, Ekbom A, Amini RM, Feltelius N, Enblad G, Sundström C, Klareskog L, Askling J, Rosenquist R: Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis. Arthritis Rheum; 2006 Dec;54(12):3774-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis.
  • OBJECTIVE: Patients with rheumatoid arthritis (RA) are at increased risk of malignant lymphomas, with a correlation between RA disease severity and lymphoma risk, most pronounced for diffuse large B cell lymphomas (DLBCLs), which also constitute the majority of RA-associated lymphomas.
  • DLBCLs can be further subdivided into germinal center (GC)-like and non-GC-like subtypes, with different cellular origins and prognoses.
  • METHODS: We identified 139 patients with DLBCLs within a population-based case-control study of 378 RA patients with lymphoma.
  • The DLBCLs were examined for CD10, Bcl-6, and interferon regulatory factor 4 expression patterns, subclassified into GC and non-GC subtypes, and then correlated with clinical parameters.
  • RESULTS: We found a statistically significant predominance of the non-GC subtype (97 patients; 70% of all DLBCLs).
  • These patients more often had an advanced stage of lymphoma at diagnosis and had a worse 5-year overall survival rate (16% versus 33%) compared with patients with the GC subtype.
  • There was a strong association with RA disease activity in both subtypes, with >70% of the GC and non-GC cases occurring in RA patients with the highest overall disease activity scores.
  • CONCLUSION: These findings suggest that severe RA is particularly associated with the non-GC subtype of DLBCL, and indicate a critical role of activated peripheral B cells as the cells of origin in these lymphomas.
  • [MeSH-major] Arthritis, Rheumatoid / complications. Lymphoma, B-Cell / complications. Lymphoma, Large B-Cell, Diffuse / complications
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Case-Control Studies. Comorbidity. DNA-Binding Proteins / metabolism. Female. Germinal Center / pathology. Humans. Interferon Regulatory Factors / metabolism. Male. Middle Aged. Neprilysin / metabolism. Survival Rate. Sweden / epidemiology

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17133544.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Interferon Regulatory Factors; 0 / interferon regulatory factor-4; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


93. Moreno Nogueira JA, Casas Fernández de Tejerina A, Moreno Rey C: [Treatment of indolent non-Hodgkin's lymphomas]. Rev Clin Esp; 2009 Feb;209(2):82-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of indolent non-Hodgkin's lymphomas].
  • [Transliterated title] Tratamiento de los linfomas no hodgkinianos indolentes.
  • Non-Hodgkin's Lymphomas (NHLs) are a heterogeneous group of entities with different pathologies.
  • A total of 80% of these lymphomas are B-cell origin and only 20% T-cell.
  • B-cell lymphomas express CD-20 antigen, a specific target for the current treatment with monoclonal antibodies.
  • Indolent lymphomas in localized stages (I and II) account for 20%, only 10% being in pathological stages.
  • Rescue treatment is one of the most important problems in this type of lymphomas, many of them needing second line treatments, with survival rates under five years, in spite of the 50% response rate.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Humans. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19798845.001).
  • [ISSN] 0014-2565
  • [Journal-full-title] Revista clínica española
  • [ISO-abbreviation] Rev Clin Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


94. Mollejo M, Rodríguez-Pinilla MS, Montes-Moreno S, Algara P, Dogan A, Cigudosa JC, Juarez R, Flores T, Forteza J, Arribas A, Piris MA: Splenic follicular lymphoma: clinicopathologic characteristics of a series of 32 cases. Am J Surg Pathol; 2009 May;33(5):730-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Splenic follicular lymphoma: clinicopathologic characteristics of a series of 32 cases.
  • The spleen is frequently involved in B-cell lymphomas other than splenic marginal zone lymphoma.
  • Here we describe a series of follicular lymphoma (FL) cases diagnosed in the spleen, consisting of 32 patients who presented clinically with splenomegaly, and slight or no peripheral lymphadenopathy.
  • The splenic specimen had a micronodular pattern, germinal center cytologic composition, and frequent presence of marginal zone-like cells at the periphery of the nodules.
  • Splenic FL cases could be divided into 2 main variants: one was similar to classic FL with t(14;18) and CD10 expression, whereas the other was characterized by a higher proliferation index and histologic grade, and was more frequently diagnosed as a disease restricted to the spleen.
  • [MeSH-major] Lymphoma, B-Cell / pathology.